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baCKgrOunD
Chronic kidney disease (CKD) is a substantial health problem.1,2 A minority of patients 
with CKD will progress to end stage renal failure, resulting in a high personal and 
societal burden. An even greater concern is the association of CKD with a high risk of 
cardiovascular morbidity and mortality and with a reduction in life expectancy.3,4 Early 
detection and treatment contribute to better patient outcome.5,6 A discussion is 
ongoing of how and where to organise this care in an effective way.7 Many factors 
point to primary care as the logical environment to detect and manage the majority of 
CKD patients.8 At the same time, these very factors face the primary care organisation 
with a challenging complexity. This thesis aims to explore aspects of CKD management 
in primary care, whereby the connection with secondary care is incorporated. 
The following factors considering CKD management contribute to both the essential 
position of primary care and the organisational demands: 
 A. the high prevalence of CKD with resulting workload: it is not possible and 
necessary to manage all patients with CKD in secondary care. Care should be given 
in a primary care setting where possible. To manage the workload well, the GP will 
have to delegate tasks to assistants and nurse practitioners. Collaborative care with 
nephrology should be sought at the appropriate time.  
 B. the many co-morbid conditions and associated multitude of health care 
providers in primary and secondary care:  general practice is in the position to have 
an overview, but will have to take the responsibility to coordinate well. 
 C. medication safety: the dosage of drugs that depend on renal excretion 
should be adjusted and nephrotoxic drugs should be avoided. General practice has 
information on both medication use and renal function, but not always the knowledge 
to detect and solve all issues.  
 D. CKD is a long-term, dynamic condition which may be complicated by acute 
exacerbations. General practice, with it’s integrated care and easy access, is a good 
setting to manage long-term conditions and to recognise ‘acute-on-chronic’ situations. 
This requires knowledge and alertness through all staff layers of the practice.    
We present a clinical lesson on a patient in general practice to illustrate these factors9. 
Subsequently, the above mentioned aspects will be discussed in further depth, resulting 
in the aim and research questions of this thesis.
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Mr A, an 81-year-old man, is known with hypertension and a moderately 
decreased renal function and has a history of heart failure, colon cancer, a TIA 
and gout. Due to watery diarrhoea and abdominal pain during the previous 24 
hours the general practitioner made a home visit. There was no fever. The 
general practitioner observed nothing unusual during an examination. Three 
days later the out of hours general practitioner service was called because the 
patient could scarcely urinate any more. The patient had continued to take his 
medicine faithfully which consisted of lisinopril (20 mg once daily), amlodipine 
(10 mg once daily), atenolol (100 mg once daily), chlortalidone (12.5 mg once 
daily), acetylsalicylic acid (100 mg once daily), omeprazole (20 mg once daily), 
and diclofenac (50 mg as needed 3 times daily).
At the emergency department the internist saw a scarcely ill man with an ashen 
face. The blood pressure was 115/50 mmHg and the pulse 55 beats per minute. 
No abnormalities were found during a physical examination. The abdomen was 
non tender. Laboratory tests on admission revealed normal Hb, CRP, sodium 
and liver values. The serum creatinine (1183 μmol/l), potassium (6.5 mmol/l) and 
urea (55.7 mmol/l) values were elevated. Microbiological tests revealed negative 
blood, faeces and urine cultures. It appeared that one year before admission 
the creatinine had gradually increased from 130 μmol/l to 178 μmol/l (MDRD 34 
ml/min/1.73m2).
The clinical picture is compatible with an ‘acute-on-chronic’ renal failure, as a 
consequence of dehydration during gastroenteritis and the use of an ACE 
inhibitor, diuretics and NSAIDs. All antihypertensives and the diclofenac were 
suspended. The patient received a generous drip and glucose and insulin were 
administrated for the hyperkalaemia. The serum creatinine concentration 
decreased over 10 days to 151 μmol/l, after which the patient could be discharged 
in a reasonable condition. Of the antihypertensives only atenolol (50 mg once 
daily) was still given. One month after discharge the patient developed swollen 
feet. Under strict monitoring of renal function, diuretics were added and lisinopril 
was gradually resumed and increased to 40 mg daily. Six months after admission 
the patient was doing reasonably well. Serum creatinine concentration was 135 
μmol/l (MDRD 47 ml/min/1.73m2).
In the Netherlands, 5.3% of the general population has an MDRD-value below 60 ml/
min/1.73 m2.10 Using data from the Nijmegen Biomedical Study, we calculated that in 
a typical general practice there will be about 40 patients who use RAAS inhibitors and 
who have an MDRD < 60 ml/min/1.73 m2.11 
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Within the group of patients with chronic reduced renal function who use a RAAS 
inhibitor, the elderly and patients with a reduced cardiac function have an increased 
risk of developing an ‘acute-on-chronic’ renal failure during fever or gastroenteritis.12 
Particular attention needs to be paid during warm summer days. Patients with athero-
sclerosis have a higher chance of a poor renal circulation because renovascular athero-
sclerosis will also be present. Use of diuretics and/or NSAIDs forms an additional 
risk.13 
In our patient the creatinine values in the years prior to this hospital admission 
increased from 130 μmol/l to 178 μmol/l , which is equivalent to an estimated glomerular 
filtration rate  (MDRD formula) of 34 ml/min/1.73 m2. These are not uncommon values 
within general practice but these patients will not always be assigned a problem code 
‘chronic reduced renal function’ in the diagnosis list in the electronic health record. 
And even if this would be the case, the practice assistant or general practitioner will 
probably not be alarmed straightaway if the patient phones and says that he/she has 
gastric flu or fever. Our patient had the following risk factors: chronic reduced renal 
function, ACE inhibitor use and diuretics use in combination with diarrhoea. This should 
have been a reason to check the creatinine and potassium and to adjust the medication. 
The NSAID use formed an additional risk for the development of acute renal failure. 
RAAS inhibitors are often indicated for patients with chronic renal damage in order to 
prevent a further deterioration of the renal function and to reduce the blood pressure. 
However during intercurrent disease these should sometimes be temporarily reduced 
or suspended based on the clinical status and laboratory results. 
A. High prevalence, necessity to organise care well
The prevalence of CKD is high: more than 13% in the general population in the USA 
and 6.8%  in known patients in primary care in the UK.1,14 The expectation is that, with 
ageing of the population and rising incidence of diabetes and hypertension, the 
prevalence will even rise further in the future.1 Routine laboratory controls and default 
reporting of the estimated renal function by laboratories have added to CKD recognition 
in primary care.15 Patients like Mr A will occur more and more in general practice.   
Recommended interventions for CKD management are provided in guidelines16-18. 
Blood pressure and cholesterol lowering and reduction of proteinuria form the main 
goals of the guidance. General practitioners are in the position to carry out these 
guidelines, however treatment targets are often not met.19-21 A lack of knowledge and 
confidence in CKD management may be the cause, but also scepticism concerning 
blood pressure targets.22,23 Furthermore, guidelines are so time-consuming and of 
such a complexity that it is almost impossible to implement them in daily care.24 
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It is not clear yet which approach in organising care for CKD patients is most effective. 
Transferring knowledge and guidelines is a prerequisite, but that alone is not sufficient.25 
Of additional value could be the identification of patients from electronic patient records, 
computer decision support and collaborative care between general practitioner and 
nephrology.21 A primary care based disease management program proved to be 
effective in an observational study, but the effectiveness of a multi disciplinary approach 
in primary care has not yet been proved in randomised trials.26-29 
B. Multimorbidity
Patients with CKD often have co-morbidities: diabetes, hypertension, cardiovascular 
disease and anaemia.30 Frailty could be added to these examples. Preferably, these 
patients should not have to travel to see different doctors for their different conditions. 
Primary care is in a transition phase from demand-driven single problem care to 
pro-active care for patients with long-term conditions. Disease management programs 
for patients with diabetes and cardiovascular disease are effective and have evolved 
considerably.31,32 If treatment of patients with multiple long-term conditions would be 
split up in a number of separate disease manage programs, the risk of fragmentation 
of care is considerable.33 Primary care is in the position to integrate care and model 
guideline advice to fit the individual patient with complex unordered problems.34 As 
there are many parallels in diagnosis and treatment of CKD patients with that of 
diabetes or hypertension-patients, it might be helpful to treat CKD patients in the 
same structure as patients with diabetes or hypertension.
C. Medication safety
Patients with impaired renal function are at increased risk of preventable drug related 
morbidity and preventable medication-related hospital admissions.35,36 When renal 
function is reduced, the dosage of drugs that depend on renal excretion should be 
adjusted37. For example the dosage of digoxin should be adjusted to renal function 
to avoid the risk of digoxin toxicity.35 Nephrotoxic drugs like NSAIDs should be 
avoided.38,39
Although primary care has the tools to monitor medication safety, many medication 
errors in relation to impaired renal function occur40,41. Many factors contributing to that 
can be identified. First, digital prescribing may warn for ‘impaired renal function’, but 
hardly ever takes the value of renal function automatically into account. Second, renal 
function is fluctuating over time, so in chronic medication the appropriateness of drug 
and dosage should be reconsidered on a regular basis. Third, the paradox is that 
drugs that are in essence beneficial for CKD patients, like RAAS inhibitors, can be 
harmful in specific situations (reduction of circulating volume). Finally, the balancing 
13
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between co-morbidities that compete for attention requires distinct craftsmanship42. 
The combination of impaired renal function, heart failure and gout like in Mr A is a 
typical Scylla and Charybdis situation.
As securing medication safety in patients with CKD is complicated, safety nets must 
be built in at different stages. The pharmacist might be of additional value in this 
process.   
D. Dynamic condition
The management of chronic kidney disease is guided by the stage of the disease.16 
Change in  renal function over time is an additional consideration in judging the 
severity of the disease.43 In general practice, often series of creatinine measurements 
are available. The general practitioner should judge the course of renal function, 
proteinuria and blood pressure over time and relate the findings to medication changes 
and intercurrent diseases. These situations do not fit in the disease management 
program, but require integration and interpretation of information already available. 
This is not always easy in the hassle of daily practice. A structured presentation of 
historical data might help in getting an overview. Not only should the general 
practitioner have the knowledge, but also the practice nurse who sees the patient 
for an annual diabetes or hypertension control and the practice assistant who speaks 
to the patient on the phone in case of an intercurrent disease like gastro enteritis 
or fever.
aim Of This Thesis 
Exploring the chances and borders of CKD management in primary care implies 
knowledge about these patients and about the organisational possibilities to meet 
their needs. The general aim of this thesis was to explore these fields. 
Research questions 
1. What is the prevalence of known patients with chronic kidney disease in primary 
care?
2. What is quality of care for patients with CKD in primary care related to the 
guideline advice?
3. What is the prevalence of metabolic abnormalities in patients with CKD in primary 
care?
4. Would a shared care model between nurse practitioner, general practitioner and 
nephrologist, supported by a web-based consultation system, contribute to the 
care for patients with chronic kidney disease?
General introduction
14
5. What is the feasibility of a web-based consultation between general practitioner 
and nephrologist? 
6. What are issues in medication safety in patients with CKD and diabetes or 
hypertension? What could be the contribution of a pharmacist? 
These questions form the structure of this thesis. Secondary research questions came 
on the way, but the basic question remained paramount: how could the organisation 
in primary care be structured in a way that CKD patients get the treatment that is 
indicated, preferably in their own environment?
OuTline Of The Thesis
Chapter two describes the prevalence of CKD patients in primary practices in the 
Netherlands and the quality of care currently given compared to the Dutch inter-
disciplinary CKD-guideline for primary care and nephrology.
Chapter three gives more detailed insight in patients with CKD in primary care 
regarding abnormal serum PTH, calcium and phosphate.
In chapter four we describe the results of our study that tested a shared care model 
for patients with chronic kidney disease in nephrology and general practice in a 
cluster randomized controlled trial.  
When treating patients with CKD in primary care, consultation of a nephrologist in 
a digital environment maybe of value. In chapter five we describe the initial 
implementation of a web-based consultation process for patients with CKD.   
In chapter six we assess the pharmaceutical problems in relation to renal function in 
older patients and the potential contribution of the pharmacist in that field. 
Chapter seven comprises a validation study of 30-minute automated office blood 
pressure measurement compared to usual automated office blood pressure 
measurement.
Finally, in chapter eight the most important findings of the studies are summarised 
and discussed. 
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absTraCT
Purpose: Early detection and appropriate management of Chronic Kidney Disease 
(CKD) in primary care are essential to reducing morbidity and mortality. This study 
aimed to assess the quality of care (QoC) of CKD in primary healthcare and to identify 
related patient and practice characteristics, so improvement strategies can be based 
on these findings.
Methods: In this retrospective study, data were collected from 47 family practices 
(207,469 patients of whom 162,562 adults) in 2008–2011. CKD management of 
patients under care of their family physician(FP) was qualified using indicators 
derived from the Dutch interdisciplinary CKD-guideline for primary care and 
nephrology and included [1]monitoring of renal function, albuminuria, blood pressure 
and glucose, [2]monitoring of metabolic parameters, and alongside the guideline: [3]
recognition of CKD. The outcome indicator was [4] achieving blood pressure targets. 
Multilevel logistic regression analysis was applied to identify associated patient and 
practice characteristics.
Results: Kidney function or albuminuria data were available for 64,102 patients. 9295 
patients had CKD, of whom 8845 were under FP care. Monitoring of disease 
progression was complete in 43% of CKD-patients, monitoring of metabolic 
parameters in 2%, and blood pressure target was reached in 43.6%. FPs documented 
CKD in 31.7% of CKD-patients. High QoC was strongly associated with diabetes, and 
to a lesser extent with hypertension, male sex and rural practice location.
Conclusions: Gaps in care were found in all aspects of CKD management. As QoC 
was higher for patients participating in diabetes disease management programs, 
future CKD care may profit from embedment in comparable programs. 
Trial registration: Nederlands Trial Register NTR2368
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inTrODuCTiOn
Family physicians play a key role in the care of patients with Chronic Kidney Disease 
(CKD). Early detection and appropriate management of CKD is essential to reduce 
morbidity, mortality and disease progression. The number of patients that suffer from 
CKD is growing, as illustrated by the rise in community prevalence in the USA. 
Prevalence of CKD stages 1–4 rose from 10.0% in 1988-1994 to 13.1% in 1999-2004, 
using the definitions of CKD as proposed in the National Kidney Foundation’s ‘Kidney 
Disease Outcome Quality Initiative’ (K/DOQI) guidelines.(1-3) Considering this 
increase in health care burden, a high level of primary care engagement in the 
management of CKD not only is convenient to the patient but also contributes to 
cost-effectiveness in health care.(4-6)
The K/DOQI guidelines (USA) and the National Institute for Health and Clinical 
Excellence (NICE) CKD guideline (UK) provide family physicians with recommenda-
tions on good CKD management, including monitoring of disease progression and 
strictly controlling cardiovascular risk factors.(3, 7) The Dutch interdisciplinary 
CKD-guideline for primary care and nephrology is similar to these guidelines, but 
incorporates age in its recommendations (Appendix table 1).(8-13) 
Studies have shown that high standard CKD management attenuates and delays 
adverse outcomes such as progression to end stage renal failure, cardiovascular 
events, and disturbances in bone and mineral metabolism.(14-24) However, literature 
also notes deficiencies in the quality of care (QoC).(25-30) To our knowledge there 
has been no study that specifically addressed QoC in routine family practice for all 
stages of CKD. Our study aimed to analyze process and outcome indicators of CKD 
management in patients under care of their family physician, and to identify associated 
patient and practice characteristics. Process indicators reflect whether a caregiver 
executed specific health care activities, whereas outcome indicators reflect the effect 
of these activities on the health of the patient.(31) We hypothesized that our study 
would uncover gaps in care and reveal predictors of high QoC. Our data should 
enable development of better targeted improvement strategies. 
meThODs
Recruitment of participants
This study used baseline patient data of family practices that participated in a cluster 
randomized controlled trial on the effect of web-consultation between FP and 
nephrologist on in-person referrals: the CONTACT study (Consultation Of Nephrology 
Quality of care
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by Telenephrology Allows optimal Chronic kidney disease Treatment in primary care, 
Netherlands Trial Registration code 2368). The CONTACT study recruited family 
practices during a CKD management course for family physicians in the eastern part 
of the Netherlands. Forty seven non-academic family practices signed up for 
participation. Data between 2008-2011 were analyzed from their registered populations’ 
electronic medical records (n=207,469). In this retrospective study, we included all 
patients aged 18 years or older who met the CKD criteria: eGFR<60ml/min/1.73m2 or 
albuminuria. Patients under secondary renal care were excluded from the analysis.
Classification of patients
The interdisciplinary CKD-guideline for primary care and nephrology provides 
guidance for the FP in selecting the best suited health care setting for patients with 
CKD, based on eGFR, albuminuria and age. These settings are: treatment in primary 
care, consultation of a nephrologist without referral, and referral to secondary care. 
We applied this classification to our cohort, resulting in a ‘primary care’ group, a 
‘consultation’ group and a ‘referral’ group (Table 1). The guideline also provides 
group specific monitoring criteria. In the ‘primary care’ group this implied monitoring 
of disease progression, while the ‘consultation’ and the ‘referral’ groups additionally 
required monitoring of metabolic parameters (Appendix table 1). Serum creatinine 
measurements were either isotope dilution mass spectrometry (IDMS) traceable or 
subject to the Jaffé technique. Laboratories estimated renal function using the 
appropriate abbreviated Modification of Diet in Renal Disease (MDRD) equation for 
IDMS and Jaffé technique respectively.(32, 33) We defined microalbuminuria as an 
urinary albumin to creatinine ratio (ACR) of 2.5–25mg/mmol in men and 3.5–35mg/
mmol in women. Higher ratios were considered to reflect macroalbuminuria. If an 
ACR was unavailable, we used urine albumin concentration with cut-off values 
>20–200mg/l for microalbuminuria and >200mg/l for macroalbuminuria. Patient age 
was set on the latest eGFR date.
Process and outcome indicators (Table 2)
We derived indicators from the evidence based interdisciplinary CKD-guideline for 
primary care and nephrology.(13) Included process indicators were: [1] monitoring of 
disease progression (assessment of eGFR or serum creatinine, albuminuria, glucose, 
and blood pressure); [2] monitoring of metabolic parameters(assessment of hemoglobin, 
calcium, phosphate, parathyroid hormone (PTH), serum albumin, and potassium), 
and alongside the guideline; [3] recognition of CKD in patients with an eGFR < 60 ml/
min/1.73m2 (separate entity on the episode list in the electronic medical record with 
International Classification of Primary Care (ICPC) code U99.01 for renal impairment). 
The outcome indicator was [4] achievement of blood pressure targets. To achieve blood 
pressure targets, the mean of the two latest measurements had to be <140/90mmHg. 
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Additionally, we analyzed blood pressures <130/80mmHg to allow comparison with 
existing literature.
Patient and practice characteristics
We extracted patient demographic and clinical data concerning date of birth, sex, 
co-morbidities and medication from the electronic medical record (Table 3). Patient 
age was categorized in ranges 18-45 years, 45-60 years, 60-75 years, and over 75 
years old. Co-morbidities were defi ned by ICPC codes as a history of diabetes (T90), 
hypertension (K86,K87) and cardiovascular disease (K74-K77,K89,K90,K92).(34) We 
selected drug prescriptions issued during 2010 for medication shown in table 3 using 
Anatomical Therapeutic Chemical (ATC) codes for descriptive purposes only.(35) 
Practice characteristics included practice type (solo-,duo- or group-practice), 
vocational training practice, practice location (urban or rural based on the Statistics 
Netherlands’ Key fi gures postcode areas database of 2004), and General Practice 
Information System (5 different systems)(Appendix table 2).
Quality of care
Table 1   Classifi cation of patients using the interdisciplinary CKD-guideline for 
primary care and nephrology
Albuminuria
Not known Normal Microalbuminuria Macroalbuminuria
Patients ≥ 65 years (n = 20.867)
eGFR ≥ 60 8.488 5.653 893 74
eGFR 45 – 60 2.134 1.583 411 52
eGFR 30 – 45 642 420 195 46
eGFR < 30 181 43 33 19
Patients < 65 years (n = 43.235)
eGFR ≥ 60 32.361 8.305 693 59
eGFR 45 – 60 894 595 70 16
eGFR 30 – 45 106 51 22 7
eGFR < 30 39 3 6 8
Classifi cation of patients based on renal function, albuminuria and age. ‘primary care group’: treatment 
in primary care. ‘consultation group’: consultation of a nephrologist without referral. ‘referral group’: 
referral to secondary care. eGFR in ml/min/1.73m2
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Table 2   Performance on process and outcome indicators within 15 months prior 
to data extraction
Patient group N Monitoring of disease progression Monitoring of                                                          metabolic parameters Recog-
nition
Blood pressure 
targets
renal 
function
albu-
minuria
fasting 
glucose
blood 
pressure
complete hemo-
globin
calcium phos-
phate
PTH serum 
albumin
potassium complete <140/90 
mmHg*
<130/80 
mmHg*
Primary care group
Age ≥ 65 eGFR ≥ 60 
and micro-albuminuria
892 828 763 812 810 697
(78%)
279
(34%)
94
(12%)
Age < 65 eGFR ≥ 60 
and micro-albuminuria
693 593 556 584 545 467
(67%)
259
(48%)
85
(16%)
Age ≥ 65 eGFR 45 – 60 4124 3416 1699 2624 3040 1571
(38%)
1087
(26%)
1264
(42%)
485
(16%)
Total 
primary care
5709 4837
(84.7%)
3018
(52.9%)
4020
(70.4%)
4395
(77.0%)
2735
(47.9%)
1802
(41.0%)
664
(15.1%)
Consultation group
Age ≥ 65 
eGFR 30 – 44
1237 1033 489 704 893 452
(37%)
699 192 158 75 121 876 34
(3%)
722
(58%)
434
(49%)
199
(22%)
Age < 65 
eGFR 45 – 60
1547 1126 541 848 918 457
(30%)
623 93 73 32 47 813 15
(1%)
325
(21%)
475
(52%)
151
(16%)
Total consultation 2784 2159
(77.6%)
1030
(37.0%)
1552
(55.7%)
1811
(65.1%)
909
(32.7%)
1322
(47.5%)
285
(10.2%)
231
(8.3%)
107
(3.8%)
168
(6.0%)
1689
(60.7%)
49
(1.8%)
1047
(37.6%)
909
(50.2%)
350
(19.3%)
Referral group
Age ≥ 65 eGFR < 30 102 85 24 48 59 21
(21%)
73 24 16 5 16 72 2
(2%)
67
(66%)
27
(46%)
20
(34%)
Age < 65 eGFR 30 – 44 72 53 18 39 43 18
(25%)
40 18 13 2 10 43 2
(3%)
35
(49%)
26
(60%)
11
(26%)
Age < 65 eGFR < 30 13  10 0 4 6 0
(0%)
9 3 2 0 3 7 0
(0%)
3
(23%)
4
(67%)
2
(33%)
Macro-albuminuria 165 145 121 145 138 108
(66%)
68 19 12 3 13 126 1
(1%)
32
(42%)**
44
(32%)
15
(11%)
Total
 referral
352 293
(83.2%)
163
(46.3%)
236
(67.0%)
246
(70.1%)
147
(41.8%)
190
(54.1%)
64
(18.2%)
43
(12.3%)
10
(2.8%)
42
(12.0%)
248
(70.5%)
5
(1.4%)
137
(51.9%)
101
(41.1%)
48
(19.5%)
Total consultation and 
referral
3136 2452
(78.2%)
1193
(38.0%)
1788
(57.0%)
2057
(65.6%)
1056
(33.7%)
1512
(48.3%)
349
(11.1%)
274
(8.7%)
117
(3.7%)
210
(6.7%)
1937
(61.8%)
54
(1.7%)
1184
(38.9%)
1010
(49.1%)
398
(19.3%)
Total 8845 7289
(82.4%)
4210
(47.6%)
5808
(65.7%)
6452
(72.9%)
3791
(42.9%)
2271
(31.7%)
2812
(43.6%)
1062
(16.5%)
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care 
and nephrology. For each indicator, performance in the preceding 15 months is shown.
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Table 2   Performance on process and outcome indicators within 15 months prior 
to data extraction
Patient group N Monitoring of disease progression Monitoring of                                                          metabolic parameters Recog-
nition
Blood pressure 
targets
renal 
function
albu-
minuria
fasting 
glucose
blood 
pressure
complete hemo-
globin
calcium phos-
phate
PTH serum 
albumin
potassium complete <140/90 
mmHg*
<130/80 
mmHg*
Primary care group
Age ≥ 65 eGFR ≥ 60 
and micro-albuminuria
892 828 763 812 810 697
(78%)
279
(34%)
94
(12%)
Age < 65 eGFR ≥ 60 
and micro-albuminuria
693 593 556 584 545 467
(67%)
259
(48%)
85
(16%)
Age ≥ 65 eGFR 45 – 60 4124 3416 1699 2624 3040 1571
(38%)
1087
(26%)
1264
(42%)
485
(16%)
Total 
primary care
5709 4837
(84.7%)
3018
(52.9%)
4020
(70.4%)
4395
(77.0%)
2735
(47.9%)
1802
(41.0%)
664
(15.1%)
Consultation group
Age ≥ 65 
eGFR 30 – 44
1237 1033 489 704 893 452
(37%)
699 192 158 75 121 876 34
(3%)
722
(58%)
434
(49%)
199
(22%)
Age < 65 
eGFR 45 – 60
1547 1126 541 848 918 457
(30%)
623 93 73 32 47 813 15
(1%)
325
(21%)
475
(52%)
151
(16%)
Total consultation 2784 2159
(77.6%)
1030
(37.0%)
1552
(55.7%)
1811
(65.1%)
909
(32.7%)
1322
(47.5%)
285
(10.2%)
231
(8.3%)
107
(3.8%)
168
(6.0%)
1689
(60.7%)
49
(1.8%)
1047
(37.6%)
909
(50.2%)
350
(19.3%)
Referral group
Age ≥ 65 eGFR < 30 102 85 24 48 59 21
(21%)
73 24 16 5 16 72 2
(2%)
67
(66%)
27
(46%)
20
(34%)
Age < 65 eGFR 30 – 44 72 53 18 39 43 18
(25%)
40 18 13 2 10 43 2
(3%)
35
(49%)
26
(60%)
11
(26%)
Age < 65 eGFR < 30 13  10 0 4 6 0
(0%)
9 3 2 0 3 7 0
(0%)
3
(23%)
4
(67%)
2
(33%)
Macro-albuminuria 165 145 121 145 138 108
(66%)
68 19 12 3 13 126 1
(1%)
32
(42%)**
44
(32%)
15
(11%)
Total
 referral
352 293
(83.2%)
163
(46.3%)
236
(67.0%)
246
(70.1%)
147
(41.8%)
190
(54.1%)
64
(18.2%)
43
(12.3%)
10
(2.8%)
42
(12.0%)
248
(70.5%)
5
(1.4%)
137
(51.9%)
101
(41.1%)
48
(19.5%)
Total consultation and 
referral
3136 2452
(78.2%)
1193
(38.0%)
1788
(57.0%)
2057
(65.6%)
1056
(33.7%)
1512
(48.3%)
349
(11.1%)
274
(8.7%)
117
(3.7%)
210
(6.7%)
1937
(61.8%)
54
(1.7%)
1184
(38.9%)
1010
(49.1%)
398
(19.3%)
Total 8845 7289
(82.4%)
4210
(47.6%)
5808
(65.7%)
6452
(72.9%)
3791
(42.9%)
2271
(31.7%)
2812
(43.6%)
1062
(16.5%)
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care 
and nephrology. For each indicator, performance in the preceding 15 months is shown.
(Renal function: eGFR or serum creatinine; Albuminuria: albumin creatinine ratio or urine albumin). 
eGFR in ml/min/1.73m2. * the percentages show the achieved blood pressure targets divided by the 
number of blood pressure measurements.** Percentage calculated with patients with eGFR < 60 ml/
min/1.73m2 as denominator (n = 77).
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Table 3   Patient characteristics based on data from 2008 – 2011
Patient 
characteristic
Groups
Overall 
(n=8845)
Primary care 
(n=5709)
Consultation 
(n=2784)
Referral 
(n=352)
Demographics (SD)
Age in years 71.4 (11.9) 73.6 (10.2) 66.7 (13.3) 72.0 (14.5)
Male sex 40.1% 42.7% 33.6% 48.3%
Co morbidity
Diabetes 32.9% 35.9% 24.5% 51.4%
Hypertension 56.2% 57.8% 53.5% 52.0%
Cardiovascular 
disease
35.6% 36.2% 32.4% 52.8%
Laboratory (SD) [n]
Creatinine in μmol/l 104.5 (28.0) 
[n=8843]
95.6 (18.5) 
[n=5708]
117.4 (23.7) 
[n=2783]
145.5 (73.5) 
[n=352]
eGFR in ml/
min/1.73m2
56.4 (18.8) 
[n=8845]
61.3 (20.1) 
[n=5709]
47.1 (8.8) 
[n=2784]
41.3 (16.1) 
[n=352]
Fasting glucose in 
mmol/l
6.5 (1.8) 
[n=6968]
6.6 (1.9) 
[n=4688]
6.2 (1.6) 
[n=2001]
7.1 (2.3) 
[n=279]
Hemoglobin in g/dl 13.50 (1.55) 
[n=2087]
12.73 (1.91) 
[n=270]
Calcium in mmol/l 2.33 (0.13) 
[n=446]
2.31 (0.13) 
[n=89]
Phosphate in mmol/l 1.02 (0.19) 
[n=342]
1.13 (0.20) 
[n=59]
PTH in pmol/l 7.58 (5.02) 
[n=139]
11.74 (7.65) 
[n=17]
Albumin in g/l 38.8 (4.5) 
[n=272]
37.7 (5.8) 
[n=73]
Potassium in mmol/l 4.3 (0.45) 
[n=2241]
4.4 (0.58) 
[n=316]
Urine [(first and third quartile) n]
Albumin urine in mg/l 15.0 (3.4–51.0) 
[n=2930]
20.0 (5.0-53.0) 
[n=2048]
6.0 (2.9-18.0) 
[n=724]
210.6 (89.3–489.0) 
[n=158]
Albumin/creatinine 
ratio
2.5 (0.9-6.1) 
[n=5040]
3.2 (0.9-6.4) 
[n=3556]
0.9 (0.8-2.3) 
[n=1257]
37.7 (12.4-58.8) 
[n=227]
Physical examination [(SD) n]
Diastolic blood 
pressure in mm Hg
78.6 (9.6) 
[n=7325]
78.4 (9.3) 
[n=4888]
78.9 (9.8) 
[n=2151]
78.8 (11.2) 
[n=286]
Systolic blood 
pressure in mm Hg
142.6 (17.6) 
[n=7324]
143.8 (17.2) 
[n=4888]
139.5 (17.4) 
[n=2150]
145.2 (21.7) 
[n=286]
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Data analysis
CKD stage prevalences were calculated using the size of the registered population 
aged 18 years and over as the denominator. We used descriptive statistics to assess 
adherence to process and outcome indicators within 15 months prior to data 
extraction on March 1, 2011 and to evaluate FPs’ recognition of CKD. Because of the 
hierarchical structure of our study (patient nested within practice) the analyses were 
based on the multilevel logistic regression model (PROC GLIMMIX in SAS). In this 
model both fixed and random effects can be analyzed. We performed a model with 
a random intercept and all other variables were fixed. This model was used to identify 
patient and practice characteristics associated with high quality care. The type of General 
Practice Information System was considered as a confounder, since differences 
between the systems could affect the quality of recording of both the independent 
variables and the outcomes. We started with a full model including all independent 
variables and excluded statistically non-significant variables one by one in a backward 
procedure. We considered a P-value <0.05 statistically significant. Descriptive analysis 
was conducted using SPSS version 20.0 (IBM PASW statistics 20) and multilevel 
logistic regression analysis was conducted using SAS V9.2.
Quality of care
Table 3   Continued
Patient 
characteristic
Groups
Overall 
(n=8845)
Primary care 
(n=5709)
Consultation 
(n=2784)
Referral 
(n=352)
Medication prescribed in 2010
Renin angiotensin 
blockers 
55.9% 56.4% 53.7% 65.9%
B-blockers 46.4% 46.5% 45.4% 54.0%
Diuretics 41.6% 40.7% 41.9% 52.3%
Calcium antagonist 21.7% 21.4% 20.6% 34.1%
Statins 47.0% 48.8% 42.6% 51.7%
Vitamin D 3.9% 2.2% 6.1% 14.8%
Erythropoietin 0.3% 0.1% 0.5% 2.3%
Blood glucose 
lowering drugs
25.1% 27.3% 18.5% 40.6%
Antithrombotics 46.7% 48.3% 42.0% 57.9%
NSAIDs 21.3% 21.1% 22.2% 16.8%
‘primary care group’: treatment in primary care. ‘consultation group’: consultation of a nephrologist  
without referral. ‘referral group’: referral to secondary care. 
28
Ethical approval
Ethical approval was not required according to the accredited Medical Research 
Ethics Committee Arnhem/Nijmegen registration number 2010/187.
resulTs
Practice population
The 47 participating practices served a population of 207,469 people of whom 
162,562 were over 18 years of age. Data on renal function (n=60,143) or albuminuria 
(n=19,359) were present for 64,102 patients (31%). More data were available for 
elderly: 71% of the population over 65 years of age had a renal function assessment. 
Diabetes was recorded in 10,623 patients (6.5% of the population), hypertension in 
23,647 (14.5%) patients, and cardiovascular disease in 12,938 (8.0%) patients. 
Study population 
9295 patients met the criteria for CKD, resulting in a known prevalence of CKD in our 
study of 5.7%. K\DOQI stages 1–2 accounted for 1.05% (n=1712) and stages 3–5 for 
4.66% (n=7583). 450 patients did receive secondary renal care and were not further 
analyzed. Of note, 91.8% of these patients fulfilled the criteria for referral. In the cohort 
of 8845 CKD patients treated by their FP, the guideline recommended treatment in 
primary care in 64.5%, consultation of a nephrologist in 31.5% and referral in 4.0% of 
the patients. Table 3 provides detailed characteristics.
Process and outcome indicators 
FPs completely followed the guideline in 43% of their CKD patients for monitoring 
disease progression and in 2% for monitoring metabolic parameters in the 15 
preceding months. Blood pressure was below 140/90mmHg in 43.6% and below 
130/80mmHg in 16.5% of patients in whom a blood pressure measurement was 
available (n=6452). When we consider all patients, the achievement of blood pressure 
targets amounted 31.8% and 12.0% respectively. FPs recognized CKD in 31.7% by 
correctly using ICPC code U99.01. Table 2 provides further details on achievement of 
quality indicators.
Associated patient and practice characteristics
In the multilevel logistic regression analysis, a history of diabetes (OR 12.00; 95% CI 
10.66–13.52) or hypertension (OR 2.49; 95% CI 2.23–2.78), and male gender were 
associated with better monitoring of disease progression (Table 4a). A history of cardio - 
vascular disease was negatively correlated with monitoring of disease progression, 
as was urban practice location. Cardiovascular disease, duo practices and vocational 
training practices were positively associated with monitoring of metabolic parameters 
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(Table 4b). Younger age was negatively associated with monitoring of metabolic 
parameters. Factors associated with recognition of CKD were a history of cardio-
vascular disease, hypertension, female sex and age. Blood pressure outcome target 
<140/90mmHg was positively associated with a history of diabetes and cardiovascular 
disease, and had a negative correlation with age.
Quality of care
Table 4a   Significant results of multilevel logistic regression model on the 
association between patient- and practice-characteristics and QoC
Variable Monitoring disease progression
eGFR albumin 
urine
fasting 
glucose
blood 
pressure
complete
Patient characteristics
Age
18 - 45 0.39 
(0.29 - 0.54)
1.19 
(0.86 - 1.65)
0.58 
(0.42 - 0.81)
0.33 
(0.24 - 0.46)
45 - 60 0.58 
(0.49 - 0.68)
1.22 
(1.05 - 1.42) 
1.00 
(0.85 - 1.17)
0.62 
(0.53 - 0.73)
60 - 75 0.79 
(0.69 - 0.90)
1.26 
(1.13 - 1.40)
1.34 
(1.19 - 1.50)
0.90 
(0.80 - 1.02)
>= 75 
(reference)
Male sex 1.26 
(1.14 - 1.39)
1.26 
(1.13 - 1.40)
Diabetes 3.42
(2.94 - 3.97)
9.38
(8.39 - 10.49)
11.61 
(10.02 - 13.46)
5.08 
(4.42 - 5.84)
12.00 
(10.66 - 13.52)
Hypertension 1.91 
(1.70 - 2.14)
2.14 
(1.93 - 2.37)
2.69 
(2.42 - 2.99)
4.22 
(3.77 - 4.72)
2.49 
(2.23 - 2.78)
Cardiovascular 
disease
0.80 
(0.72 - 0.89)
0.82 
(0.74 - 0.92)
0.79 
(0.71 - 0.88)
Practice characteristics
Practice type
Solo
Duo
Group 
(reference)
Vocational 
training 
practice
Urban location 0.53 
(0.35 - 0.82)
0.47 
(0.26 - 0.84)
0.47 
(0.27 - 0.84)
Results are shown as odds ratios with 95% confidence intervals in parenthesis.
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Table 4b   Significant results of multilevel logistic regression model on the 
association between patient- and practice-characteristics and QoC
Variable Monitoring metabolic parameters Recognition Outcome variables
hemoglobin calcium phosphate PTH serum albumin potassium complete < 140/90 
mmHg
< 130/80 
mmHg
Patient characteristics
Age
18 - 45 0.41 
(0.27 - 0.62)
0.10 
(0.02 - 0.39)
0.06 
(0.01 - 0.47)
0.18 
(0.04 - 0.72)
0.22 
(0.13 - 0.35)
0.27 
(0.17 - 0.44)
1.72 
(1.14 - 2.58)
45 - 60 0.44 
(0.36 - 0.54)
0.33 
(0.24 -0.46)
0.32 
(0.22 - 0.47)
0.32 
(0.21 - 0.49)
0.50 
(0.41 - 0.63)
0.39 
(0.32 - 0.47)
2.03 
(1.72 - 2.40)
60 – 75 0.47 
(0.39 - 0.57)
0.55 
(0.42 - 0.71)
0.61 
(0.46 - 0.81)
0.55 
(0.39 - 0.76)
0.65 
(0.53 - 0.80)
0.68 
(0.61 - 0.77)
1.32 
(1.18 - 1.47)
>= 75 (reference)
Male sex 0.86
(0.78 - 0.96)
Diabetes 0.66 
(0.55 - 0.78)
1.64 
(1.36 - 1.98)
1.15 
(1.04 - 1.28)
1.18 
(1.02 - 1.35)
Hypertension 0.72 
(0.64 - 0.87)
2.72 
(2.31 - 3.19)
1.43
(1.28 - 1.60)
0.50 
(0.43 - 0.57)
Cardiovascular disease 1.28 
(1.08 - 1.52)
1.47 
(1.23 - 1.77
1.54
(1.38 - 1.72)
1.41 
(1.27 - 1.57)
1.69 
(1.47 - 1.93)
Practice characteristics
Practice type
Solo 0.91 
(0.51 - 1.62)
Duo 1.64 
(1.11 - 2.42)
Group (reference)
Vocational training 
practice
1.97 
(1.25 - 3.10)
Urban location
Results are shown as odds ratios with 95% confidence intervals in parenthesis. PTH and complete 
monitoring of metabolic parameters yielded too few results for the model to work.
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Table 4b   Significant results of multilevel logistic regression model on the 
association between patient- and practice-characteristics and QoC
Variable Monitoring metabolic parameters Recognition Outcome variables
hemoglobin calcium phosphate PTH serum albumin potassium complete < 140/90 
mmHg
< 130/80 
mmHg
Patient characteristics
Age
18 - 45 0.41 
(0.27 - 0.62)
0.10 
(0.02 - 0.39)
0.06 
(0.01 - 0.47)
0.18 
(0.04 - 0.72)
0.22 
(0.13 - 0.35)
0.27 
(0.17 - 0.44)
1.72 
(1.14 - 2.58)
45 - 60 0.44 
(0.36 - 0.54)
0.33 
(0.24 -0.46)
0.32 
(0.22 - 0.47)
0.32 
(0.21 - 0.49)
0.50 
(0.41 - 0.63)
0.39 
(0.32 - 0.47)
2.03 
(1.72 - 2.40)
60 – 75 0.47 
(0.39 - 0.57)
0.55 
(0.42 - 0.71)
0.61 
(0.46 - 0.81)
0.55 
(0.39 - 0.76)
0.65 
(0.53 - 0.80)
0.68 
(0.61 - 0.77)
1.32 
(1.18 - 1.47)
>= 75 (reference)
Male sex 0.86
(0.78 - 0.96)
Diabetes 0.66 
(0.55 - 0.78)
1.64 
(1.36 - 1.98)
1.15 
(1.04 - 1.28)
1.18 
(1.02 - 1.35)
Hypertension 0.72 
(0.64 - 0.87)
2.72 
(2.31 - 3.19)
1.43
(1.28 - 1.60)
0.50 
(0.43 - 0.57)
Cardiovascular disease 1.28 
(1.08 - 1.52)
1.47 
(1.23 - 1.77
1.54
(1.38 - 1.72)
1.41 
(1.27 - 1.57)
1.69 
(1.47 - 1.93)
Practice characteristics
Practice type
Solo 0.91 
(0.51 - 1.62)
Duo 1.64 
(1.11 - 2.42)
Group (reference)
Vocational training 
practice
1.97 
(1.25 - 3.10)
Urban location
Results are shown as odds ratios with 95% confidence intervals in parenthesis. PTH and complete 
monitoring of metabolic parameters yielded too few results for the model to work.
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Our results show important gaps in the QoC in all aspects of CKD management. 
Monitoring of disease progression (43%), monitoring of metabolic parameters (2%), 
and CKD recognition (32%) were suboptimal. Most clinical relevance lies in the 
achievement of blood pressure targets (44% <140/90mmHg), for which there was 
evident room for improvement. History of diabetes was strongly associated with high 
QoC. 
Recorded and expected prevalence and recognition 
In the Netherlands, the estimated community prevalence of CKD is 10.4%, with 5.1% 
in CKD stages 1-2, and 5.3% in stages 3-5.(36) For our data, this implies that 21% and 
88% of expected patients with K/DOQI stages 1-2 and 3-5 respectively could have 
been ascertained in primary care. Recorded CKD recognition was lower and 
amounted to 31.7% of potentially identifiable patients. Recognition is important, as it 
is associated with better quality of care.(37, 38) 
In CKD stages 1 and 2 we found a high QoC for monitoring of disease progression. 
We hypothesize that the high prevalence of diabetes in these patients (62%), and thus 
their enrolment in the disease management program for diabetes, is the key reason 
for their renal function and albuminuria assessments.(39) This suggests that 
embedding of CKD care in a disease management program, comparable to that for 
diabetes, could yield better QoC. Another contributing factor is that the Dutch 
diabetes guideline advises annual monitoring of renal function.(40)
Strengths and limitations
A key strength of our study is the utilization of routine family practice data, which 
provides a realistic view on current gaps in care. Our study represents a large 
proportion of the (potential) CKD population in primary care, as data on renal function 
were available for most patients over 65 years of age. To accurately report on the 
QoC in routine family practice, we focused on patients under care of their FP and 
excluded patients under secondary renal care. To our knowledge, this is the only 
study that incorporated all CKD stages and factored in the association of practice 
characteristics.
Several limitations should be considered. We applied the guideline classification 
based on single creatinine and albuminuria assessments whereas at least two and 
three measurements are advised.(41) This might have led to a less accurate 
classification of patients but the approach is in line with most other CKD studies. 
Quality of care might be underestimated due to analysis of data routinely recorded in 
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the electronic medical record. It is not unlikely that care was provided, but was not or 
incompletely registered. Furthermore, FPs had little time to implement the guideline 
within our studied timeframe (January 1,2010 to March 1,2011) considering the 
guideline’s introduction in November 2009.
Comparison with prior knowledge 
Our results on monitoring of disease progression are in line with previous studies. An 
American study found a comparable annual eGFR assessment rate (86%), and a 
slightly lower albuminuria testing rate (30%).(25) Their research was conducted within 
multi-specialty group practices, housing both FPs and nephrologists, and included 
patients with CKD stages 3-4. Also, impressive results are shown in primary care 
CKD management in the United Kingdom, where they recorded an 82% albuminuria 
testing rate in CKD stages 3-5.(5) This may be because in the UK a pay for performance 
system is in place for managing chronic diseases in primary care: the Quality and 
Outcomes Framework (QOF).(42) In the Netherlands, FPs are not given incentives to 
manage CKD, but for diabetes local financial incentives for optimal diabetes care 
exist.(43)
Outcomes on metabolic parameter monitoring were low in our study compared to 
others. The earlier mentioned American study reported two to threefold better 
monitoring of hemoglobin, calcium and PTH,(25) as did another study on phosphate 
and PTH monitoring in stages 3b-4 in a university based, outpatient primary care 
clinic.(27) The presence of nephrologists close to the FPs, and the academic setting 
respectively may account for these differences.
The overall level of CKD recognition is not exceptional in our study, as other studies 
report electronic documentation of CKD between 4-38%.(25, 26, 37, 44-48) However, 
results from the Quality and Outcomes Framework show that important improvements 
are possible, as their recorded recognition amounted to 72%.(42, 49, 50) Another 
factor that may contribute to suboptimal levels of CKD recognition is hesitation 
among FPs to identify and code early stage CKD. Interviews reveal professional 
concern about creating patient anxiety, particularly in older people and those with 
CKD stage 3A, in whom clinical benefit was deemed less certain.(51) 
Blood pressure targets were equally met in most other studies, as Italian research 
reports blood pressures <140/90mmHg in 45% of CKD patients; others report blood 
pressures <130/80mmHg between 13% and 54% depending on the included CKD 
stages.(37, 38, 52) The Quality and Outcomes Framework shows strong results with 
blood pressures <140/85mmHg in 72% of the CKD population.(5)
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Previous research shows that patient factors associated with high quality of care are 
concurrent diabetes, hypertension or coronary artery disease, age >75 years, and 
male sex.(25, 38, 46, 53) Patient factors associated with low QoC are female sex, 
being uninsured, and black race.(25) Our findings are in line with these previous 
findings, except that cardiovascular disease was negatively associated with monitoring 
of disease progression. Possibly, monitoring of these patients was left at the discretion 
of a cardiologist. 
Results derived from the Quality and Outcomes Framework in the UK show that 
vocational training practices, group practices and practices in less socially deprived 
areas were associated with a higher quality of care in general.(54, 55) We found a 
positive correlation between rural practice location and monitoring of disease 
progression, and between vocational training practice and monitoring of serum 
albumin.
Implications for practice and future research
The results of our study bring to light gaps in the quality of care in all aspects of CKD 
management, of which gaps in monitoring of albuminuria and metabolic parameters 
were most apparent. Of highest clinical relevance is the lack of reaching blood 
pressure targets and the lack of recognition. Comorbidity of diabetes appeared to be 
related with higher quality of care. This may well be because diabetes patients were 
treated in disease management programs. Possibilities to improve primary care CKD 
management could include the embedding of CKD care into a disease management 
program, comparable to diabetes.(56) This should not be a new single issue program, 
but should preferably be integrated in existing diabetes or cardiovascular programs 
to prevent fragmentation within primary care.(57) Feedback on laboratory results and 
FP education to increase CKD recognition can assist FPs to better identify CKD 
patients and subsequently provide a higher QoC.(37) Periodic reviewing of electronic 
medical records, with or without the support of nephrologists, could be a component 
of the disease management programs.(58) Introduction of a pay for performance 
system for CKD management has shown favorable results in the United Kingdom.
(42)
Female sex was associated with lower quality of care. This may be a reflection of the 
fact that the MDRD formula leads to an overrepresentation of CKD in females, and 
possibly FPs are aware of this.(59) The introduction of the CKD-EPI formula will partly 
correct this, but will need implementation in primary care to make FPs aware of that 
effect.(60)
35
2
This study uncovered significant gaps in QoC in CKD management. Quality improvement 
strategies should focus on better recognition, systematic monitoring of disease 
progression including albuminuria, and focus on blood pressure targets. 
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Appendix
Table 1   CKD management recommendations provided by the interdisciplinary 
CKD-guideline for primary care and nephrology
Annual monitoring of disease progression Annual monitoring of metabolic parameters
eGFR albumin  
urine
fasting  
glucose
blood  
pressure
hemoglobin calcium phosphate PTH serum albumin potassium
Patients ≥ 65 years
eGFR ≥ 60 and 
microalbuminuria
• • • •
eGFR 45 – 60 and 
normo- or micro-albuminuria
• • • •
eGFR 30 – 45 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR < 30 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR any and macroalbuminuria • • • • • • • • • •
Patients < 65 years
eGFR ≥ 60 and 
microalbuminuria
• • • •
eGFR 45 – 60 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR 30 – 45 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR < 30 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR any and macroalbuminuria • • • • • • • • • •
‘primary care group’: treatment in primary care. ‘consultation group’: consultation of a nephrologist without 
referral. ‘referral group’: referral to secondary care. eGFR in ml/min/1.73m2
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Table 1   CKD management recommendations provided by the interdisciplinary 
CKD-guideline for primary care and nephrology
Annual monitoring of disease progression Annual monitoring of metabolic parameters
eGFR albumin  
urine
fasting  
glucose
blood  
pressure
hemoglobin calcium phosphate PTH serum albumin potassium
Patients ≥ 65 years
eGFR ≥ 60 and 
microalbuminuria
• • • •
eGFR 45 – 60 and 
normo- or micro-albuminuria
• • • •
eGFR 30 – 45 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR < 30 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR any and macroalbuminuria • • • • • • • • • •
Patients < 65 years
eGFR ≥ 60 and 
microalbuminuria
• • • •
eGFR 45 – 60 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR 30 – 45 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR < 30 and 
normo- or micro-albuminuria
• • • • • • • • • •
eGFR any and macroalbuminuria • • • • • • • • • •
‘primary care group’: treatment in primary care. ‘consultation group’: consultation of a nephrologist without 
referral. ‘referral group’: referral to secondary care. eGFR in ml/min/1.73m2
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Table 2   Practice characteristics
Practice type N
Solo practice 6
Duo practice 16
Group practice 25
Vocational training practice 30
Rural location 15
General Practice Information System
Medicom 25
Micro-HIS 6
MIRA 6
Promedico ASP 8
Promedico VDF 2
Appendix
Table 3a   Classifi cation of included CDK patients with diabetes under care 
of their GP using the interdisciplinary CKD-guideline for primary care 
and nephrology
Albuminuria
Not known Normal Microalbuminuria Macroalbuminuria
Patients ≥ 65 years (n = 2.179)
eGFR ≥ 60 559 44
eGFR 45 – 60 149 673 253 30
eGFR 30 – 45 92 198 127 14
eGFR < 30 13 11 12 4
Patients < 65 years (n = 735)
eGFR ≥ 60 418 20
eGFR 45 – 60 55 177 32 9
eGFR 30 – 45 6 8 5 2
eGFR < 30 3 0 0 0
Classifi cation of patients based on renal function, albuminuria and age. ‘primary care group’: treatment in 
primary care. ‘consultation group’: consultation of a nephrologist without referral. ‘referral group’: referral to 
secondary care. eGFR in ml/min/1.73m2
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Table 3b   Classifi cation of included CKD patients without diabetes under care 
of their GP using the interdisciplinary CKD-guideline for primary care 
and nephrology
Albuminuria
Not known Normal Microalbuminuria Macroalbuminuria
Patients ≥ 65 years (n = 4.297)
eGFR ≥ 60 333 8
eGFR 45 – 60 1983 908 158 10
eGFR 30 – 45 540 216 64 9
eGFR < 30 57 6 3 2
Patients < 65 years (n = 1.634)
eGFR ≥ 60 275 9
eGFR 45 – 60 833 413 37 3
eGFR 30 – 45 38 12 3 0
eGFR < 30 8 1 1 1
Classifi cation of patients based on renal function, albuminuria and age. ‘primary care group’: treatment in 
primary care. ‘consultation group’: consultation of a nephrologist without referral. ‘referral group’: referral to 
secondary care. eGFR in ml/min/1.73m2
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Table 4a   Performance on process- and outcome indicators for CKD patients 
with diabetes, within 15 months prior to data extraction
Patient group N Monitoring of disease progression Monitoring of                                                          metabolic complications Recog-
nition
Blood pressure 
targets*
renal 
function
albu- 
minuria
Fasting 
glucose
blood 
pressure
complete hemo- 
globin
calcium phos-
phate
PTH serum 
albumin
potassium complete <140/90 
mmHg
<130/80 
mmHg
Primary care group
Age ≥ 65 eGFR ≥ 60 
and micro-albuminuria
559 526 499 539 520 473
(85%)
192
(37%)
71
(14%)
Age < 65 eGFR ≥ 60 
and micro-albuminuria
418 369 349 386 349 314
(75%)
166
(48%)
55
(16%)
Age ≥ 65 eGFR 45 – 60 1075 1013 858 1001 972 820
(76%)
334
(31%)
448
(46%)
200
(21%)
Total 
primary care
2052 1908
(93.0%)
1706
83.1%)
1926
(93.9%)
1841
(89.7%)
1607
(78.3%)
806
(43.8%)
326
(17.7%)
Consultation group
Age ≥ 65 
eGFR 30 – 44
417 376 278 350 348 273
(65%)
212 63 52 25 43 312 19
(5%)
259
(62%)
191
(55%)
89
(26%)
Age < 65 
eGFR 45 – 60
264 230 190 218 211 174
(66%)
77 15 11 3 8 175 2
(1%)
59
(22%)
104
(49%)
37
(18%)
Total consultation 681 606
(89.0%)
468
(68.7%)
568
(83.4%)
559
(82.1%)
447
(65.7%)
289
(42.4%)
78
(11.5%)
63
(9.3%)
28
(4.1%)
51
(7.5%)
487
(71.5%)
21
(3.1%)
318
(46.7%)
295
(52.8%)
126
(22.5%)
Referral group
Age ≥ 65 eGFR < 30 36 32 18 28 25 16
(44%)
23 8 4 3 4 28 1
(3%)
29
(81%)
10
(40%)
8
(32%)
Age < 65 eGFR 30 – 44 19 16 13 15 15 13
(68%)
11 7 6 1 3 16 1
(5%)
11
(58%)
8
(53%)
5
(33%)
Age < 65 eGFR < 30 3 2 0 1 2 0
(0%)
1 0 0 0 0 1 0
(0%)
1
(33%)
0
(0%)
0
(0%)
Macro-albuminuria 123 113 95 116 109 88
(72%)
48 13 7 3 8 97 1
(1%)
19**
(35%)
36
(33%)
15
(14%)
Total
 referral
181 163
(90.1%)
126
(69.6%)
160
(88.4%)
151
(83.4%)
117
(64.6%)
83
(45.9%)
28
(15.5%)
17
(9.4%)
7
(3.9%)
15
(8.3%)
142
(78.5%)
3
(1.7%)
60
(53.1%)
54
(35.8%)
28
(18.5%)
Total consultation and 
referral
862 769
(89.2%)
594
(68.9%)
728
(84.5%)
710
(82.4%)
564
(65.4%)
372
(43.2%)
106
(12.3%)
80
(9.3%)
35
(4.1%)
66
(7.7%)
629
(73.0%)
24
(2.8%)
378
(47.6%)
349
(49.2%)
154
(21.7%)
Total 2914 2677
(91.9%)
2300
(78.9%)
2654
(91.1%)
2551
(87.5%)
2171
(74.5%)
752
(40.2%)
1155
(45.3%)
480
(18.8%)
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care and 
nephrology. For each indicator, performance in the preceding 15 months is shown.
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Table 4a   Performance on process- and outcome indicators for CKD patients 
with diabetes, within 15 months prior to data extraction
Patient group N Monitoring of disease progression Monitoring of                                                          metabolic complications Recog-
nition
Blood pressure 
targets*
renal 
function
albu- 
minuria
Fasting 
glucose
blood 
pressure
complete hemo- 
globin
calcium phos-
phate
PTH serum 
albumin
potassium complete <140/90 
mmHg
<130/80 
mmHg
Primary care group
Age ≥ 65 eGFR ≥ 60 
and micro-albuminuria
559 526 499 539 520 473
(85%)
192
(37%)
71
(14%)
Age < 65 eGFR ≥ 60 
and micro-albuminuria
418 369 349 386 349 314
(75%)
166
(48%)
55
(16%)
Age ≥ 65 eGFR 45 – 60 1075 1013 858 1001 972 820
(76%)
334
(31%)
448
(46%)
200
(21%)
Total 
primary care
2052 1908
(93.0%)
1706
83.1%)
1926
(93.9%)
1841
(89.7%)
1607
(78.3%)
806
(43.8%)
326
(17.7%)
Consultation group
Age ≥ 65 
eGFR 30 – 44
417 376 278 350 348 273
(65%)
212 63 52 25 43 312 19
(5%)
259
(62%)
191
(55%)
89
(26%)
Age < 65 
eGFR 45 – 60
264 230 190 218 211 174
(66%)
77 15 11 3 8 175 2
(1%)
59
(22%)
104
(49%)
37
(18%)
Total consultation 681 606
(89.0%)
468
(68.7%)
568
(83.4%)
559
(82.1%)
447
(65.7%)
289
(42.4%)
78
(11.5%)
63
(9.3%)
28
(4.1%)
51
(7.5%)
487
(71.5%)
21
(3.1%)
318
(46.7%)
295
(52.8%)
126
(22.5%)
Referral group
Age ≥ 65 eGFR < 30 36 32 18 28 25 16
(44%)
23 8 4 3 4 28 1
(3%)
29
(81%)
10
(40%)
8
(32%)
Age < 65 eGFR 30 – 44 19 16 13 15 15 13
(68%)
11 7 6 1 3 16 1
(5%)
11
(58%)
8
(53%)
5
(33%)
Age < 65 eGFR < 30 3 2 0 1 2 0
(0%)
1 0 0 0 0 1 0
(0%)
1
(33%)
0
(0%)
0
(0%)
Macro-albuminuria 123 113 95 116 109 88
(72%)
48 13 7 3 8 97 1
(1%)
19**
(35%)
36
(33%)
15
(14%)
Total
 referral
181 163
(90.1%)
126
(69.6%)
160
(88.4%)
151
(83.4%)
117
(64.6%)
83
(45.9%)
28
(15.5%)
17
(9.4%)
7
(3.9%)
15
(8.3%)
142
(78.5%)
3
(1.7%)
60
(53.1%)
54
(35.8%)
28
(18.5%)
Total consultation and 
referral
862 769
(89.2%)
594
(68.9%)
728
(84.5%)
710
(82.4%)
564
(65.4%)
372
(43.2%)
106
(12.3%)
80
(9.3%)
35
(4.1%)
66
(7.7%)
629
(73.0%)
24
(2.8%)
378
(47.6%)
349
(49.2%)
154
(21.7%)
Total 2914 2677
(91.9%)
2300
(78.9%)
2654
(91.1%)
2551
(87.5%)
2171
(74.5%)
752
(40.2%)
1155
(45.3%)
480
(18.8%)
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care and 
nephrology. For each indicator, performance in the preceding 15 months is shown.
(Renal function: eGFR or serum creatinine; Albuminuria: albumin creatinine ratio or urine albumin). * 
the percentages show the achieved blood pressure targets divided by the number of blood pressure 
measurements. ** Percentage calculated with patients with eGFR < 60 ml/min/1.73m2 as denominator  
(n = 55).
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Table 4b   Performance on process- and outcome indicators for CKD patients 
without diabetes, within 15 months prior to data extraction
Patient group N Monitoring of disease progression Monitoring of                                                          metabolic complications Recog-
nition
Blood pressure 
targets*
renal 
function
albu-
minuria
Fasting 
glucose
blood 
pressure
complete hemo-
globin
calcium phos-
phate
PTH serum 
albumin
potassium complete <140/90 
mmHg
<130/80 
mmHg
Primary care group
Age ≥ 65 eGFR ≥ 60 
and micro-albuminuria
333 302 264 273 290 224
(67%)
87
(30%)
23
(8%)
Age < 65 eGFR ≥ 60 
and micro-albuminuria
275 224 207 198 196 153
(56%)
93
(47%)
30
(15%)
Age ≥ 65 eGFR 45 – 60 3049 2403 841 1623 2068 751
(25%)
753
(25%)
816
(39%)
285
(14%)
Total 
primary care
3657 2929
(80.1%)
1312
(35.9%)
2094
(57.3%)
2554
(69.8%)
1128
(30.8%)
996
(39.0%)
338
(13.2%)
Consultation group
Age ≥ 65 
eGFR 30 – 44
820 657 211 354 545 179
(22%)
487 129 106 50 78 564 33
(4%)
463
(56%)
243
(45%)
110
(20%)
Age < 65 
eGFR 45 – 60
1283 896 351 630 707 283
(22%)
546 78 62 29 39 638 17
(1%)
266
(21%)
371
(52%)
114
(16%)
Total consultation 2103 1553
(73.8%)
562
(26.7%)
984
(46.8%)
1252
(59.5%)
462
(22.0%)
1033
(49.1%)
207
(9.8%)
168
(8.0%)
79
(3.8%)
117
(5.6%)
1202
(57.2%)
50
(2.4%)
729
(34.7%)
614
(49.0%)
224
(17.9%)
Referral group
Age ≥ 65 eGFR < 30 66 53 6 20 34 5
(8%)
50 16 12 2 12 44 1
(2%)
38
(58%)
17
(50%)
12
(35%)
Age < 65 eGFR 30 – 44 53 37 5 24 28 5
(9%)
29 11 7 1 7 27 1
(2%)
24
(45%)
18
(64%)
6
(21%)
Age < 65 eGFR < 30 10 8 0 3 4 0
(0%)
8 3 2 0 3 6 0
(0%)
2
(20%)
4
(100%)
2
(50%)
Macro-albuminuria 42 32 26 29 29 20
(48%)
20 6 5 0 5 29 0
(0%)
13**
(59%)
8
(28%)
0
(0%)
Total
 referral
171 130
(76.0%)
37
(21.6%)
76
(44.4%)
95
(55.6%)
30
(17.5%)
107
(62.6%)
36
(21.1%)
26
(15.2%)
3
(1.8%)
27
(15.8%)
106
(62.0%)
2
(1.2%)
77
(51.0%)
47
(49.5%)
20
(21.1%)
Total consultation and 
referral
2274 1683
(74.0%)
599
(26.3%)
1060
(46.6%)
1347
(59.2%)
492
(21.6%)
1140
(50.1%)
243
(10.7%)
194
(8.5%)
82
(3.6%)
144
(6.3%)
1308
(57.5%)
52
(2.3%)
806
(35.8%)
661
(49.1%)
244
(18.1%)
Total 5931 4612
(77.8%)
1911
(32.2%)
3154
(53.2%)
3901
(65.8%)
1620
(27.3%)
1576
(29.7%)
1657
(42.5%)
582
(14.9%)
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care and 
nephrology. For each indicator, performance in the preceding 15 months is shown.
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Table 4b   Performance on process- and outcome indicators for CKD patients 
without diabetes, within 15 months prior to data extraction
Patient group N Monitoring of disease progression Monitoring of                                                          metabolic complications Recog-
nition
Blood pressure 
targets*
renal 
function
albu-
minuria
Fasting 
glucose
blood 
pressure
complete hemo-
globin
calcium phos-
phate
PTH serum 
albumin
potassium complete <140/90 
mmHg
<130/80 
mmHg
Primary care group
Age ≥ 65 eGFR ≥ 60 
and micro-albuminuria
333 302 264 273 290 224
(67%)
87
(30%)
23
(8%)
Age < 65 eGFR ≥ 60 
and micro-albuminuria
275 224 207 198 196 153
(56%)
93
(47%)
30
(15%)
Age ≥ 65 eGFR 45 – 60 3049 2403 841 1623 2068 751
(25%)
753
(25%)
816
(39%)
285
(14%)
Total 
primary care
3657 2929
(80.1%)
1312
(35.9%)
2094
(57.3%)
2554
(69.8%)
1128
(30.8%)
996
(39.0%)
338
(13.2%)
Consultation group
Age ≥ 65 
eGFR 30 – 44
820 657 211 354 545 179
(22%)
487 129 106 50 78 564 33
(4%)
463
(56%)
243
(45%)
110
(20%)
Age < 65 
eGFR 45 – 60
1283 896 351 630 707 283
(22%)
546 78 62 29 39 638 17
(1%)
266
(21%)
371
(52%)
114
(16%)
Total consultation 2103 1553
(73.8%)
562
(26.7%)
984
(46.8%)
1252
(59.5%)
462
(22.0%)
1033
(49.1%)
207
(9.8%)
168
(8.0%)
79
(3.8%)
117
(5.6%)
1202
(57.2%)
50
(2.4%)
729
(34.7%)
614
(49.0%)
224
(17.9%)
Referral group
Age ≥ 65 eGFR < 30 66 53 6 20 34 5
(8%)
50 16 12 2 12 44 1
(2%)
38
(58%)
17
(50%)
12
(35%)
Age < 65 eGFR 30 – 44 53 37 5 24 28 5
(9%)
29 11 7 1 7 27 1
(2%)
24
(45%)
18
(64%)
6
(21%)
Age < 65 eGFR < 30 10 8 0 3 4 0
(0%)
8 3 2 0 3 6 0
(0%)
2
(20%)
4
(100%)
2
(50%)
Macro-albuminuria 42 32 26 29 29 20
(48%)
20 6 5 0 5 29 0
(0%)
13**
(59%)
8
(28%)
0
(0%)
Total
 referral
171 130
(76.0%)
37
(21.6%)
76
(44.4%)
95
(55.6%)
30
(17.5%)
107
(62.6%)
36
(21.1%)
26
(15.2%)
3
(1.8%)
27
(15.8%)
106
(62.0%)
2
(1.2%)
77
(51.0%)
47
(49.5%)
20
(21.1%)
Total consultation and 
referral
2274 1683
(74.0%)
599
(26.3%)
1060
(46.6%)
1347
(59.2%)
492
(21.6%)
1140
(50.1%)
243
(10.7%)
194
(8.5%)
82
(3.6%)
144
(6.3%)
1308
(57.5%)
52
(2.3%)
806
(35.8%)
661
(49.1%)
244
(18.1%)
Total 5931 4612
(77.8%)
1911
(32.2%)
3154
(53.2%)
3901
(65.8%)
1620
(27.3%)
1576
(29.7%)
1657
(42.5%)
582
(14.9%)
Process- and outcome indicators are derived from the interdisciplinary CKD-guideline for primary care and 
nephrology. For each indicator, performance in the preceding 15 months is shown.
(Renal function: eGFR or serum creatinine; Albuminuria: albumin creatinine ratio or urine albumin). * 
the percentages show the achieved blood pressure targets divided by the number of blood pressure 
measurements. ** Percentage calculated with patients with eGFR < 60 ml/min/1.73m2 as denominator  
(n = 22).
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Background In chronic kidney disease (CKD), abnormalities of mineral metabolism 
can occur early in the disease process. Changes in calcium and phosphate homeo - 
stasis and secondary hyperparathyroidism are metabolic complications of CKD that 
impact cardiovascular health and bone turnover. Data on disturbances of mineral 
metabolism in CKD in primary care are limited. 
Aim To evaluate and find predictors of abnormalities in mineral metabolism in patients 
with CKD in primary care. 
Design and Setting Cross sectional study in nine primary care practices in the 
Netherlands 
Methods In patients with an eGFR < 60 ml/min/1.73 m2, identified during their 
evaluation for hypertension or diabetes mellitus, the prevalence of abnormal values 
of parathyroid hormone (PTH), calcium and phosphate was determined. Predictors 
of abnormal PTH levels were assessed.  
Results A total number of 174 patients in primary care were investigated. Mean eGFR 
was 50.3 ml/min/1.73 m2. An increase in PTH level above normal occurred in 40% 
of these patients with early stage of CKD in primary care. Although eGFR predicted 
abnormal PTH levels, its predictive value was low. Calcium and phosphate 
abnormalities were infrequent in this primary care population.  
Conclusion PTH testing deserves attention in patients with CKD in primary care. 
Prospective studies should clarify whether PTH lowering affects cardiovascular 
prognosis of these patients. Awaiting this evidence, we suggest to follow the K-DOQI 
guideline that advises PTH testing in patients with CKD stage 3 or worse and to treat 
patients with elevated PTH levels with vitamin D.     
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hOw This fiTs in 
Elevated PTH levels are related to cardiovascular morbidity and mortality, but data on 
mineral and bone metabolism in CKD patients under care of their general practitioner 
are scarce. PTH levels above normal were prevalent in 40% of patients with known 
chronic kidney disease in this primary care population. Since hyperparathyroidism is 
highly prevalent also in primary care, there is an urgent need to answer the question 
whether PTH-lowering will affect cardiovascular prognosis in this patient population. 
Awaiting this evidence, we suggest to follow the K-DOQI guideline that advises PTH 
testing in patients with CKD stage 3 or worse and to treat patients with persistent 
elevated PTH levels with vitamin D.     
       
inTrODuCTiOn
Chronic kidney disease (CKD) is a highly prevalent condition especially in patients 
with diabetes or hypertension.(1) In primary care, the awareness of CKD in these 
patients has increased due to regular testing of serum creatinine and albuminuria in 
patients with diabetes or hypertension and due to reporting of estimated glomerular 
filtration rate (eGFR). (2, 3) CKD is not only a risk factor for end stage renal disease, 
but may also lead to complications, among which are cardiovascular morbidity and 
mortality. (4) 
One of the complications of CKD is a change in calcium and phosphate homeostasis 
characterised by elevated serum intact parathyroid hormone (PTH) levels or abnormal 
values of calcium or phosphate. Abnormalities in these entities are considered part 
of the spectrum of CKD-Mineral and Bone disorder (CKD-MBD). A strong association 
has been established between PTH, calcium and phosphate abnormalities and 
increased risk of hypertension, CKD progression, adverse cardiovascular events, 
and mortality. (5, 6) This was also seen in CKD stage 3 and 4 where there was a 
significant increase in the prevalence of cardiovascular disease with increasing PTH 
levels.(7) Although controversy exists, prognosis of patients with secondary hyper-
parathyroidism can be improved by vitamin D treatment both in dialysis-patients and 
in non-dialysis-patients, which calls for early recognition of patients with CKD-MBD.
(5, 8, 9) 
International guidelines put emphasis on testing of metabolic disorders, but vary in 
defining the patients to be tested. The guidelines of the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (K-DOQI ) and the KDIGO guidelines 
recommend that all patients with eGFR below 60 ml/min/1.73 m2 undergo evaluation 
Disturbance of mineral metabolism
52
for CKD-MBD  by measuring PTH, calcium and phosphate.(10, 11) The NICE-guideline 
in the UK advices these measurements in patients with eGFR below 30 ml/min/1.73 
m2.(12) The Dutch interdisciplinary CKD-guideline advices evaluation in patients < 65 
year with eGFR < 60 and in patients ≥ 65 year with eGFR < 45 ml/min/1.73m2.(13) It 
is not clear which testing strategy is most effective in finding patients with elevated 
PTH. 
Data on the prevalence of metabolic disorders in primary care patients are limited. 
The few empirical data that are available, point to a limited uptake of MBD-assessment 
in primary care .(14, 15) Most data on metabolic disorders in CKD originate from 
patients referred to nephrologist care, indicating that PTH rises early in the course of 
CKD.(16-18) A better understanding of the actual prevalence and predictors of MBD 
in the CKD-population under care of general practitioners may enhance the uptake 
of testing  in primary care. 
The purpose of our cross sectional study was to evaluate the prevalence of disorders 
in PTH, calcium and phosphate in patients with CKD who are under control in primary 
care for their diabetes or hypertension. In addition, we analysed which factors 
predicted metabolic disorders in these patients. 
meThOD
Study design
In this cross-sectional study we described and analysed the data of patients with 
CKD in a primary care setting. These data are part of a cluster randomised controlled 
trial in which the effectiveness of a shared care model between general practitioner 
(GP), nurse physician and nephrologist will be compared with usual care in patients 
with diabetes mellitus type 2 and/or hypertension with CKD. 
We collected baseline data regarding demographic and clinical characteristics as 
mentioned in Table 3.  
Participants
The study took place in nine general practices that are part of the Academic 
Practice-based Research Network of the Radboud University Nijmegen Medical 
Centre in 2008.(19) These practices have a total of 54.231 patients. From the electronic 
patient files we selected all adult patients with hypertension and/or diabetes mellitus 
type 2 who were under care of the GP for their diabetes or hypertension treatment. 
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Patient were eligible if the yearly measurement of eGFR was below 60 ml/min/1.73 m2. 
The GPs could also include patients if eGFR below 60 ml/min/1.73 m2 was newly 
found at the annual diabetes or hypertension control. Patients with serious medical or 
psychiatric conditions and patients under specialist care for CKD were excluded. 
Eligible patients were invited to take part in the study when they visited the practice 
for a regular consultation. In the patients who agreed to participate, eGFR was 
measured again and if the result was found to be below 60 ml/min/1.73 m2 the patients 
were included in the study.  
Laboratory measurements
Samples for PTH-analysis were put on ice immediately after blood sampling and 
analysed within two hours. If this was not possible, samples were centrifuged for 10 
minutes at a minimum of 3000 rotations per minute and the serum was saved in a 
refrigerator until analysis. All clinical chemical analyses were performed by the 
Laboratory of Clinical Chemistry of the Canisius Wilhelmina Hospital in Nijmegen, the 
Netherlands. Creatinine, calcium, phosphate and PTH were measured on a routine 
chemistry analyzer (Roche Modular PE Analytics). PTH was measured with the 
Sandwich principle using an ECLIA technique (Elecsys PTH reagens, Roche). The 
normal value for PTH was < 6.9 pmol/l. Serum creatinine was measured enzymatically. 
Calibration was traceable to isotope dilution mass spectrometry. The eGFR was 
calculated from the Modification of Diet in Renal disease (MDRD) equation: 
eGFR=175x (serum creatinine (μmol/l) x0.0113) -1.154 x (age) -0.203 x (0.742 if female) x 
(1.210 if black).(20) Calcium levels were corrected for albumin levels. 
Albuminuria was defined as an albumin/creatinineratio ≥ 2.5 mg/mmol in male or 
≥ 3.5 mg/mmol in female patients. Blood pressure was measured three times after a 
five-minute rest with an oscillometric device. The mean of the two last measurements 
was used for the analysis.   
Statistical analysis
Statistical differences between the variables were calculated by Student’s t-tests for 
continuous outcomes and Chi-square tests for dichotomous outcomes using SAS 
version 9.2. For the application of the Student’s t-test Pooled standard error or 
Satterthwaite approximation were chosen based on the F-test for variances. Stepwise 
logistic regression was used to determine risk factors for abnormal PTH-levels. For 
this model variables were selected with a univariate p-value <0.15. 
We considered a p-value of less than 0.05 statistically significant.
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resulTs
Participants
4393 patients with diabetes and/or hypertension were under care of the GPs. Figure 1 
gives an overview of the inclusion process. When comparing the included group to 
the non-included group of patients with an eGFR below 60 ml/min/1.73 m2 no differences 
were found besides vitamin D treatment and heart failure (table 1). Relatively more male 
patients were included. Table 2. Shows the distribution of patients over CKD-stages. 
PTH
In 11 patients a PTH-analysis could not be performed due to practical barriers. Mean 
PTH-level was 7.2 (SD 3.7) pmol/L. An elevated PTH level (PTH ≥ 6.9 pmol/L) was found 
in 40.5% of the patients (Table 3). Patients with an elevated PTH level had a significantly 
lower eGFR than those with a normal PTH level (difference 4.5 ml/min/1.73 m2). 
Figure 1   Inclusion process
Patients with diabetes 
and/or hypertension 
under care of general 
practitoner (n=4393)
Patients with diabetes 
or hypertension and 
eGFR <60 ml/min/1.73 m2 
found by case finding 
(n=46)
Declined to 
participate (n=9)
Assessed for eligibility: 
File extraction: 
patients with diabetes or 
hypertension and 
eGFR <60 ml/min/1.73 m2 
(n=590)
• Not meeting inclusion criteria (n)
 - Comorbidity, 
  limited life expectancy:  n=86
 -  Under nephrologist care n=50
 -  Not speaking dutch language n  
 -  Involved in other trial n=  0
 -  More recent eGFR 
  ≥60 ml/min/1.73 m2 n=59
•  Patient did not visit the 
 practicepati»nt was not asked (n )
•  Patient declined to participate (n)
Invited for second eGFR 
measurement (n=181)
eGFR ≥60 ml/min/1.73 m2 after 
second measurement (n=7)
Included  (n=174)
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Variables that entered the equation for stepwise logistic regression modelling were 
eGFR, triglycerides, heart failure and diuretics as factors predicting abnormal PTH, 
with p-values in univariate analysis of 0.0004, 0.0008, 0.06 and 0.07 respectively. For 
diuretics the odds ratio was 2.7 (95% confidence interval 0.9 to 7.9); for heart failure 
the odds ratio was 4.7 (95% confidence interval 0.9 to 24.3). Age, sex, myocardial 
infarction, body mass index, blood pressure, fasting glucose, HbA1c, haemoglobin, 
LDL-cholesterol, HDL-cholesterol, potassium and urine albumine-creatinine ratio did 
not enter the equation because p-values in univariate analysis were >0.15. By 
stepwise logistic regression eGFR and triglycerides were identified as predicting 
abnormal PTH-levels (chi-square statistic 0.0012 and 0.0017). The Receiver Operating 
Characteristic curve of eGFR  predicting abnormal PTH was very flat and not of any 
help in defining eGFR cut-off values (appendix 1).  
We additionally performed stepwise linear regression to assess what factors contributed 
to the absolute level of PTH. eGFR, heart failure and triglycerides contributed (partial 
R-square 13.5%, 6.0% and 2.0% respectively). Use of diuretics showed multicollinearity 
with heart failure. 
Other metabolic disturbances
All serum calcium levels were above 2.1 mmol/l. Three subjects showed a calcium 
level ≥ 2.54 mmol/l. None of the subjects had an elevated phosphate level. 
Table 2   Distribution of patients over CKD-stages and prevalence of PTH-levels 
in these stages
Number (%), 
n=174
Number PTH 
known 
PTH  
<6.9 pmol/l, 
n=97*
PTH  
≥6.9 pmol/l, 
n=66*
Stage 3a 129 (74.1%) 123 83 (67.5 %) 40 (32.5%)
eGFR 45-60 ml/min/1.73 m2
Stage 3b  40 (23.0%) 36 14 (38.9%) 22 (61.1%)
eGFR 30-45 ml/min/1.73 m2
Stage 4   5 (2.9 %) 4 0    4 (100%)
15-30 ml/min/1.73 m2
Stage 5 - - -
<15 ml/min/1.73 m2
*patients with missing PTH levels are excluded
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DisCussiOn
 
In this observational study in primary care we found that serum PTH levels rose early 
in the disease process. Increased PTH values occurred in 40 % of the patients with eGFR 
below 60 ml/min/1.73 m2. In contrast, abnormal values of calcium and phosphorus 
were rare.  
Strengths and limitations 
This study made use of carefully defined diagnosis and laboratory results. The diagnosis 
of CKD was based on two evaluations of eGFR three or more months apart, whereas 
other studies in the general population only use one eGFR measurement on which to 
base diagnosis. One single laboratory performed the measurements and measurements 
were well-standardised. Furthermore we paid close attention to the pre-analytical handling 
of PTH samples. The laboratory assessment was performed within a few hours after 
sampling or blood was saved on ice.(21)  The study size is relatively small, but large 
enough to explore quality and quantity of metabolic disturbances in a group of CKD 
patients that is daily seen in primary care.  
We should consider some limitations of this study. First, our research was based on 
patients with diabetes or hypertension. We chose to focus on this group since the majority 
of patients under care for CKD in general practice will have diabetes or hypertension.
(11, 22) Second, the protocol of the Sharing study- that asked patients to come four 
times to the practice- may have caused a selection of patients. Table 1 however 
reveals that the included patients did not differ from the non-included patients with 
respect to co-morbidity. If there has been a selection, it would have been the relatively 
vital patients that were included. For interpretation of the results this would mean that 
prevalence of metabolic abnormalities is more likely to be higher lower than the results 
we found. Third, the K-DOQI guideline advises yearly measurement of serum bicarbonate 
to detect metabolic acidosis in patients with CKD. Bicarbonate measurement however 
was not possible yet in our primary care setting. Bicarbonate disorders are mainly 
observed in patients with eGFR < 30 ml/min/1.73 m2.(23) As 97% of our study 
population had an eGFR≥30 ml/min/1.73 m2, we presume that metabolic acidosis will 
not play a major role in our study population. 
Comparison with existing literature
We did not find other studies that evaluated the prevalence of disorders of mineral 
metabolism in known CKD patients in primary care only. The most comparable data 
derive from the prevalence of abnormalities in serum calcium, phosphate and PTH in 
a cross-sectional analysis of 1814 out-patient-clinic patients (71% primary care 
practices) with CKD stages 3–5 in North America.(24) Elevated PTH was present in 
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56% of patients with eGFR <60 ml/min/1.73m2, which is higher than the 40.5 % we 
found.  This can be explained by the fact that mean eGFR in the US study was 40 ml/
min/1.73 m2, clearly below the mean of 50 ml/min/1.73 m2 in our study. A difference in 
race could also have been of influence; we will comment on that further in the 
discussion. In line with our data, calcium and phosphate values did not become 
abnormal until eGFR fell below 40 ml/min per 1.73m2. In a community-based screening 
program -the Kidney Early Evaluation Program (KEEP)- and in epidemiological data 
from the National Health and Nutrition Examination Survey, Vasalotti et al found that 
as eGFR fell from 60 to 30 ml/min/1.73 m2, calcium level decreased, phosphate level 
increased, and PTH level increased.(25) In summary, the evidence available points to 
a rise of PTH in early stages of CKD and our study confirms that this is the case in 
CKD patients with diabetes of hypertension in general practice. 
Secondary hyperparathyroidism can be caused by a lack of renal activation of 25-
hydroxyvitamin D3 to 1,25-dihydroxyvitaminD3 but could -especially in elderly patients- 
as well be caused by a lack in inactive vitamin D. As laboratory results on vitamin D 
levels were not available, we cannot comment on that aspect. 
Race may be of influence on secondary hyperparathyroidism. In blacks secondary 
hyperparathyroidism was more prevalent than in whites.(26) We were not informed on 
the race of patients in our study, but know that the population in the research practices 
is mainly (>95%) Caucasian. 
Predicting factors
In our study, eGFR and triglycerides predicted abnormal PTH levels and heart failure 
contributed to the absolute PTH-height. The relation of elevated PTH with eGFR and 
heart failure is in line with findings in other studies. Cardiovascular disease, age, BMI 
≥30, albuminuria and absence of diabetes were predicting factors in the community 
based study of Vassalotti et al. (25) De Boer et al. found in 218 outpatient nephrology 
patients that PTH was associated with eGFR and with a history of congestive heart 
failure and myocardial infarction.(27) The relation of triglycerides to elevated PTH was 
not found in other studies. In our study the overall contribution was very low and 
probably not of any clinical significance. Based on our results, we cannot define a 
PTH-testing strategy. Applications of the PTH-testing advices of the guidelines 
available (appendix 2) revealed that the K-DOQI and KDIGO guidelines best enable 
finding patients with secondary hyperparathyroidism. 
Other metabolic disturbances
Further metabolic disturbances were found in a cross sectional study in veterans 
(>65 years) with mean eGFR of 47 ml/min/1.73m2. 2.5% of participants had hyper - 
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kalemia and 4.4% had hyperphosphatemia. PTH was not tested.(28) Hyperphosphatemia 
was not found in our study. This could be due to the small number of patients tested 
and the fact that mean eGFR was relatively high.  
Implications for research and practice
As PTH is related with adverse outcomes in CKD, and the prevalence of abnormal 
PTH in early stages of CKD is high, PTH-testing in primary care deserves more 
attention. The effectiveness of vitamin D in lowering PTH levels has been proved and 
the effects on prognosis were positive as well in dialysis as in non-dialysis patients.
(5, 9, 29) The K-DOQI-guideline advises correction of MBD-abnormalities by native 
vitamin D amongst other therapies. In patients in whom serum PTH is rising and 
remains above the upper limit of normal for the assay despite correction of modifiable 
factors, treatment with calcitriol or vitamin D analogs is suggested by the KDIGO 
guideline.(11) However, convincing evidence that adverse cardiovascular outcome 
could be prevented or delayed by early detection and treatment of elevated PTH is 
not available yet.(8, 30) In primary care, PTH may prove to be a useful additive risk 
factor in identifying CKD patients who have a higher cardiovascular risk. 
Given the frequency of elevated serum-PTH in a primary care population that comes 
forward in this study there is a need for further research on the effects of PTH lowering 
in primary care on cardiovascular morbidity and mortality.  Awaiting this evidence, 
general practitioners may consider to check PTH-levels in patients with CKD stage 3 
or worse and prescribe vitamin D in patients with elevated PTH levels. 
Acknowledgements
Marjan Schoneveld and Wouter Koop of the laboratory of the Canisius Wilhelmina Hospital 
Nijmegen were very helpful in organising the laboratory tests. 
We would like to thank the participating patients, the general practitioners and assistants 
of the NMP-practices.
61
3
referenCes
1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney 
disease in the United States. JAMA. 2007;298(17):2038-47.
2. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management 
of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J 
Hum Hypertens. 2004;18(3):139-85. Epub 2004/02/20.
3. Hemmelgarn BR, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P, et al. Nephrology visits and 
health care resource use before and after reporting estimated glomerular filtration rate. JAMA. 
2010;303(12):1151-8.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of 
estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in 
general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. Epub 
2010/05/21.
5. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, et al. Changes in serum calcium, 
phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 
2006;70(2):351-7.
6. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, et al. Plasma parathyroid 
hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119(21):2765-71. 
Epub 2009/05/20.
7. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL. Plasma parathyroid hormone level and prevalent 
cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program 
(KEEP). AmJKidney Dis. 2009;53(4 Suppl 4):S3-10.
8. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for 
people with chronic kidney disease not requiring dialysis. CochraneDatabaseSystRev. 2009(4):CD008175.
9. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with 
improved survival in nondialyzed CKD. Journal of the American Society of Nephrology : JASN. 2008; 
19(8):1613-9. Epub 2008/05/09.
10. National Kidney Foudation. K/DOQI Guidelines[internet]. New York; 2002 [accessed 2008]. Available 
from http://www.kidney.org/professionals/KDOQI/guidelines_commentaries.cfm
11. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic 
Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney IntSuppl. 2009(113):S1-130.
12. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults 
in Primary and Secondary CareNational Collaborating Centre for Chronic Conditions. London: Royal 
College of Physicians; 2008. http://www.nice.org.uk accessed 11 June 2012
13. Grauw de W, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S, Gaillard C, et al. Landelijke Transmurale 
Afspraak Chronische nierschade. Huisarts en Wetenschap. 2009;52(12):586-7.
14. Philipneri MD, Rocca Rey LA, Schnitzler MA, Abbott KC, Brennan DC, Takemoto SK, et al. Delivery 
patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based 
analysis and systematic literature review. Clin Exp Nephrol. 2008;12(1):41-52. Epub 2008/01/05.
15. Bhan I, Dubey A, Wolf M. Diagnosis and management of mineral metabolism in CKD. J Gen Intern 
Med. 2010;25(7):710-6. Epub 2010/03/31.
16. Martinez-Castelao A, Gorriz JL, Portoles JM, De Alvaro F, Cases A, Luno J, et al. Baseline characteris-
tics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational 
cohort study. BMC nephrology. 2011;12:53. Epub 2011/10/06.
17. Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJ. eGFR and creatinine clearance in relation to 
metabolic changes in an unselected patient population. EurJInternMed. 2009;20(7):722-7.
18. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al. Chronic Renal Insufficiency Cohort (CRIC) 
Study: baseline characteristics and associations with kidney function. Clinical journal of the American 
Society of Nephrology : CJASN. 2009;4(8):1302-11. Epub 2009/06/23.
19. van Weel C. Longitudinal research and data collection in primary care. AnnFamMed. 2005;3 Suppl 
1:S46-51.:S46-S51.
Disturbance of mineral metabolism
62
20. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of 
Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum 
creatinine values. Clinical chemistry. 2007;53(4):766-72. Epub 2007/03/03.
21. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 
2010;77(2):93-100.
22. Stevens PE, O’Donoghue DJ, de LS, Van VJ, Klebe B, Middleton R, et al. Chronic kidney disease 
management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72(1):92-9.
23. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J. Prevalence of acidosis and inflammation and 
their association with low serum albumin in chronic kidney disease. Kidney Int. 2004;65(3):1031-40.
24. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum 
vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study 
to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8.
25. Vassalotti JA, Uribarri J, Chen SC, Li S, Wang C, Collins AJ, et al. Trends in mineral metabolism: Kidney 
Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 
1999-2004. AmJKidney Dis. 2008;51(4 Suppl 2):S56-S68.
26. Gutierrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin 
D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination 
Survey. Osteoporosis international : a journal established as result of cooperation between the 
European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 
2011;22(6):1745-53. Epub 2010/09/18.
27. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathy-
roidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with 
cardiovascular disease. Journal of the American Society of Nephrology : JASN. 2002;13(11):2762-9. 
Epub 2002/10/25.
28. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney 
disease. Journal of the American Geriatrics Society. 2012;60(2):310-5. Epub 2012/01/31.
29. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D 
treatment and mortality in chronic kidney disease. ArchInternMed. 2008;168(4):397-403.
30. Brosnahan G, Fraer M. Management of chronic kidney disease: what is the evidence? SouthMedJ. 
2010;103(3):222-30.
63
3
Disturbance of mineral metabolism
Appendix 1   Receiver Operating Characteristic curve of eGFR MDRD predicting 
PTH-levels
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absTraCT
Background: Chronic kidney disease (CKD) is highly prevalent in patients with 
diabetes or hypertension in primary care. A shared care model between general 
practitioner, nurse practitioner and nephrologist could improve quality of care in 
these patients. 
Aim: to assess the effect of a shared care model in managing CKD-patients with 
diabetes or hypertension 
Design: A cluster randomised controlled trial
Setting: Nine general practices in the Netherlands
Method: Five practices were allocated to the shared care model and four to usual 
care during one year. Primary outcome was the achievement of blood pressure(BP)-
targets (130/80mmHg) and lowering of BP in patients with diabetes mellitus or 
hypertension and estimated Glomerular Filtration Rate(eGFR)<60ml/min/1.73 m2. 
Secondary outcome measures: laboratory variables, use of lipid lowering drugs or 
renin-angiotensin system inhibitors, smoking and functional health status.
Results: 99 intervention and 75 control patients were included. Data of 90 intervention 
and 74 control patients could be analysed. BP after one year was 134.7/73.8mmHg in 
the intervention and 142.9/80.9mmHg in the control group (difference systolic:8.2 
mmHg, 95%CI 3.6to12.9; diastolic:4.7mmHg, 95%CI 1.1to8.4). The proportion of 
patients that achieved systolic and diastolic BP-targets was 44%/71% in the 
intervention group versus 22%/50% in the control group. BP in the intervention group 
decreased with 8.1(95%CI 4.8to 11.3) /1.1(95%CI -1.0to3.2)mmHg compared to 
-0.2(95%CI -3.8to3.6)/-0.5(95%CI-2.9to1.8) mmHg in the control group. Use of lipid 
lowering drugs, angiotensine-system inhibitors and vitamin D was higher in the 
intervention group. Parathyroid hormone was lower in the intervention group. Other 
laboratory variables, functional health status and smoking did not differ. 
Conclusion: A shared care model between general practitioner, nurse practitioner 
and nephrologist is beneficial in reducing BP in CKD-patients in primary care. 
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inTrODuCTiOn
The high and rising prevalence of Chronic Kidney Disease (CKD), amounting to 13% 
in the general population in the USA and 7% in primary care in the UK, places a 
burden on health care facilities.(1, 2) Among the risk factors contributing to CKD, 
diabetes and hypertension are the most common.(3) CKD can progress to end stage 
renal disease. The awareness of CKD is predominantly fostered by the recognition 
that CKD is an important risk predictor for coronary events and cardiovascular 
mortality.(4, 5) Timely intervention, directed at cardiovascular risk factors, can 
decrease the loss of renal function and the incidence of cardiovascular disease.(6-8) 
Guidelines provide recommendations for treatment of CKD.(9, 10) However, treatment 
targets are often not met.(11-13)
There is a significant evidence gap in how to best organise the care for CKD-patients.
(14) A multidisciplinary approach has been proposed.(15) Shared care between 
primary and secondary care has been successful in other chronic conditions.(16) 
Observational studies on shared care for patients with CKD show promising results.
(17) However, the effectiveness of shared care for CKD-patients has not yet been 
proved in randomised trials.(18) 
We developed a shared care model for CKD-patients in primary care in which the 
nurse practitioner (NP) played a central role and a nephrologist and a nephrology 
nurse could be consulted. In a cluster randomised controlled trial we tested whether 
the model led to improved quality of care in patients with CKD and diabetes or 
hypertension. Lowering of blood pressure (BP) was the primary outcome.
meThOD
 
Setting
The study concerned nine general practices (54,231 patients) that are part of the 
Academic Practice-based Research Network of the Radboud University Nijmegen 
Medical Centre.(19) Usual care for diabetic and hypertensive patients in these 
practices is given in a structured setting with the help of NPs. Patients with diabetes 
or hypertension are seen every three months. Once a year an extensive control 
including renal function monitoring is performed according to the national evidence 
based practice guidelines.(20, 21) BP-measurements are performed according to a 
BP-measurement protocol, which requires a rest period and noting the mean of two 
BP-measurements.
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We included adult patients (>18 years old) who were treated for hypertension or 
diabetes mellitus type 2 by their general practitioner(GP) and had an estimated 
glomerular filtration rate(eGFR) measurement<60ml/min/1.73 m2(MDRD formula). 
We informed the GPs which patients lacked the annual information on renal function, 
so the GPs could have them tested and include them if an eGFR below 60 ml/min/1.73 
m2 was newly found. Exclusion criteria were serious medical or psychiatric conditions, 
drug or alcohol abuse, specialist CKD-care in the last year, inability to understand 
Dutch language (including cognitive disorders) and participation in another 
intervention trial. Eligible patients were invited to take part in the study when they 
visited the practice for a regular consultation until a minimum of 20 and a maximum 
of 28 patients per practice were included. Patients were included if they had given 
written informed consent and if a second eGFR-measurement was still below 60 ml/
min/1.73 m2.
Randomisation was carried out at the level of general practices because the 
intervention involved changes to the practice organisation. Practices were stratified 
by the mean BP of all eligible patients and then randomly allocated to intervention or 
control group. In the control practices patients were  identified and included at the 
start of the study. To avoid bias by study inclusion, patients were asked to give written 
informed consent only at the time of the final measurement at the end of the trial, and 
their GPs and NPs were informed at that occasion. 
To show a clinically relevant difference in the decline of BP of 5mmHg (standard 
deviation of BP difference 10mmHg, alpha=0.05  beta= 0.20 and intra-cluster 
correlation coefficient (ICC) 0.03) the study was powered to contain nine practices 
with 25 patients per practice.  
Intervention 
The multifaceted intervention consisted of training of professionals, structured care 
by NPs and the opportunity to ask advice from a nephrology team. In Spring 2008 
NPs and GPs of intervention practices were trained by a nephrology team. 
BP-measurement and treatment, proteinuria, cholesterol lowering, blood glucose 
management and lifestyle advice were the main issues. A protocol, based on the K/
DOQI guideline, was provided with treatment goals (Table 2) and treatment advice.
(10) During the following intervention year, NPs received two extra training sessions 
on treatment of hyperparathyreoidism and anaemia. The NP saw patients every three 
months for a 20-minute consultation, in which BP-treatment was the main aim. Patient 
and NP decided together which other treatment goals were to be prioritised. GPs 
supervised the consultation afterwards. GPs and NPs could, if necessary, consult a 
nephrology team in a protected digital environment.(22)
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Outcome
Reduction in BP was the primary outcome, defined as the difference between the 
usual BP- measurement at baseline and the study BP-measurement after one year. 
At the end of the trial, BP and the number of patients meeting the BP-
target(130/80mmHg) were compared between control- and intervention group. Other 
quality of care variables were kidney disease measures (as mentioned in table 2) and 
the number of patients that reached the treatment goals. Additionally, functional 
status and use of angiotensin system inhibitors and lipid modifying agents were 
measured. The number of consultations with the nephrologist and the number of 
referrals were described. 
At baseline, the NP collected data in the intervention group (as mentioned in table 2). 
After one year the same measurements were performed in patients in both intervention 
and control practices. Study BP was measured with an oscillometric device (Stabil-O-
Graph). After a five-minute rest, three measurements were taken with  the patient in a sitting 
position. The mean of the last two measurements was used for analysis. In patients 
with atrial fibrillation BP was measured manually with a sphygmanometer. The latest 
noted usual BP-measurement before inclusion was used as the baseline value for BP. 
Clinical chemical analyses were performed by the laboratory of the Canisius 
Wilhelmina Hospital in Nijmegen, the Netherlands. Creatinine, calcium, phosphate 
and PTH were measured by a Roche Modular analyser. Blood samples for PTH 
analysis were put on ice immediately after blood sampling and analysed within two 
hours. If this was not possible, samples were centrifuged and saved in a refrigerator 
until analysis. Serum creatinine was measured enzymatically with calibration 
traceable to the international standard (IDMS) reference material. The eGFR was 
calculated from the MDRD-equation.(23) Calcium levels were corrected for albumin 
levels. Haemoglobin was measured on a Sysmex XE-2100 instrument. Albuminuria 
was defined as an albumin/creatinineratio ≥ 2.5 mg/mmol in male or ≥ 3.5 mg/mmol 
in female patients. 
COOP Wonca Charts were used to obtain additional information about the patient’s 
functional capacity.(24) 
Statistical analysis
Descriptive analyses were used to describe the characteristics of the patients in both 
groups. Because of the hierarchical structure of the study (patient nested within 
practices) multilevel analyses were performed for between group and within group 
differences. These analyses took account of the variability associated with each level 
of nesting. A random intercept model with other variables fixed was used. For dichotomous 
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variables we performed a multilevel logistic model. BP comparison between intervention 
and control group  was analysed by analysis of covariance with the follow up BP 
measurement as an outcome and the baseline BP measurement (last noted BP in the 
patient file) as a covariate.(25) 
The ICC was calculated from pre-intervention BP-data from both intervention and 
control group.SAS® Proprietary Software 9·2 (SAS Institute Inc., Cary, NC, USA) was 
used for all analyses and multilevel analyses were performed with PROC MIXED for 
continuous outcomes and PROC  GLIMMIX for dichotomous variables.
resulTs
Figure 1 shows a flow-chart of participating practices and patients. Five intervention 
practices included 16, 12, 20, 23 and 28 patients respectively. Four control practices 
included 6, 23, 19 and 27 patients. Nine patients from four practices in the intervention 
group did not finish the trial. Two of them died (of lung carcinoma and heart failure), 
three patients stopped because their general condition worsened, four because they 
did not want to come for extra control visits any more. One patient in the control group 
was excluded from the analysis because of extreme BP-values, that were considered 
as invalid measurements (270/170mmHg). Usual systolic BP at baseline did not 
differ between intervention and control group, whereas diastolic BP was lower in the 
intervention group (table 1). 
BP after 1 year was lower in the intervention group than in the control group: systolic 
BP was 8.2(95%CI:3.6 to 12.9) mmHg lower, diastolic BP was 4.7(95%CI:1.1 to 8.4)
mmHg lower. The number of patients that reached the treatment goal for systolic BP 
in the intervention group (44.4%) was higher than in the control group (21.6%)(OR 2.9 
(95%CI 1.4 to 5.8; p=0.003). For diastolic BP these percentages were 71.1% and 
50.0% respectively(OR 2.5; 95%CI 1.3 to 4.7; p=0.007)(table 2). The decrease in 
systolic BP in the intervention group was 8.1 (95% CI 4.8 to 11.3) mHg compared to 
-0.2(95% CI -3.8 to 3.6)mmHg in the control group (table 2). The decrease in diastolic 
BP did not differ between intervention and control group. The ICC was 0.11 for systolic 
BP and 0.15 for diastolic BP. Patients in the intervention group received more renin-
angiotensin system inhibitors, lipid lowering drugs and vitamin D than patients in the 
control group. Laboratory values did not differ between intervention and control 
group, besides PTH, which was lower in the intervention group (table 2). 
During the intervention cholesterol and LDL-levels decreased in the intervention 
group, parallel with an increase in the use of lipid lowering drugs (appendix 2). 
73
4
In 31 patients in the intervention group 50 consultations were performed between GP 
and nephrologist. None of these 50 consultations resulted in a referral. In the intervention 
group two patients were referred to a nephrologist. In the control group one patient 
was referred. 
Shared care in nephrology and general practice
Figure 1   Flow chart of participating practices and patients
5 intervention practices, 30.898 patients
Patients with diabetes or hypertension under 
treatment in primary care with eGFR 
<60ml/min/1.73m2: n=354
Excluded: n=81 (comorbidity, limited life 
expectancy n=52, under nephrologist care n=28, 
not speaking Dutch language n=1) 
Eligible patients n=273 
Did not visit the practice/not asked n=5 
Not asked because practice included max 
nr of patients n=78
Recruited n=190 (69.9% of eligible patients)
Agreed to participate n=105, (55.3% of recruited 
patients)
Second eGFR >=60ml/min/1.73m2: n=6
Baseline measurement: n=99
4 control practices, 23.333 patients
Patients with diabetes or hypertension 
under treatment in primary care with eGFR 
<60ml/min/1.73m2: n=223
Excluded: n=62 (comorbidity, limited life 
expectancy n=34, under nephrologist care 
n=22, not speaking Dutch language n=6)
Eligible patients n=161
Did not visit the practice/not asked n=8 
Recruited n=153 (95% of eligible patients)
Agreed to participate n=76 (49.7% of 
recruited patients) second eGFR 
>=60ml/min/1.73m2n=1
Lost to follow-up: died n=2, refused to continue n=7
Final measurement: n=90 Final measurement: n=75
Analysed: n=90 Excluded for analysis because BP270/170: n=1
Analysed: n=74
Randomised:
9 practices
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Table 1   Patient characteristics at baseline, derived from the electronic patient 
record
Control group Intervention group
Sex(N), male (%) 39 (52.7) 34 (37.8)
Age (year) 72.4 (8.2) 73.9 (8.0)
Creatinine (μmol/l) 117.6(21.2) 109.0(24.9)
eGFR (ml/min/1.73 m2) 50.0 (6.7) 49.1( 7.9)
Systolic usual office BP (mmHg)1 142.5(15.1) 142.7 (17.6)
Diastolic usual office BP (mmHg)1 80.4 (8.2) 74.9 (9.2)
Diabetes 35.1% 37.8 %
Hypertension 93.2 % 90.0 %
Myocardial infarction  5.4  % 13.3 %
Heart failure  4.1 %  5.6 %
TIA  8.1 %  6.7 %
CVA  8.1 % 11.1 %
PAD  6.7 % 14.4 %
Co-morbidity is based on ICPC coding in the problem list in the electronic patient record. eGFR 
=estimated Glomerular Filtration Rate. TIA=Transient Ischaemic Attack; CVA=cerebrovascular accident;  
PAD=peripheral artery disease. Values are given as mean and standard deviation or number (percentage).
1 In one patient in the control group a usual blood pressure at baseline could not be found in the 
electronic patient file
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DisCussiOn
Summary
The shared care model for patients with CKD and diabetes or hypertension lead to a 
significant BP-lowering in the intervention group compared to the control group and 
a better achievement of BP-targets along with increased use of renin-angiotensin 
system inhibitors. The intervention also lead to lower PTH-levels along with an 
increased use of vitamin D and to an increased use of lipid lowering drugs. Although 
LDL-cholesterol decreased in the intervention group, LDL-levels at the end of the 
study did not differ between intervention and control group. 
It is promising that BP-targets were better met in the shared care practices, because 
a lower BP is associated with better patient outcome.(6) Hypertension management 
is generally recognised as a primary care task, but BP-management in CKD-patients 
in primary care is not as effective as it is in nephrology.(26) Underlying factors are that 
the GP-confidence in treating CKD is lower than in treating diabetes and hypertension 
and that BP-targets in CKD are often regarded with scepticism.(27, 28) A discussion 
is ongoing on optimal BP-targets.(29) Systolic BP below 120mmHg is associated with 
stroke and diastolic BP below 60mmHg is associated with increased mortality in frail 
elderly.(30, 31) Nephrologists could be of help in the titration of antihypertensive 
agents. 
Albuminuria did not change during our study.  This was due to the fact that albuminuria 
treatment goals were already highly met at baseline. In a sub analysis we did not find 
albuminuria differences between  diabetes and non-diabetes patients. 
Strengths and limitations
A strength of the study is that it used a cluster randomised trial design. Usual care for 
diabetes and hypertension patients in the practices was already well organised, 
which makes the additive value of the shared care model robust. Baseline BP-values 
were at a relatively low level. In practices with less favourable baseline BP-levels, it 
may be possible to see even more improvement. We reduced potential bias in the 
usual care group by informing these patients, GPs and NPs at the end of the trial. The 
setting in research practices enabled retrospective collection of usual BP-measure-
ments to serve as baseline measurements for the control group. A further strength is 
that, before entry, participants had two consecutive measurements of eGFR < 60 ml/
min/1.73 m2 to confirm CKD-diagnosis.
Several limitations need to be mentioned. We followed a pragmatic recruitment 
procedure: when the maximum number of patients in one cluster was reached, we 
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stopped the inclusion in that practice. It may have caused a selection of relatively 
well-off patients who neatly obeyed to the control visits. On the other side, not all 
practices reached the required minimum of 20 patients. As a second limitation we 
should mention that we had to rely on usual BP-measurements to serve as baseline 
values. It is well known that usual BP-measurements lead to higher results than BP-
measurements in a study-setting.(32) The fact that the usual BP-measurement in the 
control group did not differ from the study-BP at the end of the study reduces the 
concerns about comparability of usual and study BP-measurements in this trial. A 
third limitation is a potential selection bias because in the control group patients were 
asked informed consent one year after randomisation of their practice took place. 
However, they were identified at the beginning of the trial. A further point is about 
generalisability. One should realise that our population was mainly Caucasian, so our 
study results are not representative of a population with a greater proportion of 
non-Caucasian patients, who may have different BP outcomes. A final limitation is 
that cost-effectiveness was not evaluated in this trial and will require future study. 
 
Comparison with existing literature
The effect of structured care by nurses was assessed in an observational study of 
Richards et al.(33) CKD-patients were enrolled in a disease management program. 
BP decreased with 9/5mmHg, but only in patients without diabetes or proteinuria. In 
secondary care, several studies have been performed on the role of nurses in the 
management of CKD-patients, with varying success. A study on elderly patients 
referred to a multidisciplinary care clinic with a nephrologist and a specialized nurse 
showed a 50% reduction of the risk for all cause mortality in an observational study.
(34) In a comparison between additional intensive NP support and nephrologist care 
BP-decrease in the intervention group was 3/2mmHg more (p<0.001) than in the 
control group.(35) However, in a randomised trial where patients were randomly 
assigned to a nurse-coordinated team in secondary care or to usual care in general 
practice, no effect on cardiovascular risk factor control or on clinical end points was 
found.(36) 
The opportunity to ask advice from a nephrologist has been studied in a shared care 
system in the United Kingdom.(17) Patients were treated in primary care sustained by 
continuous feedback by nephrologists on the laboratory and BP-results. BP decreased 
and prescribing of renin-angiotensin system inhibitors increased. 
In summary, the existing literature endorses our findings that structuring care for 
CKD-patients is beneficial in reducing BP. However, study designs were mainly 
observational with consequentially low level of evidence. Cluster randomised trials 
like ours are scarce. We are awaiting the results of the QICKDstudy, a cluster 
Shared care in nephrology and general practice
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randomised trial to compare quality improvement interventions to lower systolic BP in 
CKD in primary care.(37) The results when published will provide interesting material 
to compare our data with. 
Implications for research or practice
It is promising that an intervention of shared care showed BP-lowering during a one 
year intervention, even in practices that already had a well structured care for patients 
with diabetes or hypertension. Statements on more relevant endpoints like cardiovascular 
events and hospital admissions would need larger and longer cluster randomised 
trials. Future studies should provide information on cost-effectiveness. CKD has a 
high financial burden. As this model aims to provide optimal care at the cheapest 
level possible, it may prove to be cost-effective in lowering cardiovascular morbidity 
and mortality. 
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Appendix 1   Overview of Blood pressure measurement results 
Baseline T=1 year
Parameter  Control  Intervention Control Intervention
N= 73 90 74 90
Systolic usual BP 
(mmHg)
142.5 (15.1) 142.7 (17.6) n.a. n.a.
Diastolic usual BP 
(mmHg)
80.4 (8.2) 74.9 (9.2) n.a. n.a.
Systolic study BP 
(mmHg)
n.a. 137.1 (16.5) 142.9 (16.8) 134.7 (15.7)
Diastolic study BP 
(mmHg)
n.a. 75.4 (10.7) 80.9 (11.2) 73.8 (9.6)
n.a.=not available; * missing values excluded
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Population based screening for chronic 
kidney disease not cost effective; shared care 
in chronic kidney disease more attractive
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Manns et al conclude that population based screening for chronic kidney disease 
(CKD) by eGFR measurement is not cost effective, unless used in patients with 
diabetes.1 We can agree with their conclusion. Nevertheless, we would like to address 
a few of the assumptions made in this study, illustrated by initiatives in the management 
of chronic kidney disease in the Netherlands. By sharing treatment between primary 
and secondary care, costs could be less. By defining benefits a bit broader, the 
balance would be more positive than calculated. 
First, chronic kidney disease is defined as a single health state by an eGFR below 60 
ml/min/1.73 m2. As prognosis is mainly affected in patients with eGFR below 45 ml/
min/1.73 m2, a worldwide discussion is ongoing concerning potential modification of 
the grading of chronic kidney disease. A subdivision of stage 3 CKD at 45 ml/min/1.73 
m2 has been proposed.2 Also age as a factor in the judgment of the grade of renal 
function is under discussion. The consequence of this growing insight is, that not all 
patients with an eGFR < 60 ml/min/1.73m2 require an expensive nephrologist visit. 
Daily practice is that general practitioners mainly refer patients with an eGFR < 30 ml/
min/1.73 m2. 3,4 In the Netherlands, national guidelines have been developed to share 
the care for patients with CKD between primary and secondary care.5 Screening is 
advised in high risk patients. Next the pragmatic advice is to refer patients with overt 
proteinuria or patients with eGFR < 30 ml/min/1.73m2 (age > 65 years) or eGFR <45 
ml/min/1.73 m2 (age < 65 yrs). Consultation of a nephrologist (without referral) is 
advised if eGFR is between 30 and 45 ml/min/1.73 m2 in patients over 65 years or 
between 45 and 60 ml/min/1.73 m2 in younger patients. In that way, the largest part of 
CKD stage 3 patients will be treated in primary care with support from a nephrologist. 
To facilitate this consultation, we developed Telenephrology, a webbased consultation 
aid. By Telenephrology, specialist’s knowledge is transferred to primary care in a 
structured way. We studied 105 patients with diabetes and or hypertension in primary 
care with CKD stage 3 or worse. In this study, only two patients had to be referred 
from primary care to a nephrologist during one year. The others could be treated in 
general practice, with the aid of Telenephrology. This underlines the message of 
Gifford et al that screening will be less costly than suggested.3 
A second aspect is the fact that the model only accounts for prevention of end stage 
renal disease and mortality. These outcomes are mainly associated with urinary 
protein loss. The benefits of reducing cardiovascular events in patients with reduced 
kidney function by treatment of hypertension6 and lipid lowering are not included in 
the model of Manns. In the Sharp study (http://www.ctsu.ox.ac.uk/~sharp/slides.
htm), lipid lowering in patients with reduced kidney function led to a reduction of 17% 
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in major atherosclerotic events. The reduction of cardiovascular morbidity might be 
more important than that of cardiovascular mortality. Data on multidisciplinary 
treatment of cardiovascular risk factors will be provided by the MASTERPLAN study 
that aims to reduce cardiovascular risk and to slow the decline of kidney function by 
a multifactorial approach in patients with moderate to severe CKD (stage 3 and 4) 
existing of a polydrug strategy and lifestyle treatment.7 
Third, identifying decreased renal function could also lead to a better medication 
safety regime, provided that doctors and pharmacists take into account renal function 
in their drug prescribing. Impaired renal function appeared to be an important 
determinant in preventable medication -related hospital admissions.8 
Our final remark is a small correction; Manns pointed that the Netherlands have an 
active population based screening program. This is not the case. This statement is 
probably based on a once only initiative of the Dutch Kidney Foundation in 2006 to 
provide people with urinary dipsticks for self-diagnosis of urinary protein loss.9 
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absTraCT
Purpose A web-based consultation system (telenephrology) enables family physicians 
to consult a nephrologist on a patient with Chronic Kidney Disease: relevant data are 
exported from the electronic patient file to a protected digital environment from which 
advice can be formulated by the nephrologist.  The primary purpose of this study was 
to assess the potential of telenephrology to reduce in-person referrals.
Methods In an observational, prospective study we analyzed telenephrology- 
consultations by 28 family practices and five nephrology departments in the 
Netherlands between May 2009 and August 2011. The primary outcome was the 
potential reduction in in-person referrals, measured as the difference between the 
number of intended referrals as stated by the family physician and the number of 
referrals requested by the nephrologist. Secondary outcome was the usability of the 
system, expressed as time invested, implementation in daily work hours and response 
time. Furthermore we evaluated the questions asked.
Results 122 new consultations were included. In the absence of telenephrology 
43 patients (35.3%) would have been referred by their family physicians, whereas the 
nephrologist considered referral necessary in only 17 patients (13.9%) (p<0.001). The 
family physician would have treated 79 patients in primary care. In 10 of these patients 
the nephrologist deemed referral necessary. Time investment per consultation 
amounted to less than 10 minutes. Consultations were mainly performed during 
office hours. Response time was 1.6 days (95% CI: 1.2 – 1.9). Most questions 
concerned estimated glomerular filtration rate, proteinuria and blood pressure.
Conclusion A web-based consultation system might reduce the number of referrals 
and is usable. Telenephrology may contribute to an effective use of health facilities by 
allowing patients to be treated in primary care with remote support by a nephrologist. 
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inTrODuCTiOn
In 2002, the National Kidney Foundation released the ‘Kidney Disease Outcome 
Quality Initiative’ (K/DOQI) guideline for the evaluation and treatment of patients with 
chronic kidney disease (CKD) .1 This guideline has been instrumental in improving the 
care of patients with CKD.  According to the guideline definition the prevalence of 
CKD in the US has increased from 10% in 1994 to 13% in 2004.2 In Western-Europe 
the prevalence of CKD is only slightly lower. 3,4 The widely implemented default 
laboratory reporting of estimated glomerular filtration rate (eGFR) has raised the 
awareness of CKD in primary and secondary healthcare, and, together with the 
increased prevalence, has increased the economic burden on the health care system. 5-7
Cost-effective management of CKD patients requires that care should be given in a 
primary care setting where possible and in a secondary care setting where necessary. 
In the UK, the NICE guidelines on CKD provide family physicians (FPs) with tools to 
decide which healthcare setting, primary or secondary, is best suited for providing 
the patient’s required care.8 In the Netherlands, the interdisciplinary CKD-guideline 
for primary care and nephrology serves the same purpose.9 To facilitate good care in 
a primary care setting, the advice of a nephrologist may be helpful and would limit 
referrals to only those that need an in-person referral.
Consultation between an FP and a nephrologist is traditionally performed by 
telephone or e-mail. The first may be inconvenient since a lot of detailed information 
has to be communicated, a report of the consultation is lacking and a timeslot that 
suits both doctors has to be found.10,11 The latter is impractical because all relevant 
data must be transferred from the medical record to the e-mail message and most 
e-mail services are not sufficiently protected. Studies have reported electronic 
consulting  where nephrologists had full access to the electronic health record of the 
patient.12,13  This may raise privacy issues, as more information is available to the 
nephrologist than is necessary for the consultation.   
To overcome these shortcomings, the Radboud University Nijmegen Medical Centre 
(RUNMC) Departments of Primary and Community Care and Nephrology have 
devised a web-based consultation system: telenephrology. FPs upload defined data 
that are relevant to CKD. These data are automatically extracted from the FP’s 
electronic health record to a secured digital environment. FPs and nephrologists can 
use the system independently at a convenient time. The nephrologist gives treatment 
advice to the physician based on the patient’s information, and by so doing, the need 
for referral may be reduced.
Web-based consultation
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This observational study describes and analyzes the use of telenephrology by FPs 
and nephrologists. The primary objective was to assess the potential of telenephrology 
to affect referral rate. A secondary objective was to examine the usability of 
telenephrology by judging time investment, implementation in daily work and the 
nephrologist’s response time.  Finally, we explored the areas of patient care FPs were 
likely to consult about through telenephrology. 
 
meThODs
The content of telenephrology was developed in the RUNMC by the Departments of 
Primary and Community Care and Nephrology. TeleMC, a company in telemedicine 
applications, was responsible for the technical development of the system. 
Telenephrology was introduced in 2009 in the RUNMC and five family practices. In 
2011 it was expanded to a total of 28 family practices and five hospitals with 
nephrology care. This observational prospective study described and analyzed 
web-based consultations between May 2009 and August 2011 by 42 FPs and five 
nurse practitioners in 28 family practices and 14 nephrologists from five participating 
hospitals. Nurse practitioners worked on behalf of the FPs. We included all new 
consultations. In case the consultation resulted in recommendation for additional 
(diagnostic) testing, we also used the follow-up consultations to establish the 
outcome of the process. Data extraction was conducted by TeleMC for the variables 
shown in table 1. Data categorization was performed by VG and NS. 
The usual referral process consisted of a face-to-face consultation between patient 
and nephrologist. The FP wrote a paper or electronic referral letter to inform the 
nephrologist and to request an appointment for the patient. Besides these regular 
referrals an FP could phone the nephrologist for advice. The FP’s in our study had the 
choice to either refer the patient in the usual way or to consult a nephrologist by 
telenephrology and then, based on the advice given, decide how and where to 
manage the patient. The FP started the telenephrology-system directly from the 
patient file in the electronic health record. He logged on through a username and 
password. Essential patient data on medical history, medication, laboratory results 
and blood pressure, were automatically extracted from the patient’s electronic health 
record and presented in an orderly manner. Where the FP judged part of the 
information presented not applicable, for example privacy-sensitive information, 
issues could be removed. Mandatory information that had to be filled out consisted 
of the actual question(s), whether or not the patient would have been referred if 
telenephrology were not available and time investment per consultation. The 
nephrologist was notified by e-mail or text message that a consultation had arrived, 
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logged onto the website, and advised based upon the information presented how to 
treat the patient in primary care, to refer, or to refer if additional diagnostic information 
met conditions specified by the nephrologist. The nephrologist could request 
additional information and defer management advice until this was available. 
Subsequently, the FP was informed in a similar manner when a reply had arrived. The 
reply was automatically noted in the electronic health record of the patient. The FP 
could then adjust patient care or refer the patient according to the nephrologist’s 
advice. Requested additional information could be given in a follow-up consultation 
when new results had arrived. Moreover, the FP could ask for clarification or pose 
additional questions. A consultation about the same patient but addressing a new 
topic was considered a new consultation. An example of telenephrology-consultation 
can be viewed in web- appendix 1.
For the analysis, we were interested in the FP-decision to refer in relation to the 
telenephrology consultation. For this, we compared the referral decisions of the FP, 
had there not been the possibility of telenephrology, with the nephrologist’s referral 
advice, which was considered as the gold standard. The nephrologist’s advice to 
refer was collected from their entries in the web program. In case the nephrologist 
had requested additional information, the entry was taken from the follow-up 
consultation after receiving these data. We asked the FPs at every consultation 
whether the patient would have been referred to the nephrologist if telenephrology 
had not been available and, after the nephrologist-response, whether they would 
follow the referral advice given. We compared the referral rates with the recommen-
dations as advocated by the Dutch interdisciplinary CKD-guideline for primary care 
and nephrology. To determine outcome significance between the FP intention to refer 
and the nephrologist’s referral advice, McNemar’s test was conducted for comparison 
of paired proportions using SPSS version 18.0 (IBM PASW statistics 18).
To assess usability we investigated time-investment, implementation in daily work- hours 
and response time. Time investment was reported by the professionals. Implementation 
in daily work-hours was defined by the timeslot in which the consultation took place: 
06:00 – 08:00, 08:00 – 17:00, 17:00 – 19:00, or 19:00 – 06:00. This enabled evaluation 
of use during office hours, just before and after office hours, and at a later time during 
the day. The response time of the nephrologist was calculated in days. 
For analysis of the questions asked, we firstly analyzed the individual questions with 
the intention to find categories and subcategories. Subsequently we allocated the 
questions to these (sub) categories. Each consultation could contain one or more 
questions.  
Web-based consultation
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To assess the satisfaction of the professionals with the system, we sent an online 
questionnaire in 2011 to the five practices that had used telenephrology during the 
pilot-phase in the previous year.
Ethics approval was not required according to the accredited Medical Research 
Ethics Committee Arnhem/Nijmegen (ABR NL16590.091.07).
resulTs
Between May 2009 and August 2011, 125 new consultations were recorded, performed 
by 42 FPs and five nurse practitioners from 28 family practices. Three consultations 
were excluded because the FP used the system to get information on patients that had 
already been referred. The 122 included consultations concerned 116 patients. In 24 
patients a total of 52 follow-up consultations were performed. Clinical characteristics 
of the patients are given in Table 1. 
Referral 
We compared the FP’s intention to refer with the final referral advice of the nephrologist 
(table 2).  The FPs intended to refer 43 patients. The nephrologists concluded that 
referral was not necessary and care could be delivered in primary care in 36 of these 
patients (84% reduction). 
The opposite was seen in 10 patients, who according to the FP could be treated in 
primary care. The nephrologist advised referral for reasons of relatively young age 
(n=3), co-morbidity (n=1), proteinuria (n=2), rapid decline in renal function (n=2) and 
unspecified reason (n=2). The FPs agreed with all of the referral advice given, which 
meant a net referral reduction from 43 to 17( 60.5%).  
For comparison we also applied the recommendations given by the Dutch inter-
disciplinary CKD-guideline for primary care and nephrology. Explanation of the guideline 
and comparison results are given in web-appendices 2 and 3. 
Usability 
Time investment per consultation amounted to 9 minutes for FPs and nephrologists. 
73% of the FPs’ use of telenephrology was between 08:00 – 17:00. 61% of the 
consultations were answered between 08:00 – 17:00. 
The nephrologists’ average response time was 1.6 days (95% CI: 1.2 – 1.9). 43% (n = 52) 
of all consultations were answered on the day of submission, 84% (n = 102) within 
3 days. The full results are given in table 1.
Nine FPs answered the questionnaire. They all judged the amount and content of 
information that was sent by telenephrology appropriate. Ease of use was judged as 
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reasonable (2/9) to good (7/9). They found it reasonably easy (4/9) to easy (5/9) to fit 
the use of telenephrology within daily practice work. Eight out of nine users said that 
their knowledge of nephrology had increased by the use of telenephrology. The two 
nephrologists found the data supplied sufficient to get a good view on the patient’s 
case. In the future they would like the data to be graphically presented. The 
nephrologists could see a learning curve in the way FPs asked questions. 
Web-based consultation
Table 1   Patient characteristics and time-investment in telenephrology 
consultations
New consultations 
(n = 122, unless specified otherwise)
Distribution
Age (years, range) 73.6 (34 – 96) 
Gender Male/Female 40% (n = 49) / 60%   (n = 73)
Estimated GFR (mL/min/1.73 m2, range) 46 (22 – 128)
Albuminuria Normoalbuminuria 49%   (n = 48) 
Microalbuminuria 38%   (n = 38) 
Macroalbuminuria 13%   (n = 13)
Date of consultation 01/05/2009 – 09/08/2011
Time of consultation FP 06:00 – 08:00 1%   (n = 1)
08:00 – 17:00 73%   (n = 89)
17:00 – 19:00 17%   (n = 21)
19:00 – 06:00 9%   (n = 11)
Time of consultation nephrologist 06:00 – 08:00 1%   (n = 1)
08:00 – 17:00 61%   (n = 74) 
17:00 – 19:00 25%   (n = 31) 
19:00 – 06:00 13%   (n = 16)
Time investment FP, minutes 9:27 (95% CI, 8:29 to 10:25)
Time investment nephrologist, minutes 8:45 (95% CI, 8:04 to 9:27)
Days until response 1.6 (95% CI, 1.2 to 1.9)
Follow-up consultations (n=52)
Time investment FP (minutes) 6:43 (95% CI 5:48 to 7:38)
Time investment nephrologist (minutes) 6:47 (95% CI 5:55 to 7:40)
Consultations performed by 42 family physicians and  5 nurse practitioners in  28 family practices. 
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Table 2   Intended referral by family physicians and referral advice from 
nephrologist
Nephrologist 
advises  
referral
Nephrologist 
advises  
primary care
FP has intention to refer   7 (5.7%)   36 (29.5%)   43 (35.3%)
FP wants to treat in primary care 10 (8.2%)   69 (56.6 %)   79 (64.8%)
17 (13.9%) 105 (86.1%) 122 
McNemar’s test comparing FP intention to refer and the nephrologist’s referral advice: p<0.001. 
Table 3  Categorization and distribution of the questions of the family physician
Main group Subject N
Intrinsic kidney disease
60% (n = 124)
Decreased estimated GFR 19
Decreasing estimated GFR 30
Micro albuminuria 14
Macro albuminuria  6
Blood pressure in relation to CKD 23
Unspecified 32
Metabolic complications
27% (n = 55)
Bone and mineral metabolism 42
Hemoglobin 12
Acid-base homeostasis   1
Cardiovascular Risk Management
4% (n = 9)
Diabetes   5
Cholesterol   4
Comorbidity in relation to CKD
8% (n = 16)
Gout   1
Urinary tract infection   1
Patients condition   3
Drugs that interact with impaired kidney 
function
 11
Other
1% (n = 3)
Cardiomyopathy   2
Urinary tract infection   1
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Consultation content 
The result of the categorization of question topics is displayed in table 3. The 
nephrologist addressed the question in a broader context and provided advice not 
specifically asked for in 35% (n = 43) of the answers. This advice mainly considered 
medication safety in relation to renal function and advice to check the patient for 
mineral and bone disorder (secondary hyperparathyroidism, Calcium, Phosphorus, 
vitamin D) or for anaemia.    
DisCussiOn
Our data provide support for the introduction of telenephrology in primary care. The 
intended referral rate by the FP was far higher than that advised by the nephrologist. 
This could result in a more convenient care at lower health care costs. 
Telenephrology and other electronic consultation systems
Several other studies have described the use of electronic consultation technology in 
the management of patients with CKD. In Hawaii, nephrologists proactively intervened 
in primary care by using data from Kaiser Permanente’s electronic medical system 
and by providing unsolicited advice to FPs.12 Their intervention lead to an increase in 
timely referrals and a reduction in low risk referrals. This initiative was nephrologist 
driven, and was possible only because nephrologists had entry to all electronic 
health records. This meant that they had access to irrelevant data, which is not 
desirable both from an efficiency and a privacy point of view. In the United Kingdom, 
Stoves et al. set up an e-mail referral system for patients with chronic kidney disease: 
if the GP referred the patient by e-mail, the patient was asked to provide consent for 
the nephrologist to look in the electronic health record.13 Based on the information 
read, the nephrologist advised referral or gave management advice to be carried out 
in the primary care setting. This lead to a reduction in referrals from 30 to eight 
patients (73% reduction), similar to our primary outcome. The mean response time 
was 7 days and mean time needed for the consultation was 15.5 minutes. The time 
required in our study was less, which is probably because only relevant pre-formatted 
information was presented. 
Patient benefits
Depending on the extent to which FPs pose questions by telenephrology, patients 
might receive more adequate care in relation to blood pressure, hyperparathyroidism, 
anaemia and medication safety. This will most probably affect patient survival and 
morbidity.14-16 Furthermore, patients can be referred for predialysis care more timely if 
FPs and nephrologists monitor CKD progress team wise.17 The convenience for 
Web-based consultation
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patients lays in quicker specialist responses than with a usual referral, prevention of 
time-consuming hospital visits and the fact that they do not need to see another 
doctor. Although we did not study this, we expect a higher patient satisfaction if 
treatment can be given in a patients’ own environment. This was demonstrated in a 
study on joint teleconference consultations.18
Economic benefits
Telenephrology has the potential to reduce referrals and so could contribute to a cost 
reduction. A usual referral cost €600,-. A telenephrology consultation cost €107, 
including a nephrology tariff and the online facilities. Each prevented referral meant a 
saving of €493. Additional costs in primary care should be evaluated. Pan et al 
examined telehealth models in a simulation study and found that physician-to-physi-
cian  consultation systems can contribute to a substantial cost reduction. 19  
As indicated by our data, the introduction of telenephrology may also lead to referrals 
that were not primarily intended by the FP, but where the nephrologist deemed a 
referral necessary. In these cases, the higher costs of referrals are likely to be 
balanced by lower costs related to earlier detection and treatment of kidney disease. 
Broadening the concept
We think that e-consultation offers the ability to break down walls between primary 
and specialist care. It facilitates shared care in patients with chronic disease 
conditions and it might enable effective use of expensive secondary care facilities. 
Joint teleconference medical consultation is a promising development as well, but 
has the disadvantage that both FP and specialist must be available at the same 
time-slot. Furthermore, it does not provide documentation in the electronic health 
record.  Where interprofessional consultation relies mainly on measurable and 
preformulated data, web-based consultation seems more practical and effective 
than a referral or teleconferencing.      
Limitations
We must consider some limitations of this study. The web-based consultation aimed 
to lead to more appropriate referrals to the nephrologist and the primary outcome 
measure was whether intended referral rate decreased. It will be important to assess 
how robust this is, or whether at a later date patients are referred despite the 
consultation. On the subject of referrals we merely analyzed the intention to refer. 
There were no data available on the actual number of referrals following this advice. 
These data will be generated in a cluster randomized controlled trial on the influence 
of telenephrology on the actual rate of referrals:  the CONTACT study (Consultation 
Of Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment 
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in primary care, Netherlands Trial Registration code 2368). In this trial the effect of 
telenephrology on the actual referral rate and the quality of care will be evaluated. 
This study will enable a direct comparison between referrals in practices using 
telenephrology and those not, providing better evidence than the current study which 
used an internal gold standard.    
Data on professional behavior (for example referral) are subject to clustering within 
professionals,  for which we did not correct in this usability study.   
The generalizability of the telenephrology technique depends on local settings. At the 
very least the primary care physician must use an electronic health record which 
allows automatic data extraction. Although it might be possible to create a similar 
system that allows direct data entry by the FPs, this is prone to errors and certainly 
not time efficient. 
We did not evaluate patient satisfaction, which is a limitation.  The satisfaction of the 
professionals was measured in an early stage of the study, so only included five 
practices. The data are too small to interpret, but the opinion tends to be positive. In 
the implementation of tele-health, the applicability in daily work proved to be very 
important.20,21 With that in mind, it is favorable that the telenephrology system fitted in 
the daily work routine: most doctors used the system during office hours, spending 
less than 10 minutes on a consultation and nephrologists responded quickly.  
    
In conclusion, a web-based consultation system might reduce the number of referrals 
by enabling FPs to receive suitable advice from nephrologists. The system is usable 
for both nephrologist and FP and allows efficient care of patients with CKD in primary 
care.
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web appenDix 1 
Example of a telenephrology consultation
Name patient : XXX
Date of birth : X-X-1934
 Male
CONSULTATION
Name Family Physician  XXXXXX,       date of consultation, X-X-2011,       13.20
Medical history : 14042011 Chronic Kidney Disease
27032009 Smoking stopped in 1962
27102001 Hypertension
19051995 Choreoideamelanoma OD 
23111998 Diabetes mellitus type 2, 
Actual medication: 31032011  METFORMINE 500MG TABLET  2D2T
31032011  SOTALOL HCL ACTAV 80MG TABL 1D1T
31032011  SIMVASTATINE 40MG TABLET FO  1D1T
31032011  GLIMEPIRIDE RP 3MG TABLET  1D1T
31032011  LISINO/HYDTHIA SD 20/12,5 T  1D1T
31032011  ACETYLSAL CARD CF 80MG DISP  1D1T
14042011  AMLODIPINE RP TABLET  5MG 14.0 1D1T
Medication changes in last 4 months? No 
Auto-medication (NSAIDS) : No 
Referral unknown 
Web-based consultation
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Weight 77 kg 77.6 kg 77 kg 75.8 kg 75.8 kg 75.5 kg 77.6 kg 76.4 kg 76,0 kg 78,1 kg 77,6 kg 77,3 kg 77,0 kg 78,0 kg 77,9 kg 76,8 kg 77,0 kg 78,3 kg
BMI 25
Length 176
Smoking before
R
R
31
-0
3-
20
11
22
-0
3-
20
11
01
-0
2-
20
11
30
-1
2-
20
10
04
-1
0-
20
10
01
-0
7-
20
10
01
-0
4-
20
10
29
-1
2-
20
09
30
-0
9-
20
09
17
-0
6-
20
09
30
-1
2-
20
08
08
-1
2-
20
08
30
-0
9-
20
08
03
-0
6-
20
08
03
-0
4-
20
08
06
-0
7-
20
07
RR syst 164 
mmHg
138 
mmHg
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mmHg
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mmHg
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mmHg
142 
mmHg
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mmHg
149 
mmHg
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mmHg
144,0 
mmHg
151,0 
mmHg
172,0 
mmHg
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mmHg
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mmHg
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mmHg
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82,0 
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Creatinine 151 
micromol/l
141 
micromol/l
101 
micromol/l
103,0 
micromol/l
95,0 
micromol/l
94,0 
micromol/l
eGFR MDRD 42 ml/
min/1,73m2
45 ml/
min/1,73m2
>60 ml/
min/1,73m2
60,0 ml/
min/1,73m2
60,0 ml/
min/1,73m2
60,0 ml/
min/1,73m2
Fasting 
glucose 
8,0 mmol/l 10.4 mmol/l 10.4 mmol/l 13.8 mmol/l 8,6 mmol/l 10,1 mmol/l 11,8 mmol/l 8,4 mmol/l 8,8 mmol/l 9,0 mmol/l 6,3 mmol/l
HbA1c 60 mmol/l 64 mmol/l
Tot chol 2,8 mmol/l 2,5 mmol/l 2,7 mmol/l 2,4 mmol/l
HDL 0,7 mmol/l 0,8 mmol/l 1,1 mmol/l 1,1 mmol/l
LDL 1,5 mmol/l 1,2 mmol/l 1,2 mmol/l 0,9 mmol/l
Chol/HDL 3,9 3,2 2,6 2,2 
TG 1,44 mmol/l 1,13 mmol/l 0,96 mmol/l 0,96 mmol/l
Hb 7,8 mmol/l 8,0 7,8 
MCV 93,0 92,0 
Albumin
Sodium 138 139 138,0 140,0 138,0 
Potassium 3,6 mmol/l 3,7 mmol/l 3,8 mmol/l 3,8 mmol/l 3,4 mmol/l
Calcium 1,2 mmol/l
Phosphate 1,4 mmol/l
PTH 6,2 mmol/l
Vitamin B12
Folic acid
Ferritin 70,0 
Serum-iron
Iron binding 
capacity
Transferrin
Vitamin D
Urea
Bicarbonate
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Urine 25-03-2011 26-03-2010 07-04-2009 28-03-2008
Tot protein urine
Alb/creat ratio 2,1 mg/mmol 1,0 mg/mmol 0,2 mg/mmol 0,6 mg/mmol
creatinine urine 8,4 8,1 3,8 8,8 
Albumine urine
Sediment normal
Question : Dear colleague,
I saw this patient for his annual diabetes control. MDRD 
appeared to be decreased from > 60 to 45 ml/min/1.73 m2. Two 
weeks later the MDRD was 42 ml/min/1.73 m2. In the anamnesis 
I did not find a reason: no NSAID use, no recent medication 
change. The alb/creat ratio increased, but is still normal. Blood 
pressure is higher than before; I added amlodipine 5 mgr. I plan 
to refer this patient. What should I do meanwhile? 
If telenephrology were 
not available, would you 
refer the patient?
  Yes
  No 
Answer   
XXXXX, nephrologist, XXXXXXXX hospital
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Date X-X-2011, 15.30 Dear colleague,
The fact that this patient does not have proteinuria, makes it 
plausible that the decrease in renal function has a prerenal 
cause, a tubulointerstitial nefritis (TIN), or a post-renal cause 
(prostate hypertrophy/retention?). Do you have an ultra sound of 
kidneys and bladder?
A TIN could be caused by hydrochlorthiazide. The combination 
enalapril/HCT increases the risk of acute kidney injury in case of 
dehydration or fever. I suggest that you stop lisinopril/HCT for 2 
weeks and increase the dose of the Ca-antagonist, if the blood 
pressure rises. Please get in touch by Telenephrology after 2 to 3 
weeks to report  eGFR.
Take care: metformin 2x1000mg is too high for this renal 
function; 2x 500mg is the limit. Glimepiride can be increased to 6 
mg. The sotalol dose is rather high. 
Patient should be referred 
to a nephrologist:
  Yes
  No
  No,  unless:
Renal function is not ameliorating after medication change
How much time did you 
need to fill in the form?: 
10 minutes 
aDDiTOnal messages
Message from 
family physician
  I will follow your advice
  I will not follow your advice, because…………. 
XXX 
dd X -X-2011 17:32
Dear colleague,
I will order an ultrasound of kidneys and bladder.
I will change the medication conform your advice and I will report in a 
follow-up consultation
Web-based consultation
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web appenDix 2
Dutch interdisciplinary CKD-guideline for primary care and nephrology: 
recommendations for the care of patients with CKD
normo / microalbuminuria macroalbuminuria
Patients > 65 years of age
eGFR > 60 ml/min/1.73m2
eGFR 45 – 60 ml/min/1.73m2
eGFR 30 – 44 ml/min/1.73m2
eGFR < 30 ml/min/1.73m2
Patients < 65 years of age
eGFR > 60 ml/min/1.73m2
eGFR 45 – 60 ml/min/1.73m2
eGFR 30 – 44 ml/min/1.73m2
eGFR < 30 ml/min/1.73m2
Gray: evaluation and treatment in primary care. 
Light Gray: consultation of a nephrologist (without referral). 
Dark Gray: referral to secondary care. 
Adapted from Grauw de W, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S, Gaillard C, et al. 
Landelijke Transmurale Afspraak Chronische nierschade, 
http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_samenwerking/k_ltas.htm 
(with permission of the Dutch College of General  Practitioners).
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web appenDix 3
The FP’s intention to refer compared to the nephrologist’s referral advice plotted 
against the Dutch interdisciplinary CKD-guideline for primary care and 
nephrology.
Web-based consultation
Dutch CKD-guideline 
(could only be applied to  
patients with urine assessment)
Family physician Nephrologist
referral to secondary care
n = 23
Refer  n=12 Refer  n = 6
Consultation of a nephrologist
n = 43
Refer  n = 15 Refer  n =7
treatment in primary care
n = 33
Refer  n = 10 Refer  n =0

6A pharmacy medication alert system 
based on renal function in older patients
Geerts, AFJ*
Scherpbier-de Haan, ND*
De Koning, GHP
Van der Sterren, TMJW
Van Weel, C
Vervoort, GGM
De Smet, PGAM
De Grauw, WJC
*Both authors contributed equally to the manuscript
Br J Gen Pract. 2012;e525-e529
118
absTraCT
Background Patients with diabetes or cardiovascular disease are at risk for reduced 
renal function and frequently use drugs that interact with renal function. General 
Practitioners (GPs) monitor renal function in these patients. Computerised prescription 
systems produce alerts in patients labelled as having chronic kidney disease, but 
alerts are often ignored. If pharmacists use a pharmacy medication alert system 
(PMAS) based on renal function, they can provide the GP with therapeutic advice to 
optimise the medication. The extent of this advice and the feasibility in the clinical 
context are unknown.
Aim To assess the therapeutic advice formulated by pharmacists with help of a PMAS 
based on the renal function of patients aged ≥70 years with diabetes or cardiovascular 
disease.
Design and setting Observational study in primary health care in the Netherlands.
Method GPs provided pharmacists with the renal function of older patients with 
diabetes or cardiovascular disease who were using target drugs, that is, drugs 
requiring therapeutic advice in patients with reduced renal function. With the help of 
a PMAS, pharmacists assessed the actual medication. The GP weighed the advice 
in relation to the clinical context of the individual patient.
Results Six hundred and fifty patients were prescribed 1333 target drugs. Pharmacists 
formulated 143 therapeutic recommendations (11% of target drugs) concerning 89 
patients (13.7% of study population). In 71 recommendations in 52 patients (8.0% of 
study population), the GP agreed immediately.
Conclusion The use of a PMAS resulted in therapeutic advice in 11% of the target 
drugs. After weighing the clinical context, the GP agreed with half of the advice.
119
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inTrODuCTiOn
Chronic kidney disease (CKD) is a growing health problem, with a prevalence from 
4.9% in general practice in the UK to up to 13% in the US population.1-3 The medical 
consequences of CKD are not only the risk of end-stage renal disease and cardio-
vascular morbidity, but also an increased risk of adverse drug events and medication- 
related hospital admissions.4,5
When renal function is reduced, the dosage of drugs that depend on renal excretion 
should be adjusted and nephrotoxic drugs should be avoided.6-8  Patients with diabetes 
and cardiovascular disease have an augmented risk of CKD and frequently use renally 
cleared drugs.1,9  Medication alerts systems warn prescribers of medication that can 
interact with impaired renal function, but these alerts are often ignored.10-13 A medication 
alert system that weighs the actual renal function of the patient could help to reduce 
medication errors.14-16
This observational study assessed the therapeutic advice formulated by the pharmacist 
with help of a medication alert system based on the renal function of patients aged 
≥70 years with diabetes or cardiovascular disease.
meThOD
Setting and study population
The study was conducted in Arnhem, a city in the East of the Netherlands with nearly 
148 000 inhabitants. Seven GPs, belonging to the same pharmacotherapy audit 
meeting group, participated in the study. Five pharmacists who worked in close 
collaboration with this group selected the patients in their pharmacy computer system. 
Patients aged ≥ 70 years in the care of the participating GPs were eligible if they were 
on GP-prescribed maintenance therapy of blood-glucose-lowering or cardiovascular 
drugs (for example, digoxin, diuretics, or inhibitors of the renin-angiotensin system 
(RAS), including angiotensin-converting enzyme (ACE) inhibitors and angiotensin II 
receptor blockers (ARBs)). Patients also used at least one ‘target drug’ on the 
inclusion date of 4 January 2010. ‘Target drugs’ were defined as drugs requiring 
therapeutic advice in patients with decreased renal function considering the Dutch 
dosing guideline for impaired renal function.17 Patients with an estimated glomerular 
filtration rate (eGFR) < 10 ml/min/1.73m2 were excluded (Figure 1).
The GPs already used a computerised medication monitoring system. This system 
generated an alert when the GP prescribed a target drug in patients labelled as 
having CKD, but it could not consider the eGFR level.
A pharmacy medication alert system
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The use of drug dispensing data and laboratory test results in this study complied 
with Dutch privacy regulations.
Renal function monitoring
Actual eGFR was defined as an eGFR value measured within the last 12 months. If an 
actual eGFR was unknown, the GP requested the patient to undergo a blood test for 
renal function. The laboratory provided serum creatinine and an eGFR (ml/min/ 
1.73m2) calculated by the normalised four-variable Modification of Diet in Renal 
Disease (MDRD).18 Serum creatinine was measured enzymatically (Modular, Roche 
diagnostics) and was IDMS (isotope dilution mass spectrometry) calibrated. The 
actual values of eGFR data were provided to determine drug-specific risk.
Figure 1  Selection of the study population
Eligible patients 
 
Patients on blood-glucose-
lowering drug and/or 
cardiovascular drug and at 
least one target drug 
prescribed by a GP at the 
inclusion date, n = 749  
Renal function exchange  
Excluded:  n = 4  
• eGFR < 10 ml/min/1.73m2, n = 4   
Study population analysed, 
n = 650 
Not included: n = 10  
• Refused to participate, n = 10  
Patients ≥ 70 years, n = 1691   
Study population, n = 735  
Not analysed: n = 85
 
• Lost for follow up, n = 15
 
• Renal function not monitored, n = 26
• Target drug stopped, n = 44
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Assessment of renal function alerts
In this study, the pharmacists used a pharmacy medication alert system (PMAS) built 
by one of the authors (AG) in a Microsoft® Access database. The system, which was 
an addition to the current pharmacy computer system, assessed the medication in 
relation to the reported eGFR and provided an alert for target drugs according to the 
Dutch guidelines for drug administration in reduced renal function.17 These guidelines 
include drug-specific cut-off values for eGFR, accompanied by a therapy- adjustment 
advice.
After receiving a data file from the GP with the eGFR of the included patients, the 
pharmacists linked the eGFR in the PMAS. Simultaneously, the patient’s actual 
medication was electronically imported from the usual pharmacy computer system 
into the PMAS. An alert was generated to stipulate action if the eGFR was lower than 
the cut-off value of the target drug (Table 1). The software could not correct for invalid 
dose or dose interval, so the pharmacist assessed the alerts for these aspects based 
on the guideline recommendations presented in a text box. The pharmacist formulated 
therapeutic advice for either dosage adjustment, to stop the drug, or to substitute it 
by a non-contraindicated drug. Once a week, the pharmacist communicated the 
therapeutic advice to the GP by a list. The GP evaluated the therapeutic advice in 
relation to the clinical context of each individual patient, and responded with 
agreement or disagreement. Predefined reasons for disagreement could be checked 
on the list and the GP was asked to give supplementary comments in a free-text box. 
The list was returned to the pharmacist.
Outcome
The outcome of the study was the frequency of therapeutic advice formulated by the 
pharmacist (expressed as a proportion of the total number of target drugs). The 
management of the therapeutic advice by the GP was also studied.
Statistical analysis
All relevant patient data were entered into a Microsoft Access 2003 database and 
further analysed with SPSS Statistics (version 17.0) for descriptive statistics (mean, 
frequency, range).
resulTs
On the inclusion date 650 patients were included and analysed (Figure 1). These 
patients were prescribed 1333 target drugs (Table 2). An actual eGFR had been 
determined in 78.5% (n = 510) of the patients (range per GP 66-89%). In the remaining 
patients, eGFR was determined after the inclusion date.
A pharmacy medication alert system
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6Assessment of renal function alertsThe computer software generated 212 alerts (15.9%) in a total of 1333 target drugs, because the eGFR was lower than the predefined cut-off value of the target drug. 
After the pharmacist assessed the actual medication for correct dose and dose 
interval, 93 alerts (7.0%) appeared to be correct and seven alerts (0.5%) were missing. 
Therefore, action to adjust therapy was considered necessary in 112 prescriptions in 
74 patients (8.4% of the target drugs, 11.4 % of the patients). Additionally, pharmacists 
gave advice in 31 prescriptions of target drugs, even though the eGFR was just above 
the cut-off value. Eventually, 143 therapeutic recommendations (10.7% of the target 
drugs) concerning 89 patients (13.7% of analysed study population) were included 
for analysis of the GP responses. The drugs most frequently involved were diuretics 
A pharmacy medication alert system
Table 2   Characteristics of the analysed study population
Characteristics n %
Patients 650 100.0
Female 433 66.6
Target drugs 1333
Mean SD [range]
Age, years 81 6.7 [70-101]
eGFR, ml/min/1.73m2 63,3 17.0 [13- >95]
Number of drugs 5,8 2.8 [1-17]
Number of target drugs 2 1.1 [1-7]
Patients prescribed target drugs by therapeutic group n %
Blood-glucose-lowering drugs 156 24.0
Cardiac glycosides digoxin 73 11.2
Low-ceiling diuretics thiazides 259 39.8
High-ceiling diuretics 164 25.2
Potassium sparing diuretics 49 7.5
Diuretics combinations 46 7.1
Beta-blocker sotalol 33 5.1
Beta-blockers atenolol/bisoprolol 31 4.8
RAS-inhibitors 224 5.1
eGFR = estimated glomerular filtration rate. RAS = renin-angiotensin system. 
SD = standard deviation
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(41.3% of therapeutic advice), blood- glucose-lowering drugs (14.0%), digoxin 
(11.2%), and RAS inhibitors (10.5%). Almost all prescriptions that received an alert 
were chronic prescriptions taken by the patient for a longer period of time.
GP response to pharmacist advice
The GP immediately agreed with 71 recommendations (49.7% of the therapeutic 
advice) concerning 52 patients (8.0% of the study population).The GP most frequently 
disagreed with the advice on diuretics, blood-glucose-lowering drugs, digoxin, and 
RAS inhibitors. Within each of these therapeutics groups, the GP immediately 
disagreed in one-third of the advice. The responses of the GPs are shown in Table 3.
Table 3   GP response
Response n  
(total N=143)
 % Comments
Immediate agreement 71 49.7 52 patients,  
8% of study population 
Postponed reaction 20 14.0 -
• GP first wants to consult specialist 12 8.4 -
• GP first wants to speak to patient 6 4.2 -
• Further monitoring biomarker(s) 2 1.4 Potassium, creatinine
Disagreement 38 26.6 -
• No standard reason indicated 17 11.9 No adverse reactions (n=1),  
already low dose (n=2)
• Potassium normal 5 3.5
• Disease is stable 16 11.2 Diabetes (n=5),  
heart failure (n=7),  
hypertension (n=3),  
renal function (n=1)
Specialist is treating patient 14 9.8 Specialist was responsible  
for the drug therapy  
(GP only prescribed the refill 
prescriptions)
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DisCussiOn
Summary
The use of a PMAS based on renal function resulted in therapeutic advice for a 
substantial number of drugs in older patients with diabetes or cardiovascular disease. 
The GP immediately agreed with half of the advice. Overall, in 5% of the prescriptions, 
the GP agreed to rectify the prescription.
The GPs used a medication monitoring system based on the Dutch G-standard,17  the 
national drug database, which is used by all professional parties in Dutch health care. 
Despite this monitoring system, pharmacists still formulated additive therapeutic 
advice in 11% of the target drugs. What could be the reasons for this? First, it is known 
that a high number of medication alerts may cause ‘alert fatigue’ in the prescriber.10 
In the case of repeat prescriptions in particular, alerts were ignored. The extra effort 
to seek a renal function and to weigh the choice and dosage of the drug may cost too 
much time. Second, this observation could be explained because at the time of 
prescription, an actual eGFR was not available in more than 20% of the patients. 
Finally, it is important to consider the prescribing context. The alerts concerned 
chronic medication that the patient may have been using for a longer period of time, 
with an established clinical effect and with the patient accustomed to take them. 
Change of drug choice under these circumstances may disrupt the flow of treatment.
The use of PMAS reduced the number of alerts compared to the current pharmacy 
computer system. A more sophisticated clinical decision support system could 
further reduce the number of irrelevant alerts by incorporating invalid dose or dose- 
interval algorithms that can weigh comorbidity and other patient-related risk factors 
that may affect the reliability of the eGFR,19  and by linking laboratory to pharmacy 
data. Currently, some of these principles are already incorporated in new versions of 
medication monitoring systems.
Strengths and limitations
This study revealed the benefit of therapeutic advice automatically generated by a 
PMAS based on renal function. The clinical relevance is substantial: prescribing of 
target drugs to older patients with diabetes of cardiovascular disease is a daily 
activity in primary care, and the risk of complications related to renal function is high.4 
Primary care studies on compliance to dosing guidelines in patients with CKD are 
rare.6 Recently, Bhardwaja et al demonstrated in a large US study of 32 917 patients 
with an eGFR below 50 ml/min/1.73m2, that an alert system in the pharmacy can 
result in a reduction of medication errors from 49% to 33%.14
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The data may not be generalisable to other settings because of the small number of 
participating practices, but the underlying problem of medication safety in relation to 
renal function and the intervention of a PMAS is of general interest.
The advice given was based on a single eGFR value obtained not more 1 year 
previously. This was for pragmatic reasons: renal function of patients who are in a 
diabetes or hypertension control system should be monitored yearly. However, 
variability in serum creatinine measurements necessitates at least two creatinine 
measurements,20,21 and even more frequent monitoring of renal function is needed in 
patients who are not stable.22 
Comparison with existing literature
GPs immediately agreed with half of the therapeutic advice. This is in accordance 
with the acceptance rate in a study in which clinical pharmacists gave therapeutic 
recommendations to GPs based on the medical records of 200 patients with diabetes 
or hypertension.23 In a hospital setting, the acceptance rate was the same: 55% of the 
pharmacist advice was accepted by the clinician.15
Besides the predefined reasons for disagreement, the GPs were not very explicit with 
their comments in the free-text box. Disagreement could be explained by a difference 
between the dosage guidelines and clinical practice. An example is the advice to 
start with low doses of RAS inhibitors to prevent adverse drug reactions, whereas 
current clinical practice guidelines do advise to prescribe RAS inhibitors in high 
doses in order to protect kidney function (with monitoring of renal function and serum 
potassium).24-26 Meanwhile, the advice in the Dutch dosage guidelines has been 
adjusted to clinical practice.
Implications for research and practice
To optimise drug prescribing in patients with decreased renal function, many steps 
need to be taken: systematic renal function monitoring in patients on target drugs, 
linking the laboratory to the pharmacy, assessment of the alerts by both pharmacist 
and GP and communication with the patient on the proposed prescription change. 
When implementing a PMAS, all above-mentioned steps deserve attention.
A PMAS based on renal function resulted in therapeutic advice in one of every nine 
target drugs in older patients on blood-glucose-lowering or cardiovascular drugs. 
After weighing the clinical context, the GP agreed with half of the advice. Collaboration 
between GP and pharmacist, using their clinical and pharmacological expertise 
respectively, can contribute to patient safety.
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absTraCT
Background Although blood pressure measurement is one of the most frequently 
performed measurements in clinical practice, there are concerns of its reliability. 
Serial, automated oscillometric blood pressure measurement has the potential to 
reduce measurement bias and white coat effect.
Aim To study agreement of 30-minute office blood pressure measurement (OBPM) 
with standardised OBPM and to compare repeatability.
Design and setting Method comparison study in two general practices in the 
Netherlands.
Methods Thirty-minute and standardised OBPM was carried out with the same, 
validated device in 83 adult patients, and the procedure was repeated after 2 weeks. 
During 30-minute OBPM, blood pressure was measured automatically every 
3minutes, with the patient in a sitting position, alone in a quiet room. Agreement 
between 30-minute and standardised OBPM was assessed by Bland–Altman 
analysis. Repeatability of the blood pressure measurement methods after 2 weeks 
was expressed as the mean difference in combination with the standard deviation of 
difference (SDD). 
Results Mean 30-minute OBPM readings were 7.6/2.5 mmHg (95% CI 6.1 to 9.1/1.5 
to 3.4 mmHg) lower than standardised OBPM readings. The mean difference and 
SDD between repeated 30-minute OBPM’s (mean difference 3/1 mmHg, 95% CI 1 to 
5/0 to 2 mmHg, SDD 9.5/5.3 mmHg) were lower than those of standardised OBPM’s 
(mean difference 6/2 mmHg, 95% CI 4 to 8/1 to 4 mmHg, SDD 10.9/6.3 mmHg).
Conclusion Thirty minute OBPM resulted in lower readings than standardised OBPM 
and had a better repeatability. These results suggest that 30-minute OBPM better 
reflects the patient’s true blood pressure than standardised OBPM does.  
How this fits in Office blood pressure measurement is rarely carried out according 
to guidelines, introducing bias in blood pressure measurements. In addition, the 
white coat effect contributes to unreliable blood pressure readings in up to 20% of 
patients. A reliable office based blood pressure measurement method that can 
overcome both these forms of bias is lacking. Thirty minute office blood pressure 
measurement appears to better reflect patient’s true blood pressure status, as its 
readings are lower and more reproducible than those of standardised office blood 
pressure measurement.  
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inTrODuCTiOn 
In everyday practice, blood pressure measurements are often of poor quality, mostly 
resulting in overestimation of the patient’s blood pressure.1 But even when performed 
according to the ‘state of the art’, blood pressure measurements in the office may not 
be representative of the patient’s true blood pressure status because the phenomenon 
‘white coat effect’ can introduce an additional level of bias.2 Overestimation of blood 
pressure leads to overprescribing of antihypertensive drugs, with avoidable side 
effects and costs. 
Until recently, observer bias and ‘white-coat effect’ could be eliminated sufficiently 
only with the ambulatory blood pressure measurement techniques like home blood 
pressure monitoring and ambulatory blood pressure monitoring (ABPM).3;4  However, 
these advantages of ambulatory techniques come with a price. ABPM is not very 
patient- friendly5 and is associated with disturbed sleep.6 Home blood pressure 
measurements may be inaccurate because of poor measurement  technique7 and 
report bias.8  These aspects make ABPM techniques less suitable for routine use in 
daily practice.  
Serial automated blood pressure measurement , without a doctor or nurse present, 
also has the potential to eliminate observer bias and reduce white coat effect.9-12 
Compared to ambulatory techniques, this could be used much more easily in routine 
practice. The results are available during a single consultation and the procedure 
appears to be more patient- friendly than ABPM. In a recent study 30-minute 
automated blood pressure measurement (30-minute OBPM) agreed well with 
daytime ABPM and classified normotension, white coat hypertension, masked 
hypertension and sustained hypertension similarly to daytime ABPM.13
 
The aim of this study was to compare 30-minute OBPM with standardised OBPM in 
general practice. The level of agreement between both methods was studied the 
repeatability compared. 
meThOD
Design
A method comparison study was performed to investigate how 30-minute OBPM 
agreed with standardised OBPM. As part of the method comparison, a repeatability 
study of 30-minute OBPM compared to standardised OBPM was carried out.14
30-minute office blood pressure measurement
134
Participants and setting
The study took place in two general practices of the academic practice-based 
research network 15 of the Radboud University Nijmegen Medical Centre. Each 
consecutive patient who attended the practice with a main reason for encounter that 
warranted blood pressure measurement was invited by the practice assistant to 
participate in the study. Patients gave written informed consent before participation. 
Exclusion criteria were atrial fibrillation, documented heart valve disease, complete 
axillary lymph node excision on the right side, and upper arm circumference more 
than 35 centimetres. Smoking, diabetes, cardiovascular disease and medication 
were recorded.
Blood pressure measurements
Both standardised OBPM and 30-minute OBPM were taken with the same, validated, 
automated oscillometric device, the Mobil-O-Graph NG (IEM GMBH, Stolberg, 
Germany).16 The devices are calibrated annually. Different bladder sizes were used to 
match the different arm circumferences. 
Two researchers (GS and SB) were trained to perform the OBPMs according to a 
detailed protocol (available on request) based on the recommendations of the 
European Society of Hypertension17 and the American Heart Association.18 The key 
elements of this protocol are listed in Boxes 1 and 2. During visit 1, standardised 
OBPM was carried out after a 5 minute rest period in the absence of the observer. 
The measurement consisted of three readings. 
Immediately afterwards, 30-minute OBPM followed, consisting of 11 measurements, 
of which 10 were made in the absence of the researcher. The position of the patient 
and cuff were not altered. The result of the first measurement of both standardised 
and 30-minute OBPM was discarded. After two weeks the measurements were 
repeated by the same researcher in the same room at the same time of the day (visit 2). 
To assess whether the measurement order influenced the results, an additional 
standardised OBPM was performed after the second 30-minute OBPM. 
The last noted usual blood pressure was collected to compare with the study’ 
standardised procedure (Table 1). The last ‘usual blood pressure’ was not included if there 
had been a medication change between this measurement and the start of the study. 
Sample size  
A priori a difference in blood pressure of 5 mmHg or more was deemed to be clinically 
relevant. To detect such a difference with a power of 90%, a significance level of 5% 
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7and assuming a standard deviation of the difference (SDD) of 14 mmHg, 82 patients would be needed. Considering a drop-out of 20 %, the study aimed to recruit 110 
participants.
30-minute office blood pressure measurement
Box 1  Key elements of blood pressure measurement
Key elements of standardized  
office blood pressure measurement 
Key elements of 30 minute automated 
 office blood pressure measurement
No talking Same position of patient and cuff as  
in standardized office blood pressure 
measurement
Temperature in the room 22 degrees Celsius 30 seconds after standardized office blood 
pressure measurement
Right arm
Placement of the cuff: 2 cm above  
antecubital fossa
Observer checks first measurement, then 
leaves the room. Patient stays in same position
Position of patient: sitting, back supported, 
feet flat on the floor, middle of cuff on level  
of right atrium
11 measurements every 3 minutes, first 
measurement discarded
5 minutes rest in the absence of the observer 
before office blood pressure measurement
3 readings with 30 seconds in between,  
first reading discarded
Box 2   Overview of study method
Time
Retrospectively Usual blood pressure
Visit 1, T=0 Standardised OBPM:
5 minutes rest
3 measurements,
First measurement 
discarded
30-min OBPM
11 measurements
First measurement 
discarded
Visit 2, T=2 weeks Standardised OBPM 30-min OBPM Standardised OBPM
OBPM= Office Blood Pressure Measurement
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Statistical methods
All data were registered and analysed in SPSS (version 16, Chicago, USA). Data were 
excluded for analysis if there was a change of medication type or doses between the 
two visits, or if fewer then 9 measurements were valid during the 30-minute OBPM.
 
The level of agreement between standardised OBPM and 30-minute OBPM was 
assessed by Bland and Altman’s  approach of difference-against-mean plots.19 
Because the difference increased with increasing blood pressure (positive rank 
correlation between the standard deviation (SD) and mean of the two blood pressure 
measurement methods), data were logarithmically transformed.14 The back transformed 
limits of agreement were added to Bland-Altman plots on the original scale.20 For 
comparison of means 95% confidence intervals(CIs) were presented For evaluation 
of the repeatability the mean difference was used in combination with the SDD. The 
repeatability of the two methods was compared by performing the Wilcoxon 
signed-rank test on the difference of the SD of the (logarithmically transformed) 
standardised OBPMs and of the SD of the 30-minute OBPMs. 
resulTs
Participants
A total of 105 patients agreed to participate in the study. Twenty-two patients were 
excluded from analysis: 10 because fewer than nine measurements of 30-minute 
OBPM were valid, six because of medication change between the two visits, two 
because they felt unwell during the measurements, two because they altered the 
Table 1   Characteristics of subjects
Number ( male/ female) 83     (32/51)
Age in years: mean (SD) 62.1 (10.7)
Mean last noted systolic blood pressure   in GP record (SD) mmHg, n=78 152.8(16.5)
Mean last noted diastolic blood pressure in GP record (SD) mmHg, n=78 82.0 (10.0)
On antihypertensive drugs: number (%) 69 (83)
Smoking: number (%) 10 (12)
Cardiovascular disease: number (%) 17 (20)
Diabetes mellitus type 2: number (%) 9 (11)
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position of their arm during the measurements and two because they were unable to 
come for the second visit. The characteristics of included patients are shown in Table 1. 
Agreement between 30-minute OBPM and standardised OBPM
Mean 30-minute OBPM readings were significantly lower than standardised OBPM 
readings, with a mean (absolute) difference of 7.6/2.5 mmHg (Table 2). 
Figure 1a and 1b shows Bland-Altman plots of systolic and diastolic blood pressures 
during the first visit. These plots show the differences between 30-minuteand 
standardised OBPM against their mean. As the difference increased with increasing 
blood pressure, the diverging limits of agreement were based on back transformation 
of results of logarithmically transformed data. The median difference in systolic blood 
pressure between standardised OBPM and 30-minute OBPM was 6% (95% limits of 
agreement ranging from -4% to 15%). The median difference in diastolic blood 
pressure between standardised OBPM and 30-minute OBPM was 3% (95% limits of 
agreement from -7% to 13%). 
30-minute office blood pressure measurement
Table 2  Blood pressure results
Mean blood pressure (SD) in mmHg Mean difference
Standardized OBPM
(n=83)
Systolic
Diastolic
visit 1 
134.4 (16.4)
84.1   (10.8)
visit 2
128.4 (14.8)
81.8   (10.7)
Δ visit 1-visit2 (95% CI)
[SDD]
6.0 (3.6 to 8.3) [10.9]
2.3 (1.0 to 3.7) [ 6.3]    
30-minute OBPM
(n=83)
Systolic
Diastolic
visit 1
126.8 (14.1)
81.6   (10.1)
visit 2
123.8 (13.3)
80.6   (10.5)
Δ visit 1- visit 2 (95% CI)
[SDD]
3.0 ( 0.9 to 5.1)[9.5]   
1.0 (-0.1 to 2.2) [5.3]  
Mean difference in blood pressure 
(95%CI)[SDD] in mmHg
Δ standardized 
OBPM-30min OBPM
(n=83)
Systolic
Diastolic
7.6 ( 6.1 to  9.1) [6.8]     
2.5 ( 1.5 to  3.4) [4.5]     
4.6(3.2 to 6.1)  [6.7] 
1.2(0.3 to 2.0)  [3.7] 
OBPM=office blood pressure measurement, Δ=difference, SDD=standard deviation of the difference, 
SD=standard deviation, CI=confidence interval
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Figure 1  a. Comparison of systolic blood pressures. Bland and Altman plot of difference 
between standardised systolic office blood pressure and 30-minute systolic office blood 
pressure against theirmean (first visit). b. Comparison of diastolic blood pressure. Bland 
and Altman plot of difference between standardised diastolic office blood pressure and 
30-minute systolic office blood pressure against theirmean (first visit).
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30-minute office blood pressure measurement
Figure 2  a. Repeatability of standardised OBPM. Bland and Altman plots of the 
repeatability of standardised systolic office blood pressure; difference between visit 
1 and visit 2 against the mean. b. Repeatibility of 30-minute OBPM. Bland and Altman 
plot of repeatability of 30-minute systolic office blood pressure; difference between 
visit 1 and 2 against mean.
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Repeatability of standardised and 30-minute OBPM 
Table 2 gives an overview of the data on visit 1 and 2 for both measurement methods. 
The mean difference between the first and second visit of 30-minute systolic OBPM 
is about half the mean difference of standardised OBPM. In addition, SDDs of repeat 
30-minute OBPM were smaller than SDDs of repeat standardised OBPM. The 
Wilcoxon signed-rank test demonstrated that repeatability was significantly better for 
30-minute OBPM than for standardised OBPM (P<0.01 for systolic and diastolic 
blood pressure).
Figures 2a and 2b presents Bland-Altman plots of the repeatability of systolic blood 
pressure for standardised and 30-minute OBPM respectively. The 95% limits of 
agreement are wider for standardised than for 30-minute systolic blood pressure. (for 
data on the repeatability of diastolic blood pressure see Table 2, a figure is available 
on request).
Measurement order
Comparing blood pressures measured by standardised OBPM before (128.4/81.8 
mmHg) and after (128.3/82.1) the second 30-minute OBPM (visit2) demonstrated that 
the order of measurements did not influence the results (difference (0.1/-0.3mmHg) 
(95 % CI -1.6 to 1.9/-1.2 to 0.6 mmHg) [SDD 7.9/4.0 mmHg]).
DisCussiOn 
Summary 
In this study, mean 30-minute OBPM readings were significantly lower than standardised 
OBPM readings, with a difference of 7.6/2.5 mmHg. The repeatability in 2 weeks was 
better for 30-minute OBPM than for standardised OBPM: the difference and the SDD 
in both systolic and diastolic blood pressure between the two visits were significantly 
lower for 30-minute than for standardised OBPM. 
Strengths and limitations
This study has several strengths. It was carried out in a general practice setting, where 
most hypertension management takes place. It is the first study to perform serial 
automated OBPM (AOBPM) in general practice, with a common 24-hour ambulatory 
device. The advantage is that many practices already own one of these devices, and 
they are likely to be standard equipment in all general practices in the near future. 
With one type of device (and consequently just one type of software), practices can 
then run both office and ambulatory measurement protocols. The presentation of 
data on repeatability is of additive value in judging serial AOBPM in the office.
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This study did not randomise the measurement order, which would have been 
 methodologically more accurate. To study whether any time effect would bias the 
results, a second standardised OBPM was added after 30-minute OBPM. 
Standardised office blood pressure before and after 30-minute OBPM did not differ, 
so randomisation of measurements appear to have had no significant effect on the 
results. By introducing 30-minute OBPM, the study aimed to reduce the ‘white-coat 
effect’ by leaving the patient alone in a room. The practice setting, which is also part 
of the ‘white-coat effect’, may still contribute to a blood pressure rise. 
Thirty-minute OBPM takes less time from a healthcare professional than the 
8–12minutes required for a standardised OBPM.1 However, it takes organisational 
skills and a spare room to implement 30- minute OBPM in daily practice. Previous 
research suggests that a duration of 30minutes may not be necessary. 13 A shorter 
measurement time may help to overcome organisational problems. 
Results were presented both absolutely and relatively. The data in Table 2 were 
presented in absolute figures. However, it is important to realise that the presented 
results depend on the height of the blood pressure. Therefore, a relative measure is, 
strictly speaking, more appropriate. Most data were analysed in this relative form 
(after log transformation) as can be seen in the Bland–Altman plots, but to facilitate 
interpretation and enable comparison with other studies, absolute figures are 
presented in Table 2.
Comparison with existing literature
The study data support abundant evidence on the difference between usual blood 
pressure measurement and standardised OBPM based on measurement bias.1,21 In 
real life, the difference between office blood pressure measurement and 30-minute 
OBPM will be greater than the difference found in this study, as lack of measurement 
technique in daily practice will lead to higher blood pressure results.
The mean last noted usual systolic blood pressure was 18mmHg higher than 
standardised OBPM (Tables 1 and 2). With the choice to compare 30-minute OBPM 
with standardised OBPM measurement, bias was eliminated as potential 
(confounding) cause for a difference in blood pressure. It is therefore hypothesised 
that the presented difference in blood pressure is a result of the reduction of the 
‘white-coat effect’ with 30-minute OBPM. The fact that standardised OBPMs before 
and after 30-minute OBPM were the same, underlines that a fall in blood pressure 
during 30-minute OBPM is influenced by the absence of the healthcare professional 
(and, less so, caused by a long rest period or regression to the mean). Other studies 
also demonstrated that repeated automated measurements with the patient alone in 
30-minute office blood pressure measurement
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an examining room give lower results than standardised measurements. Recently, 
Myers et al found a difference of 5.4/2.1mmHg between automated office blood 
pressure and conventional manual office blood pressure.22 These findings, which 
point in the same direction of lower results of automated measurements, are 
interesting, as their approach differed from the present one in two aspects: the 
researchers followed a shorter measurement procedure (10 minutes) and they used 
routine — not standardised — OBPM as the reference. It would be valuable to 
establish the repeatability of Myers et al’s short procedure. Considering the wide 
limits of agreement in relation to awake ambulatory blood pressure (limits of 
agreement –31.9 to 36.6mmHg,22 where 30-minute OBPM compared to daytime 
ambulatory blood pressure revealed limits of –19 to 19mmHg13), one may assume 
that the repeatability of their short procedure will not be as good as the present 
longer procedure. 
The differences between automated measurements with the patient alone in an 
examining room and standardised measurements seem to depend on the baseline 
blood pressure level of the study population; mean automated blood pressure was 
142/80mmHg in an outpatient clinic population (difference 20/5mmHg)10 and 
115/71mmHg in an open population study (difference 3/3mmHg ).23 The mean 
automated blood pressure of the present study population (134/84mmHg) was 
intermediate compared to the abovementioned studies, with the differences also 
intermediate. This is in line with the observation in the present study that differences 
are related to blood pressure level (Figures 1a and b).
To the authors’ knowledge, data on the repeatability of any serial AOBPM were 
lacking until now. This is unfortunate because study of repeatability should be part of 
every validation procedure.14 The relevance of repeatability was underlined recently 
by Palatini et al, who reported that ABPM only predicted end-organ damage in 
subjects with reproducible recordings.24 
In the absence of data on the repeatability of serial AOBPM, data in the present study 
were compared with reproducibility studies of 24-hour ABPM. In a study in 508 
hypertensive patients,24 the SDD of 24-hour ABPM was 8.3/6.4mmHg. Stergiou et al 
reported an SDD of 8.3/5.6mmHg for 24-hour ABPM; the SDD of the awake 24-hour 
ABPM was 10.0/6.6.25 In this last-mentioned article, the SDD for clinic blood pressure 
measurement was 11.0/6.6mmHg,25 comparable to the SDD reported in the present 
study for standardised OBPM (10.9/6.3mmHg).This study revealed that 30-minute 
OBPM had a good repeatability, as the difference between visits 1 and 2 was less 
than 5mmHg and the SDD (9.5/5.3mmHg) was in agreement with above-mentioned 
studies concerning the repeatability of 24- hour ABPM.
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Implications for practice and research
The results of this study demonstrate the potential of 30-minute OBPM to reduce 
measurement bias and ‘white-coat effect’ in the office, without the need for ambulatory 
techniques. Combined with the authors’ previous work, a 30-minute OBPM is 
suggested to be a valid, office-based alternative to daytime ABPM or home blood 
pressure measurement, in attempting to determine one’s true blood pressure status. 
Meanwhile, the authors realise that 30-minute OBPM cannot replace several relevant 
features that are unique for 24-hour ABPM, like measurement of blood pressure 
variability and nighttime blood pressure.
Myers has already suggested how to implement the use of serial AOBPM in daily 
practice.26 He advocates using the same reference value for the diagnosis of 
hypertension as in home blood pressure monitoring or daytime ABPM(135/85mmHg). 
The author’s previous finding that 30-minute OBPM outcome agreed well with 
daytime values of ABPM supports our proposal.13 
Further research should focus on the comparison of serial AOBPM with home blood 
pressure measurement and on the optimal measurement duration. In addition, 
implementation studies on cost effectiveness are required.
In conclusion, 30-minute office blood pressure measurement resulted in lower 
readings than standardised office blood pressure measurement and had a better 
repeatability. The favourable repeatability and the lower values of 30-minute OBPM 
are promising for its value in blood pressure management in general practice.
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We welcomed the article from Myers et al1 on automated office blood pressure (AOBP) 
measurement. It is well known that the differences between routine blood pressure (BP) 
measurements taken by health professionals in daily practice and BP measurements 
taken by well-trained observers within the framework of scientific studies are impressive. 
Because of this, routine BP measurement is of limited value. The studies on AOBP 
open the way in realizing a valid BP measurement in the office. We would like to add a 
few comments on the data presentation and on the proposed algorithm.
Differences in BP readings between different measurement methods are strongly 
dependent on the population in which BP measurements are taken. A high mean 
difference of 20/5 mm Hg between standardized automated measurements and 
automated measurements with the patient alone in a room was found in patients 
referred to a specialist for hypertension treatment. A low difference of 3/3 mm Hg was 
found in an open population. The mean automated BP was 142/80 mm Hg in the first 
mentioned study by Myers2 and 115/71 mm Hg in the open population study.3 In the 
recent article by Myers et al,1 Bland-Altman plots show the differences between 
manual office BP measurement and the daytime ambulatory BP against their mean 
(Figure 1A in Reference 1) . As one can see in the plots, the differences tend to 0 at 
normal BP levels and increase with increasing BP, the so-called positive rank 
correlation. So there is a proportional error indicating that the differences are not 
normally distributed. Therefore, the data need to be logarithmically transformed to 
specify the limits of agreement. After back transformation of the data, limits of 
agreement are percentage-plotted in the original scale. The median difference in 
systolic BP between office BP measurement and awake ambulatory BP measurement 
against their mean is then presented as a relative difference (a percentage).4
Considering the fact that the difference between manual office BP and awake 
ambulatory systolic BP tends to 0 in patients with normotension, we only advise an AOBP 
for those with an elevated routine BP. This would mean that AOBP is not mandatory 
for every BP measurement but only in case of a manual office BP >140/90 mm Hg.
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summary anD general DisCussiOn
The aim of this thesis was to explore current management of patients with Chronic 
Kidney Disease (CKD) in primary care and to evaluate shared care models that 
should facilitate optimal treatment in the patients’  own environment. In the previous 
chapters we presented the results of the individual studies. In this last chapter the 
findings will be summarised and discussed. Furthermore, we will outline implications 
for daily practice and future research.
main finDings 
1. Prevalence of patients with chronic kidney disease in primary care
We studied a primary care database of 207,469 patients. Data on kidney function or 
albuminuria were known in 64,102 patients. 9295 patients met the criteria for CKD 
stages 1 to 5 as defined by the KDOQI (Kidney Disease Outcomes Quality Initiative) 
guidelines, resulting in a prevalence of patients with CKD of 5.7% (chapter two). 
In our study KDOQI stages 1 to 2 accounted for 1.05% and stages 3 to 5 for 4.66%. 
2.  Quality of care for patients with CKD in primary care related to the 
guideline advice
Evidence based guidance aims to improve quality of CKD care. In the Netherlands, 
the interdisciplinary CKD-guideline for primary care and nephrology serves this 
purpose.1 This guideline has many similarities to the CKD-guideline from the National 
Institute for Health and Clinical Excellence (NICE) in the UK.2 Quality of care can be 
judged by the following components: a)monitoring of disease progression (kidney 
function, albuminuria, blood pressure); b)monitoring of renal metabolic parameters; 
c)recognition of CKD by coding the diagnosis on the episode list in the electronic 
medical record and d)achieving blood pressure targets. In chapter two we described 
the results of a study which evaluated these quality of care aspects in a retrospective 
analysis of the data of 8845 patients with CKD over a period of 15 months prior to 
data extraction. Patients under nephrology care were not included. 
a) Monitoring of disease progression was performed according to the guideline 
recommendations in 43% of the CKD patients;
b) Monitoring of metabolic parameters was complete in only 2% of the patients 
where it was indicated;
c) Recognition of CKD: 32% of the CKD patients had CKD documented on the 
episode list in the electronic patient file as ICPC code. For CKD stages 1 to 2 and 
3 to 5 ICPC-coding was 4% and 34% respectively;
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d) Blood pressure was below 140/90 mmHg in 44% of the patients.
Characteristics related to high quality of care were diabetes, and to a lesser extent 
hypertension, male sex and rural practice location. We concluded that there is room 
for improvement in all quality of care aspects for CKD patients in primary care.  
3.  Prevalence of renal metabolic abnormalities in patients with CKD in 
primary care
Currently, bone and mineral disorders are considered an important constituent of 
CKD. Monitoring of these abnormalities occurs infrequently in primary care and this 
was confirmed in our study on quality of care(chapter two).3 We used patient data 
from a randomised study to assess abnormalities in PTH, calcium, and phosphate 
levels. A total number of 174 patients in primary care was included (chapter three). 
Mean eGFR was 50.3 ml/min/1.73 m2. Calcium and phosphate abnormalities were 
infrequent. In contrast, elevated PTH levels occurred very often: in 40% of the patients 
PTH levels were above normal. We determined risk factors for abnormal PTH-levels 
by stepwise logistic regression. eGFR, heart failure and triglycerides contributed to 
elevated PTH, but their predictive value was very limited (partial R-square 13.5%, 
6.0% and 2.0% respectively).
4.  Would a shared care model between nurse practitioner, general 
practitioner and nephrologist, supported by a web-based consultation 
system (Telenephrology), contribute to the quality of care for patients  
with chronic kidney disease?
Organising care for patients with CKD, who often have many co-morbid conditions, 
is challenging. A shared care model between general practitioner, nurse practitioner 
and a nephrology team could improve quality of care and outcomes in patients with 
CKD.4 In the SHARING study (SHARed care for patients with chronic kidney disease 
In Nephrology and General practice) we assessed the effect of a shared care model 
on blood pressure, on kidney disease measures, on use of lipid lowering drugs or 
renin-angiotensin system inhibitors and on functional health status (chapter four). In 
a cluster randomised controlled trial in the Netherlands five primary care practices 
were allocated to the shared care model and four practices to usual care during one 
year. The multifaceted model consisted of training of professionals, structured care 
by a nurse practitioner in primary care and the opportunity to consult a nephrology 
team in a protected digital environment (Telenephrology). 164 patients with diabetes 
mellitus type 2 and/or hypertension with an estimated GFR < 60 ml/min/1.73 m2 were 
included for analysis. Main outcome measures were lowering of blood pressure and 
the achievement of blood pressure targets (130/80 mmHg). Secondary outcome 
measures were laboratory parameters and functional health status.
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BP after one year was 134.7/73.8 mmHg in the intervention group and 142.9/80.9 
mmHg in the control group (difference systolic: 8.2 mmHg, 95%CI 3.6 to 12.9 mmHg; 
diastolic: 4.7mmHg, 95%CI 1.1 to 8.4 mmHg). Blood pressure decreased with 8.1 
(95% CI 4.8 to 11.3) /1.1 (95% CI -1.0 to 3.2) mmHg in the intervention group compared 
to -0.2 (95% CI -3.8 to 3.6)/-0.5 (95% CI -2.9 to 1.8)mmHg in the control group. 
Achievement of systolic and diastolic blood pressure targets was 44%/71% in the 
intervention group versus 22%/50% in the control group (p= 0.003/0.007). The 
improvement in blood pressure control was paralleled with an increase in the use of 
renin-angiotensin system inhibitors (73% versus 51%)(p=0.01). PTH was 6.1 pmol/l in 
the intervention group and 8.2 pmol/l in the control group (p=0.02). This was in 
parallel with the more frequent use of vitamin D, which was 15% and 1% respectively. 
Other kidney disease measures did not show clinically relevant differences between 
the intervention and the control group. Cholesterol and LDL levels decreased in the 
intervention group during the intervention from 4.9 to 4.6 mmol/l  and from 2.9 to 2.5 
mmol/l respectively (p<0.001 and p<0.001). This was in parallel with an increase in 
the use of lipid lowering drugs from 59% to 73% (p<0.001).
Since blood pressure is the most important modifiable risk factor for disease 
progression and outcome in CKD patients, we concluded that a shared care model 
seems beneficial in patients with CKD in primary care.
5.  Feasibility of a web-based consultation between general practitioner and 
nephrologist 
During the SHARING study we developed a web-based consultation system: 
Telenephrology. With this system, relevant data are exported from the electronic 
patient file to a protected digital environment from which advice can be formulated by 
the nephrologist. In chapter five we described the results of an observational, 
prospective study in which we analysed Telenephrology-consultations by 28 general 
practices and five nephrology departments. The primary outcome was the potential 
reduction in in-person referrals, measured as the difference between the number of 
intended referrals as stated by the general practitioner and the number of referrals 
requested by the nephrologist. 122 new consultations were included. In the absence 
of Telenephrology 43 patients (35.3%) would have been referred by their general 
practitioners, whereas the nephrologist considered referral necessary in only 17 
patients (13.9%) (p<0.001). The general practitioner would have treated 79 patients in 
primary care. In ten of these patients the nephrologist deemed referral necessary. 
We concluded that a web-based consultation system could reduce the number of 
referrals. In that way Telenephrology may contribute to an effective use of health 
facilities by allowing patients to be treated in primary care with remote support by a 
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nephrologist. The system was feasible, since it was mainly used during office hours 
and mean consultation time was only nine minutes. 
6.  How could general practitioners and pharmacists contribute to medication 
safety in patients with CKD and diabetes or hypertension?  
The prescription of potentially harmful drugs is a threat for CKD patients: impaired 
renal function leads to increased serum drug levels in drugs that depend on renal 
excretion, drugs that can be directly nephrotoxic or that can indirectly damage the 
kidney by affecting renal perfusion. Collaboration between general practitioner and 
community pharmacist may contribute in finding and reducing medication errors. 
In chapter six we described a pharmacy medication alert system based on renal 
function. This system resulted in therapeutic advice with respect to dosage of 
 discontinuation in one of every nine prescriptions of target drugs in elderly patients 
using blood-glucose lowering or cardiovascular drugs. Taking the clinical context into 
account, the general practitioner agreed with the advice half the time. Overall, the 
general practitioner agreed to rectify the prescription in 5% of the cases. The drugs 
most frequently involved were diuretics (41.3% of therapeutic advice), blood glucose-
lowering drugs (14.0%), digoxin (11.2%), and renin-angiotensin system inhibitors 
(10.5%). We concluded that collaboration between general practitioner and 
pharmacist, using their clinical and pharmacological expertise respectively, can 
contribute to patient safety. 
7.  Validation study
As blood pressure is related to cardiovascular and renal outcome in patients with 
CKD, adequate measurement of blood pressure is essential in directing treatment 
decisions. We validated a 30-minute automated blood pressure measurement 
(30-min AOBPM) in primary care (chapter seven). This measurement method 
resulted in lower readings than standardised office blood pressure measurement and 
had a better repeatability. 30-min AOBPM may be of value in the diagnosis and 
treatment of hypertension, but prognostic studies on the relation between 30-min 
AOBPM measurement results and cardiovascular outcome are needed to validate 
the clinical value.
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DisCussiOn
CKD and its complications have, beside the personal impact, a high impact on 
organisational and economic systems.5 With an ageing population and increasing 
prevalence of diabetes and hypertension, the prevalence of CKD has risen to 13% in 
2004 in the USA and 10% in the Netherlands.6,7 Patients with CKD are at risk for both 
renal and cardiovascular morbidity. The increased cardiovascular risk in CKD patients 
is a major concern and leads to a high burden of adverse outcomes.8,9 This, added 
to the fact that patients with CKD often suffer from other chronic conditions, makes 
management complex.10,11 In the primary care setting CKD is characteristically 
associated with hypertension or diabetes and a predominant occurrence in the 
elderly. It is only since the last decade that the potential adverse outcomes of CKD 
may count on awareness in primary care. The international classification of CKD and 
the default reporting of estimated glomerular filtration rates (eGFR) have contributed 
to this awareness.12 Furthermore, the recommendations for regular serum creatinine 
measurements in high-risk groups have led to a high proportion of patients with 
diabetes and hypertension who have their renal function checked on a regular basis. 
The high prevalence of recognised CKD patients not only brings along a burden of 
disease but also a burden of treatment. Management of CKD should preferably take 
place in primary care, while secondary care facilities should be used when needed.13,14 
The engagement of primary care in CKD management can lead to an increase in 
quality of care in relation to evidence-based guidance.15 This will not only be cost-
effective, but also is more convenient for the patient. In our studies we identified 
possibilities to improve care at the primary-secondary care interface: the delegation 
of tasks to a nurse practitioner, web-based consultation of a nephrology team and 
collaboration between general practice and pharmacy. We will discuss our findings 
in the light of what was already known on CKD management in primary care. Then we 
will discuss the hurdles that need to be taken to optimise CKD management in 
primary care, followed by recommendations for daily practice and for further research.
Findings in the light of prior knowledge
Prevalence
We found a prevalence of known CKD patients of 5.7%. A population study in the 
Netherlands showed that the community prevalence of CKD is 10.4%, with 5.1% in 
CKD stage 1-2 (predominantly defined by the presence of micro-albuminuria), and 
5.3% in CKD stage 3-5 (eGFR < 60ml/min/1.73m2 with or without albuminuria). 7  In our 
study KDOQI stages 1 – 2 accounted for 1.05% (21% of the population prevalence) and 
stages 3 – 5 for 4.66% (88% of the population prevalence). These data clearly reflect 
current guidelines, which do not support routine testing for micro-albuminuria. Most 
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importantly, and relevant in view of the debate on the need for CKD-screening 
programs, almost 90% of patients with CKD and impaired renal function could be 
identified by searching primary care records.
Quality of care 
With respect to quality of care, the performance on monitoring of disease progression 
was similar to other studies in primary care.16,17 Monitoring of metabolic abnormalities 
in our study was very low: PTH was monitored in 4% of the patients where it was 
indicated versus 13% in an American study.17 The follow-up of albumin creatinine ratio 
and blood pressure in our study was much lower than the 82% for urine albumin 
creatinine ratio and 98% for blood pressure readings that were found in the United 
Kingdom in 2010/2011.18 
The blood pressure target of 140/90 mmHg was met in 44% of the patients, which is 
comparable to other studies. Italian researchers found that 44% of CKD patients in 
primary care had a blood pressure <140/90 mm Hg and in other studies a lower 
target of 130/80 was met in 27% to 54% of the patients. 19-21 
Recognition (ICPC-coding on the episode list in the electronic medical record) is 
much more than an administrative issue: improved recognition appeared to be 
related with a better quality of care.19,21. When it comes to recognition results vary 
enormously between studies: recognition varied between 2.4% and 24 % in routine 
practice and increased to 70% after introduction of a quality improvement 
program.17,19,22-24 National or local agreements may well be the reason for this wide 
variation. In the United Kingdom, the introduction of the Quality of Outcome 
Framework, in combination with pay for performance, has led to a rise in quality of 
care in all aspects.15,18,25  
All in all, quality of CKD care in daily general practice in the Netherlands offers room 
for improvement. One should realise that our data originated from the year following 
introduction of the interdisciplinary CKD-guideline for primary care and nephrology. 
It may well be that a few years later targets will be better met. It will be interesting to 
see whether the Telenephrology intervention in the CONTACT study (Consultation Of 
Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment in 
primary care, final results due in 2013) leads to better quality of care. Preliminary 
results suggest that the mere focus on CKD, by providing lists of patients that met 
CKD criteria, improved quality of care even in the control group.26 
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Metabolic abnormalities
Elevated PTH levels are associated with adverse cardiovascular outcomes in patients 
with CKD.27-29. Elevated PTH-levels occur in earlier stages of CKD than generally is 
expected.30-32 Studies on PTH have been mainly performed in secondary care. Data 
on prevalence of metabolic abnormalities in patients that are under care of their 
general practitioner are rare. In our study PTH levels were above normal in 40% of 
patients with known chronic kidney disease and diabetes or hypertension. This was 
in line with what was found in a study in out-patient clinics.33 Guidelines vary in their 
recommendations on testing for metabolic abnormalities. The NICE guideline advises 
measurement of PTH, calcium and phosphate in patients with eGFR < 30 ml/min/1.73 
m2.2 The KDOQI and KDIGO guidelines recommend these measurements in patients 
with eGFR < 60 ml/min/1.73 m2.12,34 This difference can be traced to the lack of 
evidence on the effect of PTH lowering on cardiovascular outcomes in primary care. 
Awaiting further evidence, we suggest that general practitioners test patients with 
CKD stage 3 or worse on PTH, calcium and phosphate as advised in the KDIGO and 
KDOQI guidelines. We may not that elevated PTH levels could be a reflection of 
vitamin D deficiency, which is frequent in the elderly.
As vitamin D treatment is cheap and safe, GPs could consider prescribing vitamin D 
in patients with elevated PTH levels. 
Shared care
The call for shared care in managing CKD is not new. Many initiatives in that direction 
have been described with predominantly positive results.4,14,35,36 However, firm 
evidence of the efficacy of such an approach based on data from  cluster randomised 
controlled trials was not available.37 The QICKD study, a cluster randomised trial that 
compares several quality improvement interventions to lower systolic blood pressure 
in CKD patients in primary care, will hopefully provide further evidence on quality 
improvement strategies. 
Our SHARING trial has provided strong encouragement to embed primary care CKD 
management in an organisation model which includes nurse practitioner and 
nephrologist. We noted, though, that our results were weakened somewhat by a high 
value for the intra-cluster correlation coefficient.  
Telenephrology
We evaluated the implementation of Telenephrology and the potential of reducing 
referrals. Some other studies focused on improvement of the referral process in CKD 
patients. For example, a system of continuous education, (email)consultations and 
shared clinical information in Barcelona led to more adequate and better prioritised 
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referrals. 38 In Hawaii nephrologists went a step further: they evaluated electronic 
patient records on population level and gave unsolicited advice to general practitioners 
on referral and patient management. This led to an increase of timely referrals for 
renal replacement therapy and a reduction in low-risk referrals.39 In the United 
Kingdom electronic sharing of primary care electronic patient records led to a 
reduction of paper referrals but it was not clear whether the total number of referrals 
changed.40
Our Telenephrology system was unique in the sense that only relevant information 
was presented in a protected digital environment and that the communication was 
embedded in the electronic patient record. The CONTACT study ( Consultation Of 
Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment in 
primary care) will evaluate the effect of Telenephrology on referrals and quality of care 
in a cluster randomised controlled trial. 
Teleconsultation is a very promising instrument to dissiminate secondary care 
knowledge to primary care. Application of Teledermatology for example, proved to 
realise higher quality of care at a lower cost. 41 The high demands on health care from 
an ageing population with many chronic conditions, ask for creative innovations in 
the primary-secondary care interface. Telenephrology can well be one of these.
Shared care with pharmacist
Evaluation of medication errors in relation to renal function (HARM study: Hospital 
Admissions Related to Medication) teaches us that in the patient group monitored by 
general practitioners, renal function was available but the proper actions were 
undertaken less often than in the hospital monitored group. This may have been the 
result of general practitioners’ lack of knowledge on the appropriate actions. 42 This 
underlines our aim to involve pharmacists in preventing medication errors in relation 
to renal function. Our study showed implementation of a pharmacy medication alert 
system led of rectification by the general practitioner in 5% of prescriptions in high-risk 
patients. In Germany, a multifaceted intervention including the use of a software 
program reduced the number of prescriptions that exceeded the maximum 
recommended standard daily doses in relation to renal function.43
Quality improvement strategies between pharmacist and general practitioner can be 
(cost) effective, but are also labour intensive.44-47 Focusing on high risk patients, 
sensibly using information technology and linking of laboratory to pharmacy can 
contribute to an efficient way of working.48 
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Hurdles
In our studies we identified the following hurdles that need to be cleared to bring CKD 
management in primary care in accordance with the prevailing guidance: 
1.  Recognition of CKD was poor. Although routine primary care laboratory data 
identified the majority of patients with CKD stage 3 to 5, only one third of these 
patients had an ICPC code of CKD on the diagnosis list. This does not necessarily 
mean that un-coded CKD patients do not receive adequate follow-up and 
treatment, but it certainly implies that prescribing alerts regarding renal function will 
not be generated.
2.  Quality of care regarding adequate follow-up was suboptimal: the number of 
CKD patients that had a record of a urine albumin creatinine ratio in the previous 
15 months was only 48%. Also, the number of CKD patients that had blood 
pressure readings in the previous 15 months was 73%, which was lower than has 
been observed in structured diabetes care in the Netherlands (99%).49
3.  Although the prevalence of elevated serum parathyroid hormone (PTH) levels in 
primary care is high, testing of metabolic parameters was very low.
4. Blood pressure targets were not well met.  
5.  Only 54 % of patients that should have been referred according to the prevailing 
guideline were actually referred (there might have been good reasons for this).
6.  Safe prescribing in relation to renal function was not a reality yet. It was remarkable 
that data on renal function were available in many patients (more frequently in 
patients with diabetes than in patients with hypertension), but appropriate action 
was often not taken. 
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 Innovative aspects of this study: 
• Monitoring of disease progression and recognition of CKD is suboptimal
• Monitoring of eGFR and albuminuria is better in patients with diabetes than in patients 
without diabetes
• Monitoring of metabolic disturbances is far below the guideline advice
• Elevated PTH-levels are highly prevalent in patients with CKD and diabetes or 
hypertension in general practice 
• Blood pressure targets are often not met
• Shared care between general practice and nephrology is beneficial in reducing blood 
pressure 
• Telenephrology is a feasible instrument to disseminate secondary care nephrology 
knowledge to primary care and to optimise referrals
• A pharmacy medication alert system can contribute to a reduction in medication errors 
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Recommendations for daily practice  
The previously mentioned hurdles lead to suggestions for improvement: 
1. Feedback to general practices, based on laboratory findings in the electronic 
patient record, could be an effective way to help practices improve their recognition 
of CKD patients.50,51
2.  To improve follow-up, nurse practitioners can contribute to quality of care by 
performing regular patient evaluations (chapter 4). This can well be integrated in 
the current diabetes and hypertension schemes in general practice that are run 
by nurse practitioners. Incentives to promote structured follow-up could be of help.
3.  Follow-up of metabolic abnormalities could be improved by educating general 
practitioners and by providing feedback on data extracted from the electronic 
patient record. Our research showed that shared care, supported by Tele-
nephrology consultations, will also be of help in focussing attention on mineral 
and bone metabolism (chapter 5). Clinical decision support systems have shown 
to be of benefit. 52,53 More fundamental, the lack of evidence on the effect of PTH 
lowering on cardiovascular outcome should be addressed first of all. 
4.  Blood pressure targets in CKD management require more awareness in primary 
care. General practitioners have less confidence in treating CKD than in treating 
diabetes and hypertension. This is reflected in a lower achievement of targets.54 
On the other hand, too much lowering of blood pressure is associated with stroke 
and increased mortality in frail elderly.55,56 Additive markers for overtreatment are 
needed. 57 Shared care could contribute to titration of blood pressure lowering 
(chapter 4). Furthermore adequate blood pressure measurement requires attention. 
58 Home blood pressure measurements (self monitoring or 24 –hour ABPM) and 
30-minute automated measurement in the office provide validated blood pressure 
measurement techniques (chapter 7). Further implementation of these techniques 
and adequate reporting in primary care computer records is advisable.    
5. The low referral rate in patients in whom referral was indicated (chapter 2) could 
partly be due to a lack of recognition, severe co-morbidity or to scepticism 
regarding the guideline advice. The fact that impaired renal function is highly 
prevalent in elderly people and renal prognosis and mortality are often not 
affected, may make it difficult to distinguish which patients are at risk.59 Easily 
accessible consultation of a nephrology team to discuss necessity of referral will 
be of added value. 
6.  To optimise drug prescribing in patients with decreased renal function, many 
steps need to be taken: systematic renal function monitoring in patients on target 
drugs and registering a diagnostic code for impaired renal function to activate 
the prescribing alert system. Furthermore, in unstable clinical situations like 
dehydration, renal function needs to be re-evaluated. Electronic alert systems in 
general practices are sophisticated, but alerts are often ignored.60 Further steps 
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to optimise drug prescribing should include linking laboratory to pharmacy, 
assessment of the alerts by the pharmacist, discussion of the advice with the 
general practitioner to consider the individual clinical context and communication 
with the patient on the proposed prescription change. 
reCOmmenDaTiOns fOr fuTure researCh
In the field of CKD management at the primary-secondary care interface a lot has 
been achieved in the past decade. Areas of uncertainty remain. This brings us to the 
following recommendations for future research: 
- Study patient preferences on treatment environment and explore possibilities for 
improved self-management.
- Perform qualitative studies on general practitioners views on CKD treatment 
goals and referral.
- Identify which elderly patients with CKD in primary care are at high risk of poor 
outcomes, so that care can be focused.
- Study the effect of PTH lowering in primary care patients on cardiovascular 
outcome. 
- Explore possibilities for discharge from secondary care to primary care, 
supported by web-based consultation.61,62
Future studies should contribute to the primary care strength of focusing on patients 
that will benefit from our interventions, without labeling each abnormal laboratory 
result as an illness.
COnClusiOns
In the field of Chronic Kidney Disease many players have a role: amongst others, 
patient, nurse practitioner, general practitioner, pharmacist and nephrologist need 
well defined tasks and responsibilities. Not only evidence-based guidance, but also 
implementation tools that address practical and mental barriers are required to let the 
players optimally perform their roles. In the collaboration between players a world 
can be gained when shared care is the starting point and communication is facilitated 
by information technology. The result could be that optimal treatment is realised in 
cooperation with the patient in his or her own environment.
Summary and discussion
164
referenCes
1. Grauw de W, Kaasjager HAH, Bilo HJG, et al. Landelijke Transmurale Afspraak Chronische nierschade. 
Huisarts en Wetenschap. 2009;52(12):586-587.
2. National Collaborating Centre for Chronic Conditions Chronic Kidney Disease. National Clinical 
Guideline for Early Identification and Management in Adults in Primary and Secondary Care.London: 
Royal College of Physicians; 2008.avialble from http://www.nice.org.uk/nicemedia/pdf/CG073NICE-
Guideline.pdf (15 November 2012 date last accessed)
3. Bhan I, Dubey A, Wolf M. Diagnosis and management of mineral metabolism in CKD. J Gen Intern 
Med. Jul 2010;25(7):710-716.
4. Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared primary and secondary care 
nephrology service for managing patients with moderate to advanced CKD. American journal of kidney 
diseases : the official journal of the National Kidney Foundation. Jan 2006;47(1):103-114.
5. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers 
of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and 
economic analysis. Health Technol Assess. Apr 2010;14(21):1-184.
6. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 
2007;298(17):2038-2047.
7. de Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker, and a new target for 
therapy. Kidney Int.Suppl. 2005(98):S25-S29.
8. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease 
compared with those with diabetes: a population-level cohort study. Lancet. Jun 18 2012.
9. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global 
burden of major noncommunicable diseases. Kidney international. Dec 2011;80(12):1258-1270.
10. Crabtree BF, Nutting PA, Miller WL, et al. Primary care practice transformation is hard work: insights 
from a 15-year developmental program of research. Medical care. Dec 2011;49 Suppl:S28-35.
11. Kernick D. A theoretical framework for multimorbidity: from complicated to chaotic. The British journal 
of general practice: the journal of the Royal College of General Practitioners. Sep 2012;62(602):659-662.
12. National Kidney Foudation. K/DOQI Guidelines[internet]. New York; 2002. Available from http://www.
kidney.org/professionals/KDOQI/guidelines_commentaries.cfm NKF K/DOQI Guidelines. 2008. [11 
November 2012 date last accessed] 
13. McIntyre NJ, Fluck R, McIntyre C, Taal M. Treatment needs and diagnosis awareness in primary care 
patients with chronic kidney disease. The British journal of general practice : the journal of the Royal 
College of General Practitioners. Apr 2012;62(597):e227-232.
14. Dean J. Organising care for people with diabetes and renal disease. Journal of renal care. Feb 2012;38 
Suppl 1:23-29.
15. Stevens PE, de Lusignan S, Farmer CK, Tomson CR. Engaging primary care in CKD initiatives: the UK 
experience. Nephrol Dial Transplant. Oct 2012;27 Suppl 3:iii5-iii11.
16. Stevens PE, O’Donoghue DJ, de LS, et al. Chronic kidney disease management in the United Kingdom: 
NEOERICA project results. Kidney Int. 2007;72(1):92-99.
17. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of 
chronic kidney disease. J Gen Intern Med. Apr 2011;26(4):386-392.
18. The quality and outcomes framework. Available from: http://www.ic.nhs.uk/statistics-and-data-collec-
tions/audits-and-performance/the-quality-and-outcomes-framework (12November 2012, date last 
accessed)
19. Ravera M, Noberasco G, Weiss U, et al. CKD awareness and blood pressure control in the primary 
care hypertensive population. Am.J.Kidney Dis. 2011;57(1):71-77.
20. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in 
chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. Sep 25 
2006;166(17):1884-1891.
21. Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. May 2007;49(5):634-641.
165 8
22. Minutolo R, De Nicola L, Mazzaglia G, et al. Detection and awareness of moderate to advanced CKD 
by primary care practitioners: a cross-sectional study from Italy. American journal of kidney diseases : 
the official journal of the National Kidney Foundation. Sep 2008;52(3):444-453.
23. Guessous I, McClellan W, Vupputuri S, Wasse H. Low documentation of chronic kidney disease 
among high-risk patients in a managed care population: a retrospective cohort study. BMC.Nephrol. 
2009;10:25.:25.
24. Wentworth AL, Fox CH, Kahn LS, Glaser K, Cadzow R. Two years after a quality improvement intervention 
for chronic kidney disease care in a primary care office. American journal of medical quality : the official 
journal of the American College of Medical Quality. May-Jun 2011;26(3):200-205.
25. de Lusignan S, Mimnagh C. Breaking the first law of informatics: the Quality and Outcomes Framework 
(QOF) in the dock. Informatics in primary care. 2006;14(3):153-156.
26. van Gelder V, Scherpbier-de Haan ND. Personal observation from the CONTACT study. 1 November 2012; 
27. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL. Plasma parathyroid hormone level and prevalent 
cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program 
(KEEP). Am.J.Kidney Dis. 2009;53(4 Suppl 4):S3-10.
28. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the 
risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70(2):351-357.
29. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular 
mortality in the community. Circulation. Jun 2 2009;119(21):2765-2771.
30. Martinez-Castelao A, Gorriz JL, Portoles JM, et al. Baseline characteristics of patients with chronic kidney 
disease stage 3 and stage 4 in spain: the MERENA observational cohort study. BMC nephrology. 2011;12:53.
31. Lash JP, Go AS, Appel LJ, et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline character-
istics and associations with kidney function. Clinical journal of the American Society of Nephrology : 
CJASN. Aug 2009;4(8):1302-1311.
32. Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJ. eGFR and creatinine clearance in relation to 
metabolic changes in an unselected patient population. Eur.J.Intern.Med. 2009;20(7):722-727.
33. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and 
phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney 
disease. Kidney Int. 2007;71(1):31-38.
34. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic 
Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int.Suppl. 2009(113):S1-130.
35. Hemmelgarn BR, Manns BJ, Zhang J, et al. Association between multidisciplinary care and survival for 
elderly patients with chronic kidney disease. Journal of the American Society of Nephrology : JASN. 
Mar 2007;18(3):993-999.
36. Barrett BJ, Garg AX, Goeree R, et al. A nurse-coordinated model of care versus usual care for stage 
3/4 chronic kidney disease in the community: a randomized controlled trial. Clinical journal of the 
American Society of Nephrology : CJASN. Jun 2011;6(6):1241-1247.
37. Ronksley PE, Hemmelgarn BR. Optimizing Care for Patients With CKD. American journal of kidney 
diseases : the official journal of the National Kidney Foundation. Jul 2012;60(1):133-138.
38. Garcia Garcia M, Valenzuela Mujica MP, Martinez Ocana JC, et al. Results of a coordination and 
shared clinical information programme between primary care and nephrology. Nefrologia : publicacion 
oficial de la Sociedad Espanola Nefrologia. 2011;31(1):84-90.
39. Lee BJ, Forbes K. The role of specialists in managing the health of populations with chronic illness: the 
example of chronic kidney disease. BMJ. 2009;339:b2395.
40. Stoves J, Connolly J, Cheung CK, et al. Electronic consultation as an alternative to hospital referral for 
patients with chronic kidney disease: a novel application for networked electronic health records to 
improve the accessibility and efficiency of healthcare. Qual Saf Health Care. Oct 2010;19(5):e54.
41. van der Heijden JP, de Keizer NF, Bos JD, Spuls PI, Witkamp L. Teledermatology applied following 
patient selection by general practitioners in daily practice improves efficiency and quality of care at 
lower cost. Br J Dermatol. Nov 2011;165(5):1058-1065.
Summary and discussion
166
42. Leendertse AJ, van Dijk EA, De Smet PA, Egberts TC, van den Bemt PM. Contribution of renal impairment to 
potentially preventable medication-related hospital admissions. The Annals of pharmaco therapy. May 
2012;46(5):625-633.
43. Erler A, Beyer M, Petersen JJ, et al. How to improve drug dosing for patients with renal impairment in 
primary care - a cluster-randomized controlled trial. BMC family practice. Sep 6 2012;13(1):91.
44. Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients 
at community health clinics. The Annals of pharmacotherapy. Jan 2005;39(1):22-27.
45. Bhardwaja B, Carroll NM, Raebel MA, et al. Improving prescribing safety in patients with renal 
insufficiency in the ambulatory setting: the Drug Renal Alert Pharmacy (DRAP) program. Pharmaco-
therapy. Apr 2011;31(4):346-356.
46. Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R. Impact of a renal drug dosing service on dose adjustment 
in hospitalized patients with chronic kidney disease. The Annals of pharmacotherapy. Oct 2009;43(10): 
1598-1605.
47. Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist-led information technology intervention for 
medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness 
analysis. Lancet. Apr 7 2012;379(9823):1310-1319.
48. Schiff GD, Klass D, Peterson J, Shah G, Bates DW. Linking laboratory and pharmacy: opportunities for 
reducing errors and improving care. Arch.Intern.Med. 2003;163(8):893-900.
49. van Hateren KJ, Drion I, Kleefstra N, et al. A prospective observational study of quality of diabetes care 
in a shared care setting: trends and age differences (ZODIAC-19). BMJ open. 2012;2(4).
50. Rayner HC, Hollingworth L, Higgins R, Dodds S. Systematic kidney disease management in a 
population with diabetes mellitus: turning the tide of kidney failure. BMJ quality &amp; safety. Oct 
2011;20(10):903-910.
51. de Lusignan S. Using feedback to raise the quality of primary care computer data: a literature review. 
Studies in health technology and informatics. 2005;116:593-598.
52. Klebe B, Farmer C, Cooley R, et al. Kidney disease management in UK primary care: guidelines, 
incentives and information technology. Fam.Pract. 2007;24(4):330-335.
53. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision 
support systems: a systematic review of trials to identify features critical to success. BMJ. Apr 2 
2005;330(7494):765.
54. Tahir MA, Dmitrieva O, de Lusignan S, et al. Confidence and quality in managing CKD compared with 
other cardiovascular diseases and diabetes mellitus: a linked study of questionnaire and routine 
primary care data. BMC family practice. 2011;12:83.
55. Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in 
stages 3 to 4 chronic kidney disease. Journal of the American Society of Nephrology : JASN. Mar 
2007;18(3):960-966.
56. Protogerou AD, Safar ME, Iaria P, et al. Diastolic blood pressure and mortality in the elderly with 
cardiovascular disease. Hypertension. Jul 2007;50(1):172-180.
57. Kerr EA, Lucatorto MA, Holleman R, et al. Monitoring performance for blood pressure management 
among patients with diabetes mellitus: too much of a good thing? Arch Intern Med. Jun 25 
2012;172(12):938-945.
58. Crinson I, Gallagher H, Thomas N, de LS. How ready is general practice to improve quality in chronic 
kidney disease? A diagnostic analysis. Br.J.Gen.Pract. 2010;60(575):403-409.
59. Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and 
death following attainment of stage 4 CKD in a referred cohort. American journal of kidney diseases : 
the official journal of the National Kidney Foundation. Oct 2008;52(4):661-671.
60. Isaac T, Weissman JS, Davis RB, et al. Overrides of medication alerts in ambulatory care. Arch.Intern.
Med. 2009;169(3):305-311.
167 8
61. Meran S, Don K, Shah N, Donovan K, Riley S, Phillips AO. Impact of chronic kidney disease management 
in primary care. QJM : monthly journal of the Association of Physicians. Jan 2011;104(1):27-34.
62. Phillips LA, Donovan KL, Phillips AO. Renal quality outcomes framework and eGFR: impact on 
secondary care. QJM : monthly journal of the Association of Physicians. Jun 2009;102(6):415-423.
Summary and discussion

Samenvatting
Teamwork!
List of publications
Curriculum vitae
170
171
samenvaTTing
Chronische nierschade (CNS) en de complicaties daarvan, veroorzaken, naast de grote 
persoonlijke impact, veel druk op gezondheidszorg voorzieningen. Door de vergrijzing 
en de toename van suikerziekte en hoge bloeddruk is de verwachting dat  CNS in 
de toekomst nog meer zal vóórkomen dan het al doet. Patiënten met CNS hebben 
een verhoogd risico op het ontwikkelen van hart- en vaatziekten. Bovendien hebben 
zij vaak nog andere chronische aandoeningen. Dat maakt dat een groot aantal 
behandelaars bij de patiënt is betrokken. Voornoemde facetten (chronische ziekte, 
veel bijkomende ziekten, veel behandelaars) maken de organisatie van zorg rond 
deze patiënten groep complex. Bij voorkeur vindt de zorg plaats in de eerste lijn. 
Verwijzing naar de tweede lijn dient alleen plaats te vinden waar nodig. 
Het doel van dit proefschrift was om het management van CNS in de eerste lijn in kaart 
te brengen en om te onderzoeken of een model van gedeelde zorg kan bijdragen aan 
optimale zorg in de eigen omgeving van de patiënt. In dit hoofdstuk zal ik de bevindingen 
samen vatten en een paar aspecten uit de discussie van het proefschrift naar voren halen. 
belangrijKsTe bevinDingen 
1. Vóórkomen van CNS in de eerste lijn
Wij onderzochten gegevens van ruim 200.000 patiënten uit 47 huisartspraktijken. Bij 
64.102 van hen was informatie over de nierfunctie of de eiwituitscheiding in de urine 
bekend. 9295 patiënten voldeden aan de internationale diagnose criteria voor CNS, 
wat betekent dat bij 5.7% van de patiënten in de huisartspraktijk laboratorium gegevens 
wijzen op het bestaan van CNS (hoofdstuk 2). 
2.  Kwaliteit van zorg voor patiënten met CNS in de eerstelijn vergeleken met 
de richtlijnen
Richtlijnen beogen de kwaliteit van zorg voor CNS patiënten te verbeteren. In Nederland 
geeft de Landelijke Transmurale Afspraak CNS adviezen voor diagnostiek en behandeling 
in de eerste lijn en voor afstemming van zorg met de tweede lijn. Wij onderzochten of 
de kwaliteit van zorg overeenkomt met de richtlijn. Daartoe splitsten wij de kwaliteit 
van zorg in de volgende componenten: a) monitoren van ziekte progressie (onderzoek 
van nierfunctie, eiwit uitscheiding, bloeddruk); b)monitoren van zogenaamde metabole 
parameters; c)herkennen van CNS door de ziekte te coderen in de probleemlijst van 
het elektronisch patiënten dossier, en d)het bereiken van bloeddruk doelen. We onder - 
zochten bij 8845 patiënten met CNS in hoeverre de zorg in de voorafgaande 15 maanden 
voldeed aan de richtlijn. (hoofdstuk 2)  
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a) Onderzoek naar nierfunctie en eiwituitscheiding was uitgevoerd bij respectievelijk 
82% en 48% van de CNS-patiënten. De bloeddruk was bij 73% van de patiënten 
gemeten. Bij 43% van de patiënten was de voortgang van de ziekte gecontroleerd 
volgens de richtlijn. 
b) Slechts bij 2% van de patiënten waar het volgens de richtlijn had moeten 
gebeuren waren de metabole parameters gecontroleerd. 
c) 32% van de CNS patiënten had CNS gedocumenteerd als code in de probleem 
lijst van het elektronisch patiëntendossier. 
d) Bloeddruk was onder de 140/90 mmHg bij 44% van de patiënten.
Factoren gerelateerd aan hoge kwaliteit van zorg waren het bestaan van diabetes en, 
in mindere mate, hoge bloeddruk, mannelijk geslacht en het feit dat de praktijk zich 
op het platteland bevond. We concludeerden dat er ruimte voor verbetering is in alle 
aspecten van kwaliteit van zorg voor CNS patiënten in de eerste lijn.   
3.  Vóórkomen van metabole stoornissen bij patiënten met CNS in de eerste lijn
Problemen in de botombouw worden tegenwoordig als een belangrijke factor bij 
CNS beschouwd omdat deze problemen samen hangen met het verhoogde risico 
op hart- en vaatziekten bij CNS patiënten. Door middel van bepaling van calcium-, 
fosfaat- en PTH spiegels kunnen deze zogenaamde metabole stoornissen in de 
gaten gehouden worden. Dit gebeurt nog weinig in de eerste lijn. Dit zagen we 
bevestigd in ons onderzoek naar kwaliteit van zorg. In een ander onderzoek (de 
Sharing studie, waarover later meer) beschikten wij over calcium, fosfaat en PTH 
gegevens van 174 patiënten (hoofdstuk 3). Dit stelde ons in de gelegenheid te 
onderzoeken hoe vaak metabole stoornissen voor komen in de eerste lijn. Calcium 
en fosfaat verstoringen waren zeldzaam. Verhoogde PTH spiegels daarentegen 
kwamen veel voor: bij 40% van de patiënten waren de PTH spiegels hoger dan de 
normaal waarde. We stelden voorspellende factoren vast voor een verhoogd PTH. De 
nierfunctie, hartfalen en triglyceriden droegen bij aan een verhoogd PTH, maar hun 
voorspellende waarde was zeer beperkt. 
4.  Zou een model van gedeelde zorg tussen praktijkondersteuner, huisarts 
en nefroloog, met ondersteuning van een webbased consultatie systeem 
(telenefrologie) kunnen bijdragen aan de kwaliteit van zorg voor patiënten 
met CNS?
Het is een uitdaging om de zorg voor patiënten met CNS, die vaak een aantal 
chronische aandoeningen tegelijkertijd hebben, goed te organiseren. Een model van 
gedeelde zorg tussen huisarts, praktijkondersteuner en nefroloog zou de kwaliteit 
van zorg en de uitkomsten kunnen verbeteren. In de SHARING studie (SHARed care 
for patients with chronic kidney disease In Nephrology and General practice) hebben 
173
we onderzocht wat het effect van een dergelijk model was op de bloeddruk, 
nierfunctie waarden, gebruik van medicatie en functionele gezondheidstoestand 
(hoofdstuk vier). In vijf praktijken werd gedurende een jaar het model van gedeelde 
zorg toegepast, in vier praktijken werd gebruikelijke zorg geleverd. Het model bestond 
uit een training voor medewerkers, gestructureerde zorg door een praktijk 
ondersteuner en de mogelijkheid om een nefroloog te raadplegen in een beschermde 
digitale omgeving (telenefrologie). 164 patiënten met diabetes en/of hoge bloeddruk 
en een verminderde nierfunctie (eGFR < 60 ml/min/1.73 m2) konden geanalyseerd 
worden. Na een jaar studie was de bloeddruk in de interventie groep (134.7/73.8 
mmHg) lager dan in de controle groep (142.9/80.9 mmHg). De bloeddruk daalde met 
8.1/1.1 mmHg in de interventie groep en  steeg met 0.2/0.5 mmHg in de controle 
groep. De verbetering in bloeddrukwaarden in de interventie groep liep parallel aan 
een verhoogd gebruik van bloeddruk verlagende middelen (RAAS remmers). De 
bloedwaarden van parathormoon was 6.1 pmol/l in de interventie groep en 8.2 pmol/l 
in de controle groep. Dit liep parallel aan een frequenter gebruik van vitamine D. 
Cholesterol en LDL-cholesterol waarden daalden in de interventie groep tijdens het 
jaar. Dit liep samen op met een verhoogd gebruik van cholesterol verlagende 
middelen.
Aangezien bloeddruk de meest belangrijke beïnvloedbare risicofactor is voor een 
ongunstig beloop van CNS, concludeerden wij dat een model van gedeelde zorg van 
waarde kan zijn voor patiënten met CNS in de eerste lijn. 
5.  Praktische toepassing en haalbaarheid van web-based 
consultatie tussen huisarts en nefroloog 
Tijdens de SHARING studie ontwikkelden we een web-based consultatie systeem: 
telenefrologie. Met dit systeem kunnen relevante gegevens uit het huisarts informatie 
systeem van de huisarts geëxporteerd worden naar een digitale omgeving waarin de 
nefroloog een advies kan geven. In hoofdstuk vijf beschrijven we de bevindingen bij 
122 telenefrologie-consultaties door 28 huisartspraktijken en vijf nefrologie afdelingen. 
We waren geïnteresseerd in de mogelijkheid tot het verminderen van verwijzingen. 
Dit hebben we gemeten als het verschil tussen het aantal verwijzingen dat de huisarts 
had willen doen (als er geen telenefrologie was geweest) en het aantal verwijzingen 
wat de nefroloog noodzakelijk achtte. We konden 122 consultaties analyseren. 
Zonder telenefrologie zouden 43 patiënten (35.3%) door hun huisarts verwezen zijn, 
terwijl de nefroloog slechts bij 17 patiënten (13.9%) verwijzing nodig vond. De huisarts 
had 79 patiënten in eigen beheer willen behandelen. Bij tien van deze patiënten vond 
de nefroloog het verstandiger de patiënt wel te verwijzen. Het systeem was praktisch 
toepasbaar: het werd vooral tijdens kantoortijden gebruikt en de gemiddelde consult - 
duur was slechts negen minuten. 
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We concludeerden dat een web-based consultatie systeem het aantal verwijzingen 
zou kunnen verminderen. Op die manier zou telenefrologie kunnen bijdragen aan 
een efficiënt gebruik van gezondheidszorgvoorzieningen doordat patiënten in de 
eerste lijn behandeld kunnen worden met kennis uit de tweede lijn. 
6.   Wat zou de samenwerking tussen huisarts en apotheker kunnen bijdragen 
aan medicatie veiligheid bij patiënten met CNS en diabetes of hoge 
bloeddruk? 
Er zijn verschillende redenen waarom de medicatie veiligheid bij patiënten met CNS 
in het geding kan zijn: ten gevolge van verminderde nierfunctie worden sommige 
geneesmiddelen niet goed uit het lichaam verwijderd waardoor de geneesmiddel-
spiegel in het lichaam te hoog kan worden, er zijn geneesmiddelen die de nier 
rechtstreeks beschadigen en er zijn middelen die de bloeddoorstroming door de nier 
verminderen en daarmee schade aan de nier toebrengen. Als huisartsen en apothekers 
samen werken zou dat kunnen bijdragen aan het herkennen en verminderen van 
medicatie fouten. In hoofdstuk zes beschrijven we een samenwerkingsmodel tussen 
huisarts en apotheek, waarbij de apotheek kon beschikken over nierfunctie waarden 
van oudere patiënten die geneesmiddelen gebruikten voor diabetes of hart -en 
vaatziekten. In één op de negen recepten adviseerde de apotheker een wijziging aan 
te brengen. De huisarts woog deze adviezen in het licht van de klinische context van 
de patiënt. Vervolgens besloot de huisarts de helft van de adviezen over te nemen. 
Dit leidde er toe dat de huisartsen zich voornamen om in 5% van de onderzochte 
voorschriften een wijziging aan te brengen. We concludeerden dat samenwerking 
tussen huisarts en apotheker kan bijdragen aan patiënt veiligheid, omdat beide 
disciplines vanuit verschillende invalshoeken expertise in brengen. 
7.   Onderzoek naar bloeddrukmeting
De hoogte van de bloeddruk houdt verband met de prognose op het gebied van hart 
-en vaatziekten en van nierfalen bij CNS patiënten. Om een goede behandeling te 
kunnen inzetten, dient de bloeddruk zorgvuldig gemeten te worden. In hoofdstuk 
zeven onderzochten wij de nauwkeurigheid van een 30-minuten bloeddruk meting. 
Deze meet methode, waarbij de patiënt gedurende 30 minuten alleen in een kamer 
zit, waarbij een aantal malen de bloeddruk wordt gemeten, bleek tot lagere 
meetwaarden te leiden dan een keurig volgens de regels uitgevoerde spreekkamer 
bloeddruk meting. Dit komt vermoedelijk omdat het zogenaamde ‘witte jassen effect’ 
een kleinere rol speelde bij de 30-minuten bloeddruk meting dan bij de spreekkamer 
bloeddruk meting. Bij herhaling van de meting bleken de resultaten van de 30 minuten 
meting beter te reproduceren te zijn dan die van een gewone spreekkamer bloed-
drukmeting.
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Naar aanleiding van onze onderzoeksbevindingen hebben we een aantal aanbevelingen 
gedaan voor de dagelijkse praktijk en voor toekomstig onderzoek. 
Aanbevelingen voor de dagelijkse praktijk: 
1. Feedback aan huisartspraktijken op basis van laboratorium uitslagen zou een 
goede manier kunnen zijn om praktijken te helpen om de patiënten met CNS te 
herkennen. 
2.  Praktijkondersteuners kunnen bijdragen aan de kwaliteit van zorg door de reguliere 
controles te verzorgen. Dit is goed in te bedden in de bestaande diabetes en 
hypertensie zorg. 
 3.  Controle van metabole problemen zou kunnen verbeteren door meer scholing te 
verzorgen over dit onderwerp. Feedback op basis van laboratorium uitslagen 
kan duidelijk maken welke patiënten in aanmerking komen voor controle van 
calcium, fosfaat en PTH. Telenefrologie zou kunnen bijdragen aan verspreiding 
van kennis over metabole problemen. Het is nog niet bekend of behandeling van 
een verhoogd PTH in de eerste lijn daadwerkelijk bijdraagt aan een betere 
prognose. Deze fundamentele vraag zal eerst beantwoord moeten worden. 
4.  De behandeling van de bloeddruk bij patiënten met CNS verdient meer aandacht 
in de eerste lijn. De behandeldoelen werden vaak niet gehaald. Aan de andere 
kant is het belangrijk dat de bloeddruk niet over-behandeld wordt, zeker niet bij 
kwetsbare ouderen. 
5. Van de patiënten waarbij de richtlijn verwijzing adviseert, werd slecht een klein 
percentage daadwerkelijk verwezen. Dit kan samenhangen met een lage 
herkenning van patiënten, met een slechte gezondheidstoestand van de patiënt 
waardoor de huisarts het nut van verwijzing laag inschat of met het feit dat de 
huisarts de richtlijn niet onderschrijft. Immers: een verminderde nierfunctie komt 
veel voor bij oudere patiënten en het is nog niet goed uitgekristalliseerd in 
hoeverre een intensieve behandeling bijdraagt aan een betere prognose bij 
oudere patiënten. Meer kennis daarover zou behandelbeslissingen bij deze 
groep kunnen ondersteunen.  
6.  De apotheker dient te kunnen beschikken over actuele nierfunctie waarden. 
Daarvoor is niet alleen nodig dat de nierfunctie waarden inzichtelijk zijn voor de 
apotheker, maar ook dat risico patiënten op zijn minst jaarlijks worden gecontroleerd. 
Idealiter worden in de toekomst kenmerken van de patiënt mee gewogen bij de 
automatische medicatie bewaking. 
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Aanbevelingen voor onderzoek:
- Bestudeer patiënt voorkeuren daar waar het gaat om behandeling in eerste of 
tweede lijn. Onderzoek mogelijkheden om self-management uit te breiden.
- Verricht nader onderzoek bij huisartsen naar hun mening over de behandel en 
verwijs adviezen uit de richtlijn en hun overwegingen wanneer de richtlijn niet 
gevolgd wordt. 
- Probeer vast te stellen welke oudere patiënten met CNS in de eerste lijn gebaat 
zijn bij behandeling. 
- Bestudeer het effect van PTH verlaging op het verminderen van hart- en 
vaatziekten bij patiënten in de eerste lijn. 
- Onderzoek mogelijkheden om patiënten uit de tweede lijn terug te verwijzen naar 
de eerste lijn met ondersteuning van telenefrologie. 
COnClusie
Op het gebied van CNS hebben veel spelers een rol: patiënt, praktijkondersteuner, 
huisarts, apotheker en nefroloog hebben ieder een duidelijke omschrijving van taken 
en verantwoordelijkheden nodig. Niet alleen richtlijnen, maar ook implementatie 
hulpmiddelen die praktische en mentale barrières helpen overwinnen, zijn nodig om 
ieder zijn rol optimaal te doen vervullen.  In de samenwerking tussen de verschillende 
spelers is nog een wereld te winnen als gedeelde zorg het uitgangspunt is en als 
onderlinge communicatie wordt ondersteund met ICT hulpmiddelen. Het resultaat 
zou moeten zijn dat optimale zorg wordt gerealiseerd in samenwerking met de patiënt 
in zijn eigen omgeving. 
177
Samenvatting
178
179
TeamwOrK!
‘Is shared care the answer?’ is de vraag in de subtitel van dit proefschrift. Als het gaat 
over de totstandkoming van dit proefschrift had er moeten staan: shared care ìs the 
answer!! Want wat een teamwork was dit promotie traject. Het aantal mensen wat 
samen met mij hieraan heeft gewerkt overschrijdt ruimschoots de bemanning van 
een acht, het zou een hele vloot worden. Ik bedank iedereen die een bijdrage heeft 
geleverd! 
Coaches
Chris van Weel, beste Chris. Mijn dank betreft jouw overstijgende blik op het onderzoek, 
de snelle en behulpzame reacties op steeds weer nieuwe versies van artikelen, je 
rijke taalgebruik. Heel dankbaar ben ik je ook voor de bespiegelende gesprekken, 
jouw stimulans om het academische spoor verder te volgen en over de grens te kijken. 
Jack Wetzels, beste Jack. Ik heb geweldig genoten en geprofiteerd van jouw gedreven- 
heid. Er zijn veel mensen in het Radboud die hard werken, maar jij breekt wel alle 
records. Zo langzamerhand ken ik je werkpatroon: zondagochtend kwamen de meest 
gedetailleerde reacties. Dank voor al je hulp en geduld en je betrokkenheid bij de 
eerste lijn.   
Wim de Grauw, beste Wim. Toen ik voorzichtig overwoog om het roer tijdelijk om te 
gooien van opleiding naar onderzoek, heb jij me over de streep getrokken met je 
enthousiasme. Je straalde uit dat onderzoek doen heel leuk is. En dat is het ook als 
je met iemand zoals jij kunt werken! Dank voor alle gezellige uren dat we discussieerden 
over het leven in het algemeen (wat is er privé veel gebeurd in die paar jaar) en het 
onderzoek. Naast passie voor onderzoek heb je grote passie voor je patiënten, die 
met chronische nierschade in het bijzonder. Tijdens de Sharing studie bleek er in 
jouw praktijk in Berghem een overmaat aan patiënten met chronische nierschade te 
zijn. We hebben dit  het Wim de Grauw-effect  gedoopt.       
Gerald Vervoort, beste Gerald. Jij liep helemaal warm voor de Telenefrologie. Binnen 
de kortste keren hadden we een beeld waar het op zou moeten gaan lijken en zo is 
het ook geworden, mede  dankzij jouw input. Met verve gaf jij de scholing aan de 
praktijken die participeerden in de studies. Dank daarvoor en voor het meedenken 
over methodologie en uitvoering van de studies.  
Ben Bottema, beste Ben, ook jou wil ik bedanken voor de stimulans om onderzoek te 
gaan doen. De timing kwam zeer ongelukkig uit, zo net voor de start van een nieuwe 
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groep huisartsen in opleiding. Ik vind het bijzonder dat ik nu in een deel van jouw 
voetsporen treed. 
Jozé Braspenning, beste Jozé, dank voor jouw koers bepalende uitspraken. 
Project bemanning
Dit proefschrift bestaat uit vier projecten. Elk project had zijn eigen bemanning. Een 
bemanningslid wat bijna overal opdook was Lea Peters. Allerbeste Lea, jij bent de 
smeerolie richting praktijken, rond data verzameling en registratie. En alsof dat nog 
niet genoeg is, jouw monterheid om elk probleem te tackelen gaf mij steeds weer een 
goed humeur. Voor het Sharing project over gedeelde zorg tussen huisarts, praktijk-
ondersteuner en nefroloog dank ik alle patiënten die bereid waren de metingen te 
ondergaan. De inzet van de praktijkondersteuners uit de praktijken van het Nijmeegs 
Monitoring Project was buitensporig, dank daarvoor! José van Boxtel wil ik hier met 
name even noemen: altijd stond je klaar om ons weer een stapje verder te helpen. 
Het praktisch meedenken van Wouter Koop van het klinisch chemisch laboratorium 
van het CWZ in Nijmegen (tot aan het zelf ophalen van bloed in Doesburg toe!) was 
van onschatbare waarde. Tijdens de Sharing studie ontwikkelden we Telenefrologie. 
Janneke Remmelts en Pieter Jeekel hebben daar een grote bijdrage aan geleverd. 
Vincent van Gelder hield zich als student bezig met de evaluatie van de eerste 
Telenefrologie consulten. Wat waren we blij dat hij de uitnodiging aannam om er een 
heel promotie traject van te maken. Vincent, je gaf me geweldig veel energie met 
je enthousiasme en helder verstand! Alle succes met je promotie en je opleiding! 
Jij gaat nu verder met de resultaten uit de grote Contact studie, die onderzoekt wat 
het effect is van Telenefrologie op verwijzingen en kwaliteit van zorg. Maar liefst 47 
praktijken deden daar aan mee en de nefrologen van 5 ziekenhuizen: UMC St Radboud, 
Rijnstate, Gelderse Vallei, Bernhoven en CWZ. Veel dank aan alle huisartsen, praktijk-
ondersteuners en nefrologen. Meedoen aan zorg innovatie kan heel leuk zijn, maar 
niemand zit te wachten op gedoe zoals het invullen van lijstjes, zelfs niet als het een 
trendy app is. Fijn dat jullie dat wilden doen! Dankzij de medisch studenten Niki 
Pernot en Inge de Grauw hebben we al veel data uit de Contact studie kunnen 
verwerken. Dat al die data boven tafel kwamen en geanalyseerd werden, hebben we 
te danken aan mensen die daar goed in zijn. José Donkers, Marion Biermans, Jan 
Mulder en Reinier Akkermans, dank voor alle hulp! 
Dan was er het SKIP project, over de samenwerking tussen huisarts en apotheker 
met als doel de medicatieveiligheid te vergroten. Arjen Geerts, Fred de Koning, Peter 
de Smet en alle apothekers van de Kring-apotheken in Arnhem noord en de 
huisartsen uit de FTO groep waren van onschatbare waarde. Ook de klinisch chemici 
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van het Rijnstate ziekenhuis en het SHO waren ons behulpzaam. Tim van der Sterren 
leidde als medisch student alles in goede banen. Ik dank iedereen van harte voor 
hun medewerking. 
Voor de 30 minuten bloeddrukmetingen vormden Carel Bakx, Mark van der Wel en 
Theo Thien de stuurlui. Het was een genoegen om aan te schuiven bij de dinsdag-
ochtend sessies. In die kamer vol boeken en artikelen ontstonden de meest sprankelende 
ideeën. Na het overlijden van Carel zal het nooit meer hetzelfde zijn. Steve Boudewijns 
en Gijs Schoenmakers deden de metingen in Berghem en Schaijk, dank aan hen en 
alle patiënten! 
Diverse bemanning 
De dames van het secretariaat van de opleidingen en van het onderzoek verdienen 
zeer veel lof! Wat een bereidheid om altijd weer te helpen, menig bedrijf kan daar 
jaloers op zijn! 
De gezelligheid van mijn kamergenoten Els Pelgrim, Thea van Roermund, Patrick 
Dielissen en van de gang op de derde verdieping (allemaal mensen-met-een-me-
ning) maakte dat ik altijd met plezier naar mijn werk ging en me kon verheugen op de 
leuke discussies. 
Dank aan de medewerkers van Thermion voor alle flexibiliteit!
Dan Lasserson, hoi Dan, thank you for being part of the mansuscript committee. The 
Oxford-Nijmegen renal consortium has a promising potential! If you teach me how to 
publish in the BMJ, I will help you with the BJGP. 
Malcolm Falkus, dear Malcolm. I appreciate our special friendship. We met on many 
different places on different occasions, happy and sad. Thank you so much for critically 
reading the manuscripts. 
Thuishaven 
Dit proefschrift was er nooit gekomen zonder de bijstand van onze gouden hulpen: Bets, 
Ans, Suzan, Elsje en Lula, dank jullie wel voor alles wat jullie voor ons gezin betekenen!
Ik heb genoten  van het promotie traject. Maar onze kinderen zouden zeggen YOLO, 
Lekker Belangrijk zo’n boekje. Er zijn veel leuker dingen te doen! Liefst met mijn fijne 
familie en vrienden. Het zou te ver gaan om jullie te bedanken voor jullie hulp bij het 
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proefschrift. Het is meer ondanks jullie dat het gelukt is. Diep in mijn hart was ik namelijk 
liever veel vaker ingegaan op jullie verleidingen om vakantie te vieren, te hockeyen, 
rennen, wandelen, zwemmen, skiën, film te kijken, koken, eten, muziek te maken of te 
luisteren. 
Mijn broer, lieve Enno, wat leuk dat je nu weer ceremonie meester zal zijn, net als bij 
ons trouwen! Je bent een meester in organiseren, of het nou voor de zeilvereniging is 
of voor een project in Thailand, het komt allemaal strak voor elkaar. 
Bart de Koning, lieve Bart. Super dat je mijn paranimf kunt zijn. We hebben samen de 
praktijk in Santpoort-Noord gerund. Dat was een gouden tijd. Ik had mij geen fijnere 
collega kunnen wensen. Dat we ook nog in dezelfde levensfase zaten en met onze 
gezinnen op Vlieland of Terschelling vakantie hielden was nog eens mooi meegenomen. 
Angela Spit, lieve Angela, al vanaf onze studie in Groningen hebben we veel gemeen-
schappelijk gedaan. Fijn dat je me straks zal helpen door te zeggen dat controle 
albuminurie over een jaar zeker geindiceerd is! Ik bewonder hoe je alles voor elkaar 
krijgt en ik waardeer jouw attente belangstelling geweldig. Allebei zouden we graag 
meer tijd hebben voor de leuke dingen van het leven. Als een kampeerweekendje of 
een running-date lukt, zijn we helemaal blij.  
Dankbaar ben ik voor de warmte en ruimte waarin ik ben opgegroeid. Graag noem ik 
op deze plek mijn ouders Hanna en Hidde. Zij zijn er niet meer, maar ik voel ze nog 
dagelijks om mij heen. Hidde, met zijn credo ‘deze dag komt tot ons als een geschenk’. 
Voor mij staat dat voor levenslust. Wat had hij de promotie graag mee willen maken! 
Tekenend voor mijn lieve moeder Hanna was: ‘zoals een gewas het licht zoekt, zoekt 
de mens het geluk’. Haar wijsheid en mildheid inspireren mij. Ook haar Dolf, met zijn 
grote belangstelling, is niet meer bij ons, maar Marja vormt een mooi schakeltje naar 
die tijd. In de serie ouderfiguren horen zeker ook Pieter en Betty Faber. Er is niemand 
die mij zo lang en goed kent als jullie. Heel graag laat ik mij voeden op vele fronten in 
jullie gastvrije huis aan de IJssel. En dan  nog meer ouders! Lieve Gerd, samen met 
jouw fantastische Janny, die helaas sinds vorig jaar niet meer leeft, ben je altijd vol 
belangstelling, en altijd vol raad en daad, ook ongevraagd! Het was heerlijk om bij jou 
te kunnen schrijven (ook al bij de IJssel..). Het vooruitzicht dat je straks in de corona 
zal zitten, maakt voor mij de dag bij voorbaat geslaagd! Eén van de beste dingen die 
jullie gedaan hebben is hele fijne kinderen voort brengen: Harm, Marieke en Jan-Jaap. 
Laat ik nou met die laatste getrouwd zijn. Lieve Jan-Jaap, jij maakt het allemaal 
mogelijk, zorgt dat het gezellig blijft en maakt alles meer dan de moeite waard. Hanna 
Yu, Xiaodong en Yuan, grote lieverds, het is een feest om jullie te zien opgroeien! 
Graag gaan we met jullie de toekomst tegemoet!
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CurriCulum viTae
Nynke Scherpbier-de Haan was born in Oegstgeest in 1964. Her childhood she 
spent in France and Soest. She went to grammar school (Johan van Oldenbarnevelt 
gymnasium) in Amersfoort, and started her study medicine in Groningen in 1982. Her 
internships were in Deventer, Bandung and Malawi. After her graduation in 1989 she 
worked as a resident on various departments of ‘Het Spittaal’ in Zutphen and as a 
resident in internal medicine in Apeldoorn. In 1992 she started vocational training in 
general practice at the University of Amsterdam, with traineeships in ‘t Zand with 
Jan Kos and in Haarlem with Bob Stapel. Afterwards she worked in Uitgeest and 
Santpoort-Noord. In 1997 she settled in Santpoort-Noord as a general practitioner. 
Postgraduate education was one of her activities in that time. She initiated and 
coordinated the building of a health centre, but did not have the chance to work there 
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